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TUMOUR T A R G E T I N G WITH M A C R O C Y C L E CONJUGATES 
Complexes of the radionuclides 6 7 Ga and 1 1 ' In, or of the paramagnetic contrast agent 
Gd, used in MRI, provide a means of imaging tumours. The stability of the 7 'Ga -
NOTA complex was verified by in vivo NMR spectroscopy. The novel phosphinic acid 
NOTA analogue, bearing an isopropyl substituent on phosphorus was prepared and its 
lipophilicity and 1 1 ' In biodistribution in mice determined. The crystal structure of the 
yttrium complex of N,N"-bis(benzylcarbamoylmethyl)diethylenetriamine-N,N',N"-
triacetic acid revealed amide carbonyl ligation in a distorted mono-capped square 
antiprismatic structure, with one metal-bound water. The biodistribution of the 
analogous Gd complex was examined. 
A novel series of 9N3 based ligands incorporating three further N donor atoms, 
carboxymethyl groups and a potentially larger cavity size were synthesised. The 
analogous series containing phosphinic acid groups and the 12N3 counterparts were 
also prepared. The former series formed complexes with Gd and the biodistribution in 
mice was studied. The 12N3 analogues failed to form Gd complexes. 
2-Nitroimidazoles are known to selectively target hypoxic tumour tissue. Two 
conjugates of 2-nitroimidazole for tumour imaging were prepared, the Gd complex of a 
DTPA-bis(2-nitroimidazole) amide and the 1 1 ' I n complex of a C-functionalised NOTA-
nitroimidazole conjugate. The biodistribution in mice of each was studied and 
luminescence experiments on the Tb complex of the former revealed one metal bound 
water molecule. 
Novel conjugates of the tetrapeptide tuftsin and a complexing agent based on the 12N4 
skeleton and an N-linked NOTA derivative were synthesised. Biodistributions of the 
Gd and In complexes respectively are being carried out. 
Acridine intercalators reversibly bind DNA, possibly enhancing the effectiveness of 
tumour targeting conjugates. Novel multifunctionally labelled acridines based on tris(2-
aminoethyl) amine were sought. The p-nitrophenolate active ester of 9-acridine 
carbamoyl-2-(2-aminoethyl)-2-methyl amine was also prepared as a versatile agent for 
acridine labelling. 
Fiona Calder Smith (April 1995) 
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Introduction 
CHAPTER 1: Introduction 
1.1 CANCER 
1 
1.1.1 INCIDENCE OF CANCER 
Almost all multicellular organisms can be affected by cancer.1 Palaeopathologists have 
found cancerous lesions in dinosaur bones and Egyptians wrote about human cancers in 
hieroglyphics on papyrus dated earlier than 1600 B.C., 2 but it is only in this century 
that the general population have become acutely aware of its significance. Today in the 
developed world cancer accounts for one death in every five and one person in three is 
likely to contract the disease. 
F I G U R E 1.1 Mortality Rate in the United Kingdom 1985-893; Age-standardised 
LLt-ixiti i tiiC ULi,jCli Ua Hit, ,14 
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It can be seen from figure 1.1 that malignant cancers are the second greatest killers in 
the United Kingdom. The term cancer does not refer to a single disease but to over 200 
types which vary in severity and in the age group and sex of those whom they affect. 
In almost every age group cancer is responsible for a higher proportion of deaths in 
women than men,5 incidence among younger people is less, an exception is the skin 
cancer malignant melanoma which has seen an increase of 70% since 19746 among 
the under 40's. 
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FIGURE 1.2 The ten most frequently diagnosed cancers by sex in 1991.1 
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Some types of cancer are more life threatening than others; the annual relative survival 
rates for specific cancer sites presented in figure 1.38 demonstrate this. Some types can 
be treated if detected quickly such as cervical cancer and melanoma (where 93% 
survive if the tumour is found while less than 1.5mm thick) but if allowed to spread to 
other organs, tumours are more difficult to detect and treat and are more likely to prove 
fatal. This highlights the importance of finding new methods of detection, while not 
providing a cure in themselves they are undoubtedly of great benefit because they make 
the patient more curable. 
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F I G U R E 1.3 Annual relative survival rate for patients diagnosed in 1983-87 by site of 
cancer. 
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1.1.2 CARCINOGENESIS 
Factors causing carcinogenesis are partly inherited, partly environmental and not well 
understood. Exposure to a carcinogen starts an "initiation" process in which certain 
genes in DNA are disrupted. Later division of initiated cells leads to a group of cells 
called a tumour.9 The tumour may remain where it is (in which case it is a benign 
tumour) or it may fragment and spread to other tissues (in which case it is a malignant 
tumour). The second of these processes, metastasis is the more difficult to treat and 
consequently the major cause of cancer death. The process of metastasis is summarised 
in figure 1.4. 
1.2 DIAGNOSIS OF CANCER 
1.2.1 IMAGING TECHNIQUES 
Since early and accurate diagnosis of cancer gives a patient a considerably greater 
likelihood of survival or cure, the efforts of many research groups have been directed 
towards the development of imaging techniques. In vivo imaging 1 0 relies upon a form 
of electromagnetic radiation which has minimal interaction with the biological tissues 
of the body, but which can interact efficiently with a detector to produce a signal. 
Biological tissues absorb radiation in the mid frequency range (10 I 0 -10 1 8 Hz), leaving 
the high energy and low energy ends of the spectrum for use in imaging. 
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F I G U R E 1.4 Metastasis: Ability of malignant tumour to invade surrounding cells.11 
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There are two main categories of techniques employed in the diagnosis of disease: 
(i) those involving the interaction of photons with body tissues and organs such as X-
ray computed tomography (CT), ultrasound imaging and magnetic resonance imaging 
(MRI) which are able to delineate anatomical features with high resolution but provide 
only a limited amount of information about biological function. 
(ii) those involving a radiopharmaceutical, a drug containing a radionuclide; this 
method takes advantage of the nuclear properties of the radionuclide and the 
pharmacological properties of the radiopharmaceutical to allow in vivo monitoring of 
biochemical and physiological functions. 
1.2.2 IMAGING WITH C T AND MRI 
X-ray computerised tomography (CT) presented images in a way that was completely 
new to many clinicians and so had a considerable impact, demonstrating the advantages 
of medical imaging by tomographic sections through the head or body. It works on the 
principle that the source and the detector are aligned and data is collected in segments 
at many fixed angles. The absorption data are resolved into a series of digitised images 
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representing thin slices of tissue by solving the resultant simultaneous equations 
computationally. 
The success of CT paved the way for the development of another tomographic 
technique, NMR imaging in the early 1970's.12 The advantages of being able to view 
the body in three dimensional images representing slices of tissue far outweighed the 
disadvantages of the high cost of the technology involved in developing the NMR 
imaging instrument. The instrument used in magnetic resonance imaging (MR1) differs 
little in principle from a laboratory FTNMR spectrometer, however it does present new 
engineering challenges in requiring a sample chamber large enough for a human head 
or whole body and the addition of gradient radiofrequency coils. 
Given that the body is more than 60% water, the water proton resonance is the most 
abundant resonance to detect in vivo. The gradient magnetic field which replaces the 
familiar static field used in laboratory FTNMR spectrometers makes the water proton 
resonance frequency position dependent. This provides a signal which must be 
decoded to give a digitised image. In a typical experiment for each volume element 
(with concentration of water protons = [H2O]) the signal intensity depends on the 
longitudinal and transverse water relaxation times (T1 and T2) and the nature of the 
pulse used (e.g. using the common 'spin-echo' pulse, Tg is the echo delay time and T R 
the pulse repetition rate) as shown in equation ( l ) 1 3 - 1 4 where H v is a motion factor. 
Signal intensity = [H 20]H v(exp[-TE / T 2])(l-exp[-TR / Ti]) (1) 
Paramagnetic species catalyse the proton relaxation of aqueous solutions in which they 
are dissolved, a highly paramagnetic ion like Gd 3 + or M n 2 + causes the relaxation time 
of water protons to decrease by a factor of about 106. As can be seen from equation 
(1), decreasing the relaxation times Ti and T 2 changes the signal intensity, but the two 
terms have opposing effects. In practice a "Ti-weighted" image is obtained by varying 
T E and T R appropriately. Relaxivity is the term used to describe this ability of 
paramagnetic ions to shorten the water proton relaxation rate. Gadolinium complexes 
are used commonly because the Gd 3 + ion combines a high magnetic moment with a 
long electronic relaxation time (t s = 10_9s in the case of Gd 3 +), two features that ensure 
effective nuclear spin relaxation.15 
MRI was originally considered to be a noninvasive radiological technique, but it now 
appears that contrast agents are often necessary to highlight lesions that otherwise could 
not have been detected. In clinical practice, paramagnetic contrast agents are now used 
routinely to improve the signal intensity in NMR imaging. Most of these agents are 
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based on Gd(III) because of its high relaxivity described above. When designing a 
potential new contrast agent there are some important points to note: 
(1) Since the dose given to the patient is high (ca. lOg) the contrast agent must be 
non-toxic at these levels. 
(2) The contrast agent must be soluble in water in these quantities also. 
(3) It must possess an osmolality similar to that of serum lest crenation of red blood 
cells leads to pain on administration.14 
(4) Relaxivity is further increased by contrast agents in which water molecules are 
coordinated directly to the metal ion.1 6 
1.2.3 I M A G I N G W I T H R A D I O P H A R M A C E U T I C A L S 
When a radioisotope is used in diagnosis (termed radioimmunoscintigraphy) a minimal 
interaction of radiation with the tissues of the patient is desired whilst the interaction of 
radiation with a detector outside the body is maximised. Gamma emitters may be 
suitable in this respect if they deliver photons of appropriate energy to escape from the 
body (>80 keV) and with sufficient density to achieve the necessary resolution for 
imaging.17 They fall into two main categories: 
(i) Single photon emitters where the y emission occurs as a direct result of simple 
nuclear decay. 
(ii) Positron emitters where the isotope emits a positron and leads to the 
creation of two opposing y rays. 
1.2.3.1 G A M M A R A Y S C I N T I G R A P H Y A N D S P E C T 
Single photon emission (y emission) is detected by means of an Anger camera. In view 
of the random direction of emission from gamma emitting isotopes a collimator is used 
to localise the radiation upon the detector to provide a signal which is amplified and 
counted as electrical pulses. The resolution obtainable is modest at 1-2 cm, coarser 
than that obtained using X-rays. 
A three dimensional image may be obtained by mounting the Anger camera on a 
rotating gantry, recording multiple images at different angles. The procedure is 
computerised and known as Single Photon Emission Computerised Tomography 
(SPECT). 
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1.2.3.2 P O S I T R O N E M I S S I O N T O M O G R A P H Y ( P E T ) 
7 
If a radionuclide emits a positron (p+) which annihilates with an electron from the 
surrounding tissue, two photons (511 keV) are produced which travel at 180° to each 
other as shown in figure 1.5.18 
F I G U R E 1.5 Annihilation of a positron and electron. 
a) BEFORE 
Electron e" O Positron e + 
b) Ar i fcH ANNiHiLA I iON 
* ^ N . Two photons of 0.511 MeV 
1 8 0 \ are produced. 
As a result of the directional nature of these emissions, tomographical information may 
be obtained by detecting the two gamma rays at each side of the source within the 
patient. This confines the annihilation event to a single line joining the two detectors. 
The PET scanner19 may be a series of static or mobile Anger cameras around the 
patient which scan through a given volume element. Resolution is very good, of the 
order of 3mm, but the high cost of the PET scanner has caused its use to be much more 
limited than SPECT. 
1.2.3.3 C H O I C E O F R A D I O I S O T O P E S F O R U S E I N I M A G I N G 
In addition to selecting the type of radiation required for the chosen tumour imaging 
technique there are a number of other principles to be considered when choosing the 
most suitable radionuclide.20 
(1) HALF-LIFE: This should be long enough to permit transportation to the site of 
tumour before one half-life has elapsed, but short enough to limit the radiation 
dose to which the patient is exposed. (Typical tV2 is 6 hours-8 days). 
(2) GAMMA ENERGY: Between 80 and 240 keV, (in the case of positron 
emitters, photons have an energy of 511 keV). 
(3) GAMMA ABUNDANCE: To minimise the quantity of radiopharmaceutical 
required, the radioisotope should be (i) 'carrier-free', that is with no 'cold' 
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isotopes of the same element, (ii) have a high percentage of single energy 
gamma emissions and (iii) very low abundance of any (3 or a emissions. 
(4) RADIOCHEMICAL PROPERTIES: The isotope should be easily produced at 
low cost (preferably from a generator21), be readily purified from other isotopes 
and decay without hazardous daughter products. 
FIGURE 1.6 Gamma emitting radioisotopes used in SPECT imaging. 
Radionuclide t V2 (hours) Ephoton(keV, %) source 
99nrr/c 6.02 141(89) generator 
Ulln 68 171 (88) cyclotron 
247 (94) 
67Ga 78 184 OA) cyclotron 
131j 193 364 (82) reactor 
123T 13.2 159 cyclotron 
FIGURE 1.7 Positron emitters used in PET. 
Radionuclide t V2 (hours) EohotonfteV, %) source 
68Ga 1.20 511 (178) generator 
64Cu 12.8 511 (120) reactor 
82mR b 6.4 511 generator 
1.3 TREATMENT OF CANCER 
1.3.1 TYPES OF CANCER TREATMENT. 
There are four main approaches used by physicians to destroy cancer cells selectively. 
The comparative usefulness of these may be helpfully illustrated by an analogy of 
weeds (cancer) and grass (normal cells). One weed in the middle of a plot of grass can 
be pulled out (surgery) or burned out (radiotherapy). If the weeds are widespread 
(disseminated cancer), then a solution of weedkiller (chemotherapy) can be sprayed on 
the lawn to destroy the weeds selectively, without destroying the grass. If there are 
only a few weeds throughout the grass, the addition of fertiliser (immunotherapy) to 
strengthen the growth of the grass may enable it to outgrow and choke the weeds. 
The effectiveness of surgery is limited not by the size of the tumour but by its 
distribution. Chemotherapeutics on the other hand, have had some success against 
CHAPTER I: Introduction 9 
metastatic disease, notably the drugs cisplatin (cis-(PtCl2(NH3)2)), carboplatin (C3H6-
C(C02)2-PtCl2(NH3)2)) and 5-fluorouracil. Their use is limited not by the 
distribution but by the total mass of tumour since these drugs have unpleasant side 
effects; nausea, hair loss and an increased susceptibility to infection. Immunotherapy 
capitalises on the differences between cancer cells and normal cells and employs the 
body's own immune system in the treatment of the tumour (see section 1.5). Radiation 
therapy in the form of X-rays and y-rays continues to be an important treatment 
modality for many forms of human cancer,22 although normal tissue toxicity limits the 
total dose of radiation a patient can ultimately receive. 
1.3.2 R A D I O P H A R M A C E U T I C A L S I N T U M O U R T H E R A P Y 
PaH|f»niir"]irjf>c "icf>H i n thf»rc>p\723.24 rrmgt del^VSf E Stf^'I^-SinS r S .d i&t i n r l dOSC *0 t h p 
tumour site sufficient to cause multiple double-strand cleavages of cellular D N A (600 -
4000 rads). Suitable isotopes for radioimmunotherapy are either (5 or possibly a 
emitters with very little or no y content. Many of the principles outlined in 1.2.3.3 
apply equally well to choice of radionuclides for therapy, but generally they have a 
longer half-life (1-10 days) allowing the dose to be delivered over a period of time. 
F I G U R E 1.8 Therapeutic Radioisotopes for use in radioimmunotherapy.25 
Radionuclide t V2 (hours) [ W (MeV, %) mean range in tissue (mm) 
90y 64 2.25 (100) 3.9 
67Cu 62 0.40 (45) 0.2 
0.48 (3) 
0.58 (20) 
186R e 90 1.07 (74) 1.1 
0.93 (21) 
188Re 17 1.96 (18) 3.3 
2.12 (80) 
199Au 75 0.25 (22) 0.1 
0.30 (72) 
l l lAg 179 1.04(93) 1.1 
0.69 (6) 
Win, 166 0.45 (26) 0.3 
0.57 (64) 
0.58 (10) 
131j 193 0.61 (90) 0.4 
CHAPTER 1: Introduction 10 
1.3.3 SUMMARY OF ELEMENTS USED IN TUMOUR DIAGNOSIS AND 
THERAPY 
A summary of the elements, both paramagnetic contrast agents and radioisotopes, used 
in diagnosis of disease and those used in tumour therapy is given below. Some 
elements have more than one useful isotope, iodine also has a gamma emitting isotope, 
copper and gallium also have positron emitting isotopes and dysprosium may also be 
used as a contrast agent in MRI. 
FIGURE 1.9 Periodic Table: summary of metals and radioisotopes used in diagnosis 
and therapy of tumours. 
1A 8A 
1 A A A « A 6 A 7 A 
c N O t 
3B 4B 5B 6B TR 8B 8B 8B IB 2B 
Cr Fe 
m Sr y M 
'•' 
tfl I 
La H Au As 
lanthanides Sm Gd 111 HP 
actinides 
Positron, (3+ 
Beta, (3, e-
Gamma, single photon emission. 
Alpha, a 
i Paramagnetic Contrast Agent 
Some of these elements are more widely used in clinical practice or will be particularly 
highlighted in the following chapters, the properties that lead them to be considered in 
this way are summarised below. 
Technetium - 99m (m= metastable, excited nuclear state with 
unusually long lifetime) 
FOR: 
(1) Ideal gamma energy (used to 'tune' detection equipment.) 
(2) Reasonable price - obtained from a generator. 
(3) Obtained 'carrier free' via Al203/Si02 column chromatography. 
(4) Very diverse chemistry - many complexes known.26 
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(5) Currently used in 90% of diagnostic scans in hospitals.27 
AGAINST: 
(1) Short half life - after 2 days most of activity is gone. 
(2) No stable isotopes of Tc exist 
Gallium - 67 gamma emitter 
(1) 6 7 Ga citrate concentrates in certain tumours and clears from the 
blood allowing imaging.28 
Gallium - 68 positron emitter 
(1) Reasonable price - available from a 6 8Ge generator.21 
Indium - 111 gamma emitter 
(1) Longer half-life than Tc, better for establishing high tumour : 
background relationships. 
(2) I n 3 + released in vivo scavenged by iron sequestering agent. 
(3) More expensive - obtained from a reactor. 
Gadolinium (III) Paramagnetic contrast agent. 
(1) NOT a radioactive isotope used in diagnosis, but suitable for use 
as a paramagnetic contrast agent. 
(2) , 5 3 Gd is available (y, t*/2 241 days) for tracer work such as 
biodisuibution studies. 
1.4 C O M P L E X I N G A G E N T S 
1.4.1 N E C E S S I T Y O F C O M P L E X I N G A G E N T S 
Since the majority of the radioisotopes and contrast agents required for use in the above 
imaging and therapy techniques are toxic metals it is important that they are 
administered in a form which will not harm the patient. For safe use in the body the 
metal is administered as a coordination complex26; it is of utmost importance that this 
complex remains intact in vivo and many of the desirable properties of such complexes 
listed below relate to this. 
(1) Good thermodynamic stability (log K s) is important, this serves as a guide to 
overall stability, however for applications in living systems the kinetic stability is 
of greater importance. 
(2) Conditions in blood are pH 7.4 at 37°C, but lower pH is encountered in bile/ 
stomach, there are also high local concentrations of certain metal ions. Metal 
64 
Gd 
2,8,18,25,9,2 
Gadolinium 
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complexes must be kinetically stable with respect to acid catalysed or cation 
promoted dissociation pathways. 
(3) Charge neutrality is preferred in order to resist attack by protons / cations and to 
aid diffusion through membranes. 
(4) Coordinatively saturated complexes of an oxidation state which is stable in vivo 
are preferred to minimise electron transfer. 
(5) The shape, size and lipophilicity of the complex must be tailored to aid 
transport in vivo. 
(6) The complex should be cleared from the body intact after a suitable time. 
(7) In the case of radiopharmaceuticals the complexation rate should be fast since 
the radioisotope is decaying during this time and a high radiolabelling yield is 
desired.29 Also, in the case of therapeutic isotopes, the daughter product must form 
>-> of nKIp n n m r^lpy ti/itVl t\\f^ oomo l i f tqnH 
1.4.2 A C Y C L I C C H E L A T I N G A G E N T S 
It is well known that complexes formed between metals and chelating ligands are 
generally more thermodynamically stable than those involving monodentate donor 
groups - this is the so called 'chelate effect'.30 Examples of conventional acyclic 
chelators are the polyaminocarboxylate ligands EDTA and DTPA. Both of these 
ligands demonstrate remarkable versatility in binding metal ions. 
F I G U R E 1.10 Ethylenediaminetetraacetic acid (EDTA) and diethylene 
triaminepentaacetic acid (DTPA) 
C 
p-C02H 
N, ^ C 0 2 H 
C 0 2 H 
EDTA 
EDTA DTPA 
donor set: donor set: 
N 2 0 4 N3O5 
bexadentate octadentate 
H02C 
I C 0 2 H 
{ C 0 2 H 
N 
C 0 2 H 
C 0 2 H 
DTPA 
Both of these ligands have been used in clinical practice, in the case of EDTA the 6 8Ga 
complex has been employed to detect where brain tumours have caused disruption of 
the blood brain barrier.31 Attempts have also been made to use the 6 2 Cu complex of 
EDTA but these have proved unsuccessful since this complex, and also that of 6 2 Cu-
DTPA, is unstable in vivo and leads to Cu build-up in the liver. However the anionic 
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^In-DTPA has been used with some success in evaluating cerebral spinal fluid 
pathways32 and has a high stability (logKML = 29.0 at pH 7.4)33 with DTPA chelating 
through all five O and three N donors available. The structure of 9 9 m Tc-DTPA by 
contrast is hexadentate although less well understood; it finds uses such as kidney and 
brain imaging.2 6 Gd-DTPA is also well known, being used routinely as an MRI 
contrast agent (see section 2.3.1), and is marketed under the brand-name Magnevist. 
F I G U R E 1.11 Acyclic complexing agents: further examples. 
CH 
ft 
COoH 
< HOoC P 0 3 H 2 Me 
PO3H0 N CH 
1 r\ 
CH HO Me 
H 0 2 C ^ 
N P 0 3 H 2 
L : N P 0 3 H 2 CCbH 
HBED CH EDTMP PLED 
The ligands N,N'-bis(hydroxypyridyl)ethylenediamine-N,N'-diacetic acid (PLED) and 
N,N'-bis(2-hydroxybenzyl)ethylenediamine-N,N'-diacetic acid (HBED) 3 4 both form 
complexes with 6 8Ga and are potential radiopharmaceuticals for PET, the former may 
be used for imaging the kidney since it clears from the body via the renal system, the 
latter is a liver imaging agent, being cleared by the biliary system. Finally a chelate 
undergoing trials as a therapeutic agent, ethylenediamine tetramethylenephosphonic 
acid (EDTMP) forms a complex with 1 5 3 Sm (tV2 46.27 hours, P"), this is used for 
treatment of bone cancer pain,35 although in this case the selective deposition of the 
radiolabel in the bone is the objective of the treatment.36 
1.4.3 S T A B I L I T Y O F A C Y C L I C C O M P L E X E S 
Although these complexes generally possess good thermodynamic stability their 
concentration in blood is very low and there is competition for the metal from 
transferrin, albumin and other metal binding proteins. In addition there is a high 
concentration of metals such as Z n 2 + (10"5M) and Ca 2 + (10"3M) in serum competing 
for the ligand and promoting metal ion loss.37 Moreover these complexes are very 
susceptible to protonation and their stabilities are highly pH dependent,38 Although 
acyclic ligands such as those described above are currently used in clinical practice, the 
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future success of imaging techniques depends on complexes which are less susceptible 
to dissociation in vivo. 
1.4.4 I M P R O V I N G S T A B I L I T Y O F C O M P L E X E S 
Each metal ion to be bound has distinctive coordination requirements. A chelating 
group may be designed to optimise the 'hardness', number of donor atoms and 
coordination geometry to provide a complex stable for in vivo use. 
F I G U R E 1.12'Hardness' according to the hard-soft acid-base principle of Pearson.39 
A C I D S 
H A R D S O F T 
H+, Li+ Na+ K+, Be 2 + , Mg 2 + , Ca 2 +, Sr2+, Cu+, Ag+, Au + , T1+ Hg+, Pd2+- Cd2+> 
Ba 2 + , A l 3 + , Sc3+, Ga 3 +, In 3 * La 3 + , Gd 3 + , Pt2 +, Hg 2 + , Pt*+, Te4*, Br+. I + 
L u 3 + , Cr 3 + , Co 3 +, Fe 3 +, As 3 + , Si4*, Ti 4 *, 
Zr4*, Hf4+, Th 4 + , U 4 + , Pu4*, Ce4*, Sn 4 + 
B O R D E R L I N E 
Fe2+, Co 2 +. N i 2 + , Cu 2 + , Zn 2 + , Pb2+- Sn2+- Sb3*, Bi3+, Rh 3 + , I r 3 + 
B A S E S 
H A R D S O F T 
H 2 0 , OH", F-, CH3CO2-, PO43-, S0 4 2 ", R2S, RSH, RS", I" , SCN, S2O32-, R3P, 
CI", C 0 3 2 - , CIO4-, NO3-, ROH, RO-, R 2 0, R3As, (RO)3P, CN% RNC, CO, C2H4, H-, 
NH 3 , RNH 2, NH 2 NH 2 R" 
B O R D E R L I N E 
C 6 H 5 NH 2 , C5H5N, N 3-, Br, NQ2-, N 2 , SQ32-
When designing ligands it is also important to consider the size of the 'chelate ring'. 4 0 ' 
4 1 It is commonly stated in textbooks that six membered chelate rings lead to less 
stable complexes than five membered chelate rings, but this conclusion is reached 
because stability is strongly related to the metal ion size and with the exception of Be 
(II) and B (HI) most metals commonly studied are not small enough to form stable six 
membered chelate rings. 
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F I G U R E 1.13 The ideal geometry for (A) a five membered chelate ring, with 
ethylene diamine (EN) and (B) a six membered chelate ring with trimethylenediamine 
(TN). In each the organic part of chelate ring ideally requires the same geometry as 
the cyclohexane ring. 
Idealised bite size in 
five membered rings 
Idealised bite size in 
six membered rings. 
109.5° 
1.4.5 MACROCYCLES 
Macrocyclic complexes, that is compounds containing at least nine atoms in a ring with 
at least three donor groups, are almost without exception more stable 
thermodynamically and kinetically than their corresponding open chain analogues. 
Termed the 'macrocyclic effect' 4 2 it is a more profound feature of macrocyclic 
complexes than simply an increased 'chelate effect' arising from the presence of an 
additional chelate ring. 
Much calorimetric and spectroscopic work has been done to investigate the 
thermodynamic parameters involved in the macrocyclic effect. The outcome was that it 
is neither an enthalpic or entropic effect alone, but a combination which varies 
according to the cation and macrocycle involved. Another feature associated with the 
macrocyclic effect is the kinetic inertness of macrocyclic complexes towards metal ion 
dissociation. This is because the conformational restrictions of the macrocycle make 
the transition states in the stepwise dissociation energetically unfavourable. This 
contrasts with the acyclic complexes discussed previously which, being free to change 
conformations, are likely to be less kinetically inert 
Nature has long employed macrocyclic ligands in the transportation of metal ions. 
Some examples of these include haemoglobin, chlorophyll and vitamin B12. The 
research into synthetic macrocycles was heralded by the discovery of crown ethers by 
Pedersen in the 1960's.43 These cyclic polyethers were observed to form stable 1:1 
complexes with alkali and alkaline-earth metal cations. The ring contained oxygen 
donor atoms and the metal was bound in the cavity through ion-dipole interactions to 
form 'host-guest' complexes. Since different sizes of crown ethers appeared to show 
preference for different sizes of metal ion the concept of 'size-match selectivity' was 
proposed. 
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F I G U R E 1.14 Examples of crown ethers , aza macrocycles and 9X3 
macrocycles 
r ^ r °^ n O 
^3 f \ o 
12-crown-4 15-crown-5 18-crown-6 Tnbenzo-18-crown-6 
n 
NX 
12N4 13N4 14N4 (Cyclam) 15N4 
k J r O r ^ r s 0 
12N3 9N3 9N20 9N2S 9S3 
However this is not a general principle which extends to other groups of macrocycles. 
For example, among the tetraaza macrocycles, the 14N4 ligand (cyclam) shows a 
preference for Cu (II) yet for the much larger Pb (II) ion the complex stability decreases 
with increasing cavity size, 12N4 being the most stable. The observations in this and 
other cases may be explained not by 'size-match selectivity' but by chelate ring size 
considerations. In the case of the Pb complex, although the macrocyclic cavity is 
growing larger through the series, the five membered chelate rings are being changed to 
six membered and a large metal ion such as Pb (II) does not coordinate well in six 
membered chelate rings.40 
Smaller macrocycles44'45'46 such as 9N3 and to a lesser extent 12N3 have more rigid 
structures and do tend to show some size selectivity imposed by the stringent 
requirements as to the preferred size of metal ion for coordination to the three donor 
atoms. 
Pendent donor groups have the ability to increase the stability of a macrocyclic 
complex still further. Among these are neutral oxygen donors, pyridyl, phenolate, 2-
amino ethyl, phosphinate, carboxylate and amide groups. For use in aqueous solutions 
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the choice of ionisable group is very important, stability at low pH is increased by the 
ability of carboxylate or phosphinate to aid resistance to protonation on the heteroatoms 
of the ligand. Stability at high pH is enhanced by a phenolate or 2-hydroxypyridine. 
Of all these pendent donors the carboxylate and phosphinate groups demonstrate great 
steric efficiency, that is they coordinate to metal ions without bringing large numbers of 
atoms to lie close to the metal ion. 
F I G U R E 1.15 Steric efficiency of carboxylate and phosphinate compared with 
the less efficient amine group.41 
Carboxylate 
away from metal \ 
^<. C—O 
O donor has 
no H atoms 
Phosphinate 
^ * * larger bite angle 
Amine 
V 
o 4 . 
R 
V 
-o 
H-H eclipsing interactions 
cause steric crowding 
"H 
F I G U R E 1.16 Macrocycles with pendent donor groups. 
C02H C02H C02H P03H2 P03H2 9°^ C02H 
irv W if^ 
^ ) ^ TLT^ rU^ 
C02H C02H C02H C02H P03H2 P0 3H 2 C02H C 0 2 H 
DOTA D03A DOTMP TETA 
(i) (ii) (in) (iv) 
H02C 
SH N 
C02H N 
SH N C02H TPTCN 
TS-TACN NOTA ( V I I ) 
V I ) V ) 
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1.4.6 MACROCYCLE COMPLEXES IN TUMOUR IMAGING AND 
THERAPY 
A number of 9N3 analogues have been studied with a view to forming stable Ga and In 
complexes. Of these, the ligand NOTA (V) has proved most successful, forming 
complexes of high thermodynamic and kinetic stability in vivo. 4 7 ' 4 8 Indeed the 6 7Ga-
NOTA complex remained stable with respect to acid catalysed dissociation even in 6M 
nitric acid. The lipophilic indium complex of TX-TACN ( V I I I ) 4 9 shows retention in 
liver and blood, making it a possible candidate for imaging the hepatobiliary pathway, 
but it is considerably less stable than NOTA. The TS-TACN (VI) 5 0 < 5 1 ligand has a 
much lower molecular weight whilst retaining some lipophilicity, its Ga and In 
complexes were studied to determine whether they were able to cross the blood brain 
barrier, but thev Drovp.d less linonhilic than expected and were unable to do so. 
FIGURE 1.17 Macrocycles for use in imaging and therapy of cancer. 
HO-
TX-TACN H 3 C 
(VIII) 
V - C H 3 
i-n ° H 
Tc-Cyclam 
(IX) 
C02H 
OH 
r ^ Me 
C02H 
C02H 
HPD03A 
(X) 
A /—\ ^ C02H H02MeP V ^PMe0 2 H ( ^ 9 
L J > NC^NhMe 
H0 2 MeP v AJCpMe0 2 H > \ ^ P h 
15N302 DOTPMe 
(XI) (XII) ( x m ) 
H02C 
Tetraaza macrocycles have found a wide variety of uses.16 Cyclam forms a dioxo 
complex with " m T c (LX) for imaging although, being charged it does not cross the 
blood brain barrier. DOTA (I) and D03A (II) both form seven coordinate complexes 
with l u I n which show greater stability in serum than the ^ In -DTPA complex 
discussed previously, demonstrating the suitability of the 12N4 based ligands for In 
labelling. DOTA (I) and HPD03A (X) also form stable complexes with Gd 5 2 and are 
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used routinely as MRI contrast agents (see section 2.3.1). The larger macrocycles 
TETA ( I V ) and the 13N4 analogue TRITA both form Gd complexes which are more 
fluxional than DOTA, and the complexes are less kinetically stable with respect to 
dissociation which may be related to the presence of the six-membered chelate rings. 
These two ligands do however form stable 6 4 Cu complexes allowing the possibility of 
PET imaging. The therapeutic isotope 9 0 Y also forms stable complexes with 12N4 
based ligands since the rare-earth Y 3 + has a very sirrilar coordination chemistry to the 
lanthanide Gd 3 + . It is especially important that the yttrium-90 complexes remain intact 
in the body due to the lethal consequences of 9 0 Y building up in the bone. It is also 
important that these complexes form quickly giving a high radiolabelling yield for the 
forward complexation reaction. The 15N302 ligand ( X I ) binds Y too slowly to be 
useful since the radioactive isotope decays constantly during complexation. However, 
complexes of DOTPMe (XII) and !?N4 neitfra! amides such as ( X I I I ) are suitable. 
1.5 T U M O U R T A R G E T I N G 
Nearly a century ago Ehrlich proposed that it may be possible to find a particular 
chemical which would eradicate a specific disease through the applications of drug 
action whilst leaving the host organism unharmed and so he coined the phrase 'magic 
bullet1. When applied to the diagnosis and therapy of cancer this approach seeks to 
capitalise on the differences between 'normal' and tumour cells. Since tumour cells are 
derived from normal cells such differences are limited. Differentiation between the cell 
types is evident in their rate of proliferation and hence vascularization, different 
enzyme patterns albeit with the same enzymes, and tumour cells may possess different 
macromolecules on their surfaces such as antigens and macrophages. 
The biodistribution of the majority of therapeutic and diagnostic agents discussed so far 
has been determined by blood-flow (perfusion). Where differences are observed they 
are due to factors such as the ability of the complex to cross the blood-brain barrier or 
its specificity for the hepatobiliary pathway. Such behaviour may be ascribed to factors 
such as complex shape, charge, redox properties and lipophilicity. 
Alternatively the biodistribution may be determined by specific receptor binding, a 
given biochemical interaction or both. This gives scope for designing agents targeted 
to a particular tissue or organ as Ehrlich hypothesised. In this instance the uptake and 
retention of the pharmaceutical depends on the properties of the target molecule. Some 
such examples are: 
(1) Antigen-antibody interactions. 
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(2) Enzymatic reduction within poorly vascularised hypoxic tumours of conjugates 
with electron poor heteroatomic compounds such as nitroimidazoles. 
(3) Interaction of peptides with specific receptors such as those located on 
macrophages. 
Such a targeting vehicle may be conjugated to a therapeutic agent like an a or p emitter 
or a cytotoxic drug like taxol or calicheamicin for therapy, or may be linked to a y or 
positron emitter for diagnosis. 
1.5.1 T A R G E T I N G U S I N G A N T I B O D I E S 
1.5.1.1 A N T I B O D I E S 
Cancer therapy that relies on manipulation of the patients' immune system is defined as 
immunotherapy. There are a range of approaches under development;53 one of the 
most extensive studies has been into the use of antibodies as targeting agents. 
Antibodies are proteins (immunoglobulins or IgG) produced by animals in response to 
infection by foreign substances like bacteria, viruses or tumour cells. They are 
produced by white blood corpuscles called B-lymphocytes found in the lymph nodes 
and spleen. The basic antibody structure is shown in figure 1.18, it consists of two 
pairs of heavy and light polypeptide chains linked by disulphide bonds. One light chain 
folds over the first half of one heavy chain forming a F(ab) arm (Fragment antigen 
binding) which has a complex three dimensional structure as a binding site for a 
specific antigen. 
Antigens are substances foreign to the body and antigens expressed by tumours are not 
usually produced by normal cells. The antibodies which bind to these antigens 
specifically can be generated in mice by means of 'hybridoma technology'54 for use in 
targeting, making the 'magic bullet' seem an attainable goal. 
Problems emerged because in some cases these 'murine' antibodies were rejected by the 
human immune system. This human anti-mouse antibody (HAMA) response may be 
reduced by transforming the murine monoclonal antibody into a 'chimaeric' antibody as 
shown in figure 1.19. Such an antibody combines a variable (V) or binding domain of 
mouse antibody with a human antibody constant (C) domain. Even more effective are 
the so called 'humanised' antibodies55 which combine the minimum amount of murine 
antibody with a human framework. These are substantially less immunogenic in 
humans. Another problem that was encountered was that whole antibodies were 
CHAPTER 1: Introduction 21 
transported in vivo very slowly due to their large size and were excreted slowly causing 
tissue : blood ratios to remain low. This was largely overcome by the use of antibody 
fragments 5 6 which were excreted rapidly whilst retaining specificity thus producing 
much higher tissue : blood ratios. 
F I G U R E 1.18 
fragments. 
Antibody structure and structure of F(ab') and (Fab')2 
variable region (V) 
light chain (L) 
hinge region 
with disulfide links 
IgQ 
150,000 0a 
heavy chain (H) 
constant region (C) 
(Fab-)2 
100.0000a 
Fab1 
50,0000a 
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F I G U R E 1.19 -4 chimaeric antibody retains the entire V domain from the 
murine antibody, whereas a humanized antibody retains only the complementarity 
determining regions. 
Mouse 
O Human 
H 
V 
r 
U N i 
Chimaeric Humanized 
1.5.1.2 B I F U N C T I O N A L C O M P L E X I N G A G E N T S 
Much work has been carried out on direct, non-specific radiolabelling of antibodies and 
antibody fragments with 99nrr/c 57 This is carried out by treating a F(ab) fragment with 
2-iminothiolane to generate free sulfhydryl groups which, when incubated with TCO4-
under reducing conditions bind to Tc quite avidly, but when formed these labelled 
antibodies have demonstrated relatively poor in vivo stability. 
A more successful strategy for attaching radiometals to antibodies employs bifunctional 
complexing agents. These bind the metal strongly by means of a chelating agent such 
as a macrocycle and have another site through which the chelator can be linked to the 
antibody. Proteins such as antibodies are commonly coupled via the e-amino groups of 
lysine residues of which there are about 90 in a typical monoclonal antibody. Suitable 
bifunctional complexing agents must therefore incorporate an acylating moiety such as 
an active ester. A range of suitable methods of linking bifunctional complexing agents 
to targeting vehicles is shown in figure 1.20. 
It is important to consider each component carefully. The complexing agent should 
retain its denticity and the antibody retain its ability to bind specifically. In addition the 
linkage between them should be stable to hydrolysis in vivo. 
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F I G U R E 1.20 Methods of linking Afunctional complexing agents to antibodies. 
Entry Precursor Liganci Activated Ligand Comment 
O ~ C 0 2 H 0 - ~ C 0 2 F 
R = succinimidyl, 
p-nitrophenyl or 
tetrafluorophenyl 
{J— CH 2NH : (2)—v 0 link to thiols rapidly 
0 
JJ—i in pH range 5 to 7 
H 0 
form with 
symmetrical uis-
0 ester in excess 
thiol selective 
in pH range 6-9 ; 
0 N forms stable thioether 
NO, C\—/ V - w r s f o r m s s t a b l e t n i o u r e a 
with amino groups; prepare 
with CSCI 2 
= \ H N-alkylation may compete 
\__f~ 2 ^ ~ H V _ / " N V ^ B r in formation ; link to 
J thiols 
1.5.1.3 A N T I B O D Y C O N J U G A T E S F O R U S E IN VIVO. 
The n l I n complex of DTPA-antimyosin is an example of an antibody conjugate in 
clinical use . 5 8 The DTP A is covalently linked with one carboxylate to a F(ab') 
fragment of the antimyosin antibody and the remaining four carboxylates coordinate to 
n l I n . Clearly when the n i I n - D T P A complex itself has limited in vivo stability 
(section 1.4.2), this conjugate in which only four carboxylates are binding the In, is 
susceptible to dissociation in vivo. A number of other ^ I n , 99mjc 186Rc antibody 
conjugates are undergoing clinical trials (figure 1.21), but all of these incorporate an 
acyclic chelating moiety and so do not benefit from the greater kinetic stability 
attainable by use of macrocyclic Afunctional chelating agents. 
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F I G U R E 1.21 Examples of antibody conjugates 
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Examples of promising macrocyclic bifunctional complexing agents for antibody 
conjugation are shown in figure 1.22. Ligand p-NCS-Bz-NOTA ( X I V ) forms stable 
complexes with 6 7 G a in which the aryl thiocyanate forms a stable thiourea linkage by 
reaction with the e-amino group of an antibody lysine residue. 5 9 The DOTA-
maleimide 
F I G U R E 1.22 Macrocyclic bifunctional complexing agents for antibody 
conjugation. 
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( X V ) forms ^ I n conjugates with antibodies, and can also be used in 
radioimmunotherapy with 90y,60 C-functionalised cyclam ( X V I ) was treated with 
a thiol specific vinyl pyridine linker molecule and subsequently conjugated to a thiol 
residue on an antibody. Biodistribution studies of the Cu (II) complex showed no 
observable build up of Cu in the kidneys or liver of mice, indicating that it is kinetically 
stable and potentially useful in tumour diagnosis.6 1 The C-functionalised D O T A 
derivative ( X V I I ) 6 2 was conjugated with B72.3, a tumour localising antibody which 
binds with a tumour-associated glycoprotein found in human breast and colorectal 
cancer. Biodistribution studies of the 9 0 Y complex in mice indicate that the highly 
toxic 9 0 Ydoes not dissociate in vivo.6* 
1.5.2 T A R G E T I N G USING P E P T I D E S 
Exciting work in the receptor binding area has shown that perhaps only the peptide 
sequence involved in receptor binding is necessary to achieve specific uptake in the 
given target tissue. For example, studies involving conjugates of radiolabeled 
Afunctional complexing agents with peptides have achieved tumour uptake. The use of 
peptides and other relatively low molecular weight species has many advantages over 
targeted macromolecules including comparatively higher metal and amino acid 
labelling efficiency, potentially rapid blood clearance and an increased ability to pass 
through capillary vessels into the interstitium. 
1.5.2.1 O C T R E O T I D E AND S O M A T O S T A T I N R E C E P T O R B I N D I N G 
Conjugates of the peptide octreotide have been shown to be somatostatin receptor 
binding pharmaceuticals. Octreotide is an eight amino acid peptide containing the four 
amino acids (Phe-D-Trp-Lys-Thr) required for binding to the somatostatin receptor. 6 4 
The structure of somatostatin itself is shown in figure 1.23; it is a 14 residue peptide 
normally found in hypothalamic extracts which inhibit secretion of growth hormone, 
insulin and glucagon. 6 5 Somatostatin receptor-positive tumours expressed on 
carcinoid tumours and malignant lymphomas may be imaged using radiolabeled 
octreotide. The 1 1 ] I n labelled DTPA conjugate with octreotide ( X V H I ) exhibits strong 
binding to the somatostatin receptor with an IC50 value in the nanomolar range, and 
with non specific binding less than 10% of total binding. 6 6 Clinical studies in humans 
have shown very promising results2 6 DTPA was covalently linked to D-Phe at one end 
of the octapeptide, although better tumour / tissue discrimination would be obtained if a 
C-linked DTPA or NOTA complexing agent had been used. 
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F I G U R E 1.23 Comparison of the structures of somatostatin and the DTPA-
octreotide conjugate ( X V I I I ) . 
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One of the major limitations of the use of peptides as pharmaceuticals is their 
susceptibility to proteolysis. In the case of octreotide, the four essential amino acids are 
stabilised to proteases in the body by disulphide cyclisation from the two cysteines 
incorporated in the molecule and by the placement of the D-amino acids. 
1.5.2.2 T U F T S I N AND M A C R O P H A G E R E C E P T O R S 
Tuftsin is a peptide which is targeted to normal host cells called macrophages 
associated with abnormal tissue in a tumour. Tuftsin is a naturally occurring linear 
tetrapeptide (L-Thr-L-Lys-L-Pro-L-Arg). It is generated in the body from a specific 
cytophilic fraction of the protein leukokinin through a two step enzymatic processing 
mechanism, employing tuftsin endocarboxypeptidase and then leukokinase. Tuftsin 
was isolated in the 1970's67 and it was discovered that it possesses immunologically 
mediated anti-tumour potential;68 being non toxic (LD50 mice 2.5g /kg) it became an 
ideal candidate for tumour targeting. 
Macrophages are scavenger cells which form part of the immune system and 
demonstrate a range of immunological processes.69 They recognise, engulf and dispose 
of damaged cells and foreign invaders by means of a process called phagocytosis, and 
participate in surveillance against microbial infections and cancer by antigen 
presentation, lymphocyte activation, tumoricidal and bactericidal activities. 
Macrophages differ in morphology and possess receptors for many ligands. Those 
macrophages found in human tumours form a characterised sub-population of cells for 
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targeting. The macrophage content of tumours varies considerably and it has been 
shown that the macrophage densities are highest at the tumour periphery and in areas of 
necrosis. Targeting tumour-infiltrating macrophages may detect necrotic regions and 
delineate boundaries between normal and infiltrating neoplastic tissue, it may also 
assist in detection of small metastases since the macrophage densities are highest in 
smaller lesions. 7 0 
F I G U R E 1.24 Macrophage engulfing a foreign particle by phagocytosis. 
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Macrophage phagocytic activity is stimulated by tuftsin. This takes place in stages: 
(1) Association of peptide and macrophage cell is initially electrostatic in nature. 
(2) Fast accommodation of tuftsin into specific receptor sites. 
(3) Subsequent rapid internalisation of the peptide-receptor complex. 
The nature of the binding site has been the subject of much research. 7 1 ' 7 2 - 7 3 While still 
not well understood, it is clear that binding is specific, fast, saturable and reversible. 
Analysis has shown that there is only one type of site, 7 4 but that there may be 75,000 
receptors per macrophage.75 
Binding of tuftsin to macrophages depends on strict conservation of molecular 
structure, 7 6 in formation of conjugates the following actions often impair tuftsin 
activity: 
(1) Amino acid substitution or deletion at the C-terminus, N-terminus or within 
the chain. 
(2) Absence of free amino or carboxyl groups at peptide termini. 
(3) Substitution or alteration of the guanidine side chain. 
(4) Lengthening the chain by addition of amino acids at either terminus. 
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Tuftsin analogues which have been studied, and which retain biological activity are 
formed by extension of the C-terminus,7 7 the e-amino group of the Lys residue 7 8 or the 
N-terminus. The biologically active fluorescent tuftsin analogues shown in figure 1.25 
were synthesised from the corresponding isothiocyanates to visualise the interaction of 
tuftsin with macrophages and similar cells. Tritium labelled tuftsin has also been 
utilised in these studies 7 4 but to date there have not been any reports of tuftsin used in 
tumour diagnosis. 
F I G U R E 1.25 Biologically active fluorescent tuftsin conjugates. 
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1.5.3 T A R G E T I N G U S I N G N I T R O I M I D A Z O L E S 
1.5.3.1 H Y P O X I A AND R A D I O T H E R A P Y 
Many malignant tissues are low in oxygen due to poor vascularisation during their 
rapid growth. This oxygen deficiency is termed hypoxia. 7 9 Radiation causes 
biochemical changes that interfere with the cancer cells' ability to divide indefinitely. 
Ions and fast electrons produced when radiation energy is absorbed react with 
molecules to produce free radicals. These aqueous free radicals interact with DNA's 
purine and pyrimidine bases to form organic radicals or with the phosphate bond to 
disrupt the sugar phosphate chain. Organic radicals can in turn react with oxygen to 
produce organic peroxides that prevent restoration of the molecule. Unfortunately in 
hypoxic cancer cells the oxygen concentration is so low that these peroxides do not 
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form and the radiation dosage required to kill the cells may be as much as three times 
that required to destroy normal cells. 8 0 
1.5.3.2 R A D I O S E N S I T I S E R S 
Primary effort has focused on chemical agents able to enhance radiosensitivity of 
hypoxic cells in a manner analogous to oxygen, but which have no effect upon 
normoxic cells. These oxygen mimetics have the free radical properties of dioxygen. 
Some typical examples are the nitroxyl free radicals ( X I X ) and (XX) . 
F I G U R E 1.26 Typical radiosensitisers. 
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It was also observed that in vitro radiosensitising activity correlates with electron 
affinity, partition (logP) and p K a . This prompted development of electron affinic 
agents which are (i) essentially non-toxic, (ii) able to diffuse into hypoxic cells and (iii) 
are not rapidly metabolised in vivo. The nitroarene ( X X I ) , many quinones including 
isoindole-4,7-diones and nitroheteroarenes such as ( X X I I ) are just some examples. 
Most attention has focused on nitroimidazole derivatives 8 1 ' 8 2 such as the natural 
antibiotic azomycin ( X X I I I ) and its 2-propanol derivative misonidazole ( X X I V ) which 
both show in vivo radiosensitising properties. These properties substantially increase in 
the series of compounds including etanidazole ( X X V ) and pimonidazole ( X X V I ) . 2 2 It 
is assumed that the nitro group of the nitroimidazole is reduced enzymatically in the 
absence of oxygen and retained in hypoxic tissue with some selectivity. 8 3 , 8 4' 8 5 
The one electron reduction of various nitroimidazoles has been reviewed. 8 1 In the 
absence of oxygen stable electron-adducts are observed which have been characterised 
as nitroimidazole radical anions. These react rapidly with oxygen or with other highly 
electron affinic compounds by one electron transfer reactions to regenerate the parent 
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nitroimidazole. Two and four electron reduction formally yield the corresponding 
nitroso (Ar-N=0) and hydroxylamine (Ar-NHOH) derivatives. These labile products 
are cytotoxic interacting with cellular components such ac. DNA and protein. They 
often undergo mutual condensation and further reduction to give azoxy and azo (Ar-
N=N-Ar) derivatives respectively. 
F I G U R E 1.27 TTie redox 'spectrum' showing electron affinity of nitroaromatic 
drugs compared to oxygen (most easily reduced). Nitro compounds with Ej/y < -0.5 V 
are not reduced by biological systems (Ej/y - one electron redox potential).^6 
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It was found that 2-nitroimidazole is a more efficient radiosensitiser than 5-
nitroimidazole, which is in turn more efficient than the corresponding 4-isomer. This 
would be expected, due to the large difference in electron-affinity between the 
nitroimidazoles. 8 7 Attempts were made to further increase electron-affinity and so 
radiosensitisation by means of a series of 2-nitrofurans; these were more potent in vitro. 
However they were inactive in vivo due to poor distribution, metabolism and other 
biological interactions that removed the compounds before they could reach the 
tumours. 
1.5.3.3 T A R G E T I N G O F H Y P O X I C T U M O U R T I S S U E 
Identification of regions of hypoxia is of clinical interest, and since nitroimidazoles 
accumulate preferentially in hypoxic tissue there have been some studies carried out 
using radiolabeled nitroimidazoles in order to trace these tissues. Work conducted 
with 1 4 C and 3 H labelled misonidazole88 showed accumulation in the human melanotic 
melanoma HX118 , 8 9 a tumour known to be hypoxic. Good contrast between hypoxic 
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and normoxic regions of myocardial tissue was demonstrated using an 1 8 F-labelled 
derivative of misonidazole ( X X I V ) . 9 0 
The 4-fluorobenzylamine conjugate of 2-nitroimidazole ( X X V I I ) was proposed as a 
suitable P E T hypoxia imaging agent and more recently tests have been carried out on 
the 3-iodo analogue for use in S P E C T . 9 1 Another class of nitroimidazole conjugates 
( X X V I I I ) have been developed for use in boron neutron capture therapy of cancer, 9 2- 9 3 
but unfortunately their poor water solubilities have precluded biological evaluation to 
date. 
F I G U R E 1.28 Potential nitroimidazole radiopharmaceuticals 
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Boronic Acid Adducts of Technetium diOximes (BATOs) ( X X I X ) were originally 
developed as organ perfusion radiopharmaceuticals, but by incorporating a 
nitroimidazole group onto the boronic acid they can be targeted to hypoxic tissues. A 
number of these 99nvr/c compounds incorporating different linkage groups between the 
nitroimidazole and boronic acid group have been prepared and show promising initial 
biological results. 9 4 Another potential new radiopharmaceutical of great interest is 
TcO(PnAO)-l-(2-nitroimidazole) ( X X X ) . 9 5 - 9 6 The complex is initially distributed by 
perfusion but is apparently retained selectively in regions of hypoxia within rabbit 
CHAPTER 1: Introduction 32 
hearts by metabolism. Results from electrochemical studies and enzyme studies at pH 
7.4 with xanthine oxidase showed reduction of the 2-nitroimidazole group under 
hypoxic, but not oxic, conditions. The TcO(PnAO) moiety was unaffected under 
identical conditions. Thus a potential mechanism for preferential localisation of the 
radiopharmaceutical in hypoxic tissue was demonstrated. 
1.5.4 T A R G E T I N G USING A C R I D I N E I N T E P C A L A T O R S . 
1.5.4.1 DNA I N T E R C A L A T I N G A G E N T S 
Predating antibiotics and sulphonamides, aminoacridines such as 9-aminoacridine 
found uses as antibacterial agents and phenanthridin^s such as 'ethidium' as 
trvpsnocidsl soents in cstfle T^fi^ rnods of action v»us not well understood and there 
was little progress in studies of drug-DNA interactions until 1961 when it was 
proposed that proflavine intercalates into DNA, a process whereby the planar acridine 
ring comes to be inserted between the base pairs of the Watson-Crick helix. 9 7 
F I G U R E 1.29 Some examples of DNA intercalating agents. 
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A rapid expansion in studies of physiochemical properties and the capacity of DNA 
intercalators to inhibit DNA function followed. In the 1970's attention became 
devoted largely to the development of intercalating antitumour agents; the 
anilinoacridine 'amsacrine', the 9-aminoacridine 'nitracrine' and the anthracycline 
antibiotic 'adriamycin' were all products of this era. Nowadays DNA intercalators with 
an established place in the clinic include 'actinomycin', 'daunomycin', 'adriamycin', 
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'amsacrine' and 'mitoxantone'. Many more intercalators are undergoing clinical trials as 
research in this field continues. 
1.5.4.2 I N T E R C A L A T I O N 
DNA is unusual as a drug receptor because its three-dimensional structure and dynamic 
properties are understood in great detail. In the simplified model shown in figure 1.30 
(a) the sugar-phosphate backbone is represented as a smooth coil and the base pairs are 
shown in edgewise projection. DNA-intercalator complex formation is usually freely 
reversible, its driving force being a combination of electrostatic, entropic, hydrogen 
bonding, van der Waals and hydrophobic interactions. The planar intercalator 
molecule becomes inserted between the DNA base pairs as indicated in figure 1.30 (b). 
The major changes to the DNA upon intercalation are an increase in length and some 
unwinding of the helix around the intercalation site. 
F I G U R E 1.30 The intercalation model: (a) double helical DNA (b) the same 
DNA containing intercalated drug molecules. 
Intercalating agents are cytotoxic to dividing, but not quiescent cells, they generally 
prevent progression beyond the G2 + M phase of the cell cycle. 9 8 It is at the M stage 
of the cell cycle that the nuclear membrane is ruptured to allow division, and so drugs 
which are unable to be transported across this membrane may still access the 
chromosomes within the nucleus. Intercalating agents also induce chromosomal 
abnormalities, concentrate in the nucleus or nucleolus, condense chromatin and inhibit 
D N A and RNA synthesis. 
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F I G U R E 1.31 The cell cycle. 
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1.5.4.3 A C R I D I N E S 
Acridities are often regarded as the archetypal DNA intercalating agents" since 
proflavine was first used to demonstrate this phenomenon. The driving forces for 
acridine intercalation are stacking and charge transfer interactions, with a lesser role 
being played by polar forces (H bonding and electrostatic forces). Acridines possess 
high association constants with DNA, even under high salt physiological conditions, 
where almost all intracellular acridine will be found bound to nucleic acids. 
Nitracrine was developed in Poland, and still sees widespread use there for mammary 
and ovarian carcinomas. It owes at least some (if not all) of its activity to its aromatic 
nitro group, however this also leads to avid binding of D N A and prevents good 
transport in vivo. Amsacrine is widely used in the treatment of leukaemia and 
malignant lymphomas; it binds DNA selectively over R N A and also has the ability to 
inhibit certain enzymes. 
A study was carried out to determine whether the charge-transfer and binding 
properties of 'amsacrine' could be improved by attaching a cationic side chain to the 
a c r i d i n e . 1 0 0 One of the resulting acridines in particular, 9-aminoacridine-4-
carboxamide ( X X X I ) 1 0 1 proved to have a high affinity for DNA. This compound is a 
dication at physiological pH ( p K a = 8.30) and in addition to intercalation of the 
acridine, the dimethylammonium side chain binds to the minor groove of DNA. It is 
active against leukaemia, but shows little activity against solid tumours. Removal of 
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the 9-amino group broadens the spectrum of activity to include solid tumours as 
observed with the acridine carboxamide ( X X X I I ) . 1 0 2 This compound is neutral at 
physiological pH (pK a = 3.54), leading to a ten-fold decrease in DNA affinity, but it 
shows increased antitumour activity due to improved transport properties. 
F I G U R E 1.32 Anti-tumour acridine carboxamides. 
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Acridines may be reversibly and predictably bound to cellular DNA, due to their 
classical planar, hydrophilic, weakly basic character. This favourable stability and 
accessibility of the acridine moiety has rendered the synthesis of a wide variety of 
modified structures possible. 
1.5.4.4 T A R G E T I N G DNA W I T H I N T E R C A L A T O R C O N J U G A T E S 
Attempts have been made to further enhance the selectivity of hypoxia selective 
nitroimidazoles by targeting them to the DNA of hypoxic cells with intercalating 
groups. For example the phenanthroline nitroimidazole conjugate ( X X X I I I ) 1 0 3 ' 1 0 4 was 
found to bind to DNA, show selectivity for hypoxic cells (8-fold) and produce 
radiosensitisation in vitro. 
F I G U R E 1.33 Intercalator-nitroimidazole conjugates for targeting DNA. 
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The analogous acridine compound ( X X X I V ) 1 0 5 has demonstrated a DNA binding 
affinity almost as high as 9-aminoacridine itself. It also has a similar p K a value of 9.5, 
but lacks a permanent positive charge. The solubility and reduction potential were 
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similar to that of misonidazole, but its hypoxic selectivity was only 6-fold compared to 
11-fold in the case of misonidazole. In addition this compound possesses a high 
cytotoxicity such that this group of compounds were unsuitable for use in vivo. 
Many studies have been conducted on the interaction of metal complexes with DNA, 
the metal centre has found uses as a sensitive spectroscopic handle to examine the 
region of the nucleic acid to which it is bound. The iron (II) complex of methidium 
propyl-EDTA (MPE-Fe) ( X X X V I I I ) 1 0 6 has gained rapid recognition as a D N A 
footprinting agent, useful in defining the location of small ligands that bind DNA. 
These synthetic nucleases, due to their small size and lack of specificity, have allowed 
a more accurate resolution of binding sites than other agents. 
Jb'IGUKE 1.34 intercaiaior-meiai complexes. 
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Recently it was discovered that intercalation is not restricted to completely flat, square 
planar complexes, but partial intercalation of ligands coordinated to other metal centres 
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is feasible as well. Examples of this include the bis(phenanthroline) cuprous 
i o n ( X X X V I ) , 1 0 7 tris(phenanthroline)complexes of Co(II) and Rh(II) and the 
phenanthrenequinone diimine complexes of Rh(II) ( X X X V I I ) 1 0 8 which may be used as 
spectroscopic tags or in redox cleavage of DNA. 
There has also been interest in the DNA-binding properties of intercalators and 
platinum complexes in the presence of one another. The platinum (II) complex 
( X X X V ) 1 0 9 , 1 1 0 has been prepared and studies conducted to examine the DNA-binding 
of the intercalator, and whether it enhanced the antitumour properties of the cis-
diamminedichloro-platinum (II) moiety. It may clearly be seen how development of 
such ligands could lead to the production of radiolabeled intercalator conjugates for 
targeting DNA, and in particular the DNA of tumour cells. 
1.6 SCOPE OF THIS WORK. 
It has been suggested that the state of anticancer chemotherapy at present most 
probably equates to the state of antimicrobial chemotherapy at the turn of the century 
where compounds of mercury, antimony and arsenic were used. These of course were 
better than nothing, but hardly very effective and certainly accompanied by very 
serious side effects. 
There exists much scope for improvement of cancer chemotherapy at present, in 
particular the design of new drugs which limit toxic effects by targeting the tumour 
cells and delivering their lethal dose specifically. This study contains work on ligands 
suitable for radioisotopes and paramagnetic complexing agents, for use in tumour 
diagnosis. It then goes on to address novel approaches to targeting using 
nitroimidazole, tuftsin and acridine conjugates of such ligands. 
Radiopharmaceutical chemistry is very much an interdisciplinary effort, and requires 
the collaboration of scientists from various fields, including organic and inorganic 
chemistry, biochemistry, radiochemistry and nuclear medicine. This project involves 
collaboration with the M R C Radiobiology Unit in Chilton, the Royal Marsden Hospital 
and Celltech. 
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2.1 T R I A Z A C Y C L O N O N A N E C O M P L E X E S 
2.1.1 P R E V I O U S W O R K 
Recent work 1 has shown that gallium complexes of hexadentate macrocycles such as 
those shown in Figure 2.1 are kinetically stable in vivo and are excreted intact. The Ga 
complex of (1) also tends to be retained in a malignant melanoma (a xenograft of a skin 
cancer in a mouse: HX118). Each of these ligands g :ves a radiolabeled yield of >98% 
at pH 5.5 (5 | iM, 37°C) and the radiolabeled complex following injection in a mouse is 
excreted quite rapidly (>99.8% after 72 hours) usually via the kidney, figure 2.2 
F I G U R E 2.1 
(1) X = C 0 2 H 
(2) X = PMeCbH 
(3) X = PPhCbH 
R = H (NOTA) 
R = H 
R = H 
(4) X = P C H 2 P h 0 2 H R=H 
(5) X = C 0 2 H R= Me 
(6) X = C 0 2 H R= Ph 
F I G U R E 2.2 Biodistribution of67Ga-NOTA in tumour and tissues. 
IS) 
-a a) 
u 
• blood 
E3 kidney 
• liver 
• HX118 Tumour 
1 hour 2 hours 4 hours 
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2.1.2 Ga C O M P L E X E S O F NOTA 
i ,4,7-Triazacyclononanetriacetate f N O T A ) 2 (1) was prepared starting from 1.4,7-
triazacyclononane (9N3) (7) in two steps. Initial treatment of 9N3 with 
ethylbromoacetate in dry ethanol in the presence of caesium carbonate afforded the 
triacetate (8) in 64% yield after gravitational alumina column chromatography. 
Subsequent hydrolysis produced (1) quantitatively. 
The gallium complex of NOTA (9) was formed by adding a solution of gallium nitrate 
in 0.004M nitric acid to a solution of the ligand in nitric acid and maintaining the 
mixture at room temperature for 24 hours. Recrystallisation from water produced the 
desired complex as white crystals in 68% yield. 
S C H E M E 2.1 
\ 
H 
(7 ; 
Ethylbromoacetate 
C s 2 C 0 3 
EtOH 
EtO,C 
8) 
r CO,Et 
CO,Et 
6M-HCI. A 
H 0 2 C 
r C 0 2 H (i) G a ( N 0 3 ) 3 
N - ~ ^ dil. H N 0 3 , R.T. 
(ii) 7 1 G a 2 0 3 
(1 ) 
\ dil. HCI. reflux 
^ — C 0 2 H 
(i) Ga-NOTA (9) 
(ii) 7 1 G a - N O T A (10) 
2.1.3 G A L L I U M NMR 
2.1.3.1 B A C K G R O U N D T O Ga NMR 
Gallium has two naturally occurring isotopes. 6 9 G a and 7 I G a which are 60.4% and 
39.6% abundant respectively. Both possess a nuclear spin ( I = 3/2) but the latter has 
the higher receptivity and narrower line width-3 as shown in figure 2.3 making it more 
favourable for N M R despite the less favourable natural abundance. 
The observed linewidth of the gallium resonance ((1)1/2) may be related to the local 
symmetry at gallium and to the stability of the complex with respect to exchange 
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processes. In general a 7 1 G a linewidth is much greater than would be expected by 
comparison with say, 2 7 A 1 . 6 One reason for this is that G a 3 + may undergo an exchange 
process such as self hydrolysis in aqueous solution 7 to produce the [Ga(0H)(H20)5] 2 + 
ion. Hydrolysis is suppressed at low pH, so the linewidth is greatly reduced i f spectra 
are obtained in acidic solution. 
F I G U R E 2.3 Comparison between the two natural isotopes of gallium. 
69Qa 4 7 1 G a = 
% Abundance 60% 39.6% 
I 3/-> 
r-* i Tin 3!9 
5GaPpm[Ga(H?0)6] 3 +in 0 0 
H 2 0 
(Linewidth CO1/2 Hz) (1300) (200-300) 
ScaPpmtGaCU]" in H2O +243 +257 
(Linewidth CO1/2 Hz) (870) (100) 
Relative to 1 3 C 
The iinewidth of the gallium resonance is also proportional to the interaction of the 
electric f ield gradient at the nucleus with the nuclear quadrupole moment. In highly 
symmetric complexes such as Ga(OH)4" and G a ( H 2 0 ) 6 3 + the electric field gradient at 
the nucleus is small, and relatively sharp lines may be obtained. The sharp singlet 
observed in the 7 1 G a N M R spectrum of [Ga-NOTA] indicates that the C3 symmetry 
observed in the solid state (figure 2.4) is maintained in solution. Comparison with 
other Ga complexes made in figure 2.5 indeed supports the conclusion that the C3 
symmetry leads to the observation of an uncharacteristically narrow 7 1 G a resonance. 
F I G U R E 2.4 X-ray crystal structure of Ga-NOTA showing C ? symmetry. 2 
CHAPTER 2: Synthesis, Structure and Biodistribution of Simple Complexes ofGa, In, Gd and Y 48 
F I G U R E 2.5 Comparison of7iGa NMR linewidth for a number of complexes. 
C 0 2 H 
H 0 2 C " \ l I I rN % 
(CH 2 ) „ N (CH 2 ) n . 
C 0 2 H 
Macrocycle ligand 
9N3 (1) 
10N3 n=n'=l ( I D 
11N3 n = l , n'=2 (12) 
12N3 n=n'=2 (13) 
ligand complex linewidth (Hz) 
(1) Ga.NOTA (9) 210 
(13) Ga.(13)2 3400 
(11) Ga . ( l l ) 2 2000 
(12) Ga.(12)2 unobservable 
2.1.3.2 S Y N T H E S I S O F 7 1 G a NOTA C O M P L E X 
An alternative route to the Ga-NOTA complex was also developed using enriched 
7 1 G a 2 0 3 obtained f rom Oakridge USA (99% 7 1 Ga) . NOTA was stirred in dilute HC1 
and a solution of 7 1 Ga203 in cone. HC1 was added and refluxed overnight. White 
crystals of (10) formed directly upon cooling and were used as such in 7 1 G a N M R 
experiments. 
F I G U R E 2.6 Comparison of 7 1 Ga NMR spectra for complex {9) and (10) . 
[ 
i 
L 
' 5 B mg so 
— ^ ^ ^ ^ ^ ^ — 
i s a * a a : 5 a !ae : s a : a a : i a i 5 z - s a - ' . aa - 5a - : a e -:sa -*aa ;5e -4aa -JSB. 
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2.1.3.3 IN VITRO 7 1 G a NMR 
A comparison of the 7 1 G a N M R spectra obtained under identical conditions f rom 
solutions of equal concentration of Ga-NOTA (9) and enriched 7 , G a - N O T A (10) 
clearly shows that the former has an integral 40% of the size of the latter (See figure 
2.6) reflecting the natural abundance of 7 1 G a compared to the 7 1 G a supplied by 
Oakridae. 
2.1.3.4 IN VIVO 7 1 G a NMR 
The Ga complex of NOTA had previously been observed by 7 I G a NMR spectrometry2 
in the liver of an anaesthetised mouse. 20 minutes after an intravenous injection of an 
'.lni 1£T*11 c c o m i i i c S p c c U U i i t w a s 
acquired with the aid of a Varian external 3cm surface coil probe tuned to 7 1 Ga at 61.0 
MHz which was placed over the "sample" to be analysed. The spectrum was 
callibrated using an authentic sample of Ga.NOTA complex giving 5 c a +171ppm. 
F I G U R E 2.7 In vivo 71Ga NMR (a) in the liver of an anaesthetised mouse and (b) in 
aqueous solution.^ 
I I ; : 
'•'''•'•'Vi/ . ' • , i ; . ^ v A i v.n 
(b) 
1 ,M 
'•j in 
<I,I I. ,'i11 ' M , * 
toff wyw i 
50 100 200 150 
6Ga/(PPfn) 
Now using enriched 7 1 Ga compex it was possible to make further studies using the 
same method to acquire spectra of the complex in the bladder and in a tumour 
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(HX118). Figure 2.8 clearly shows that 2 hours following injection of a 1.1 mg sample 
the complex was still intact in the bladder of the mouse. However no conclusion could 
be drawn from the spectrum acquired from the tumour 2 hours following injection. The 
problems encountered here could be due to the di f f icul ty of directing the probe at 
specific organs or a tumour in such a small animal. But the 8 c a shift does show that the 
complex is kinetically robust and suitable for in vivo use. 
F I G U R E 2.8 In vivo 7!Ga NMR in bladder and tumour of mouse. 
7 1 Ga NMR in tumour 
v 
71 Ga NMR in bladder 
71 Ga NMR of Ga-NOTA 
6G A ppm 200 250 50 150 100 
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2.1.4 INDIUM C O M P L E X O F NOTA 
Despite differences in ionic radius. Ga and In share an almost identical aqueous 
coordination chemistry 8. The indium complex of NOTA was formed in a similar way 
to (9) and used for biodistribution studies in tumour bearing mice. Figure 2.9 shows 
the distribution of 1 1 ' In-NOTA in tumour and tissues. It is interesting to note the high 
ratios of tumounblood = 16.6:1 and tumour:liver = 13.3:1 (after 2 hours) especially 
compared to those for 6 7 G a - N O T A (13.1:1 and 0.425:1 respectively ). Clearly i f the 
complex is taken up by the tumour in amounts adequate for imaging it is advantageous 
if it also clears from the blood sufficiently fast to provide a low background at early 
times after administration. 
F I G U R E 2.9 " 'In NOTA biodistriburion in tumour and tissues 
m 0.8- • BLOOD 
m LIVER 
m HX118 TUMOUR 
• LUNGS 
• SPLEEN 
• FEMUR 
1 BRAIN 
H O U R S 
Similar leveis of 1 1 ' In are also found in xenografts of human colorectal tumour (HT 
29) 9 . The reason for the differences observed in the biodistributions of the Ga and In 
complexes are not well understood, they could stem from a number of factors. 1 0 For 
example the In complex having a slightly larger mass, or the difference in shape 
between the octahedral Ga complex and the trigonally distorted In complex could both 
contribute to the observed difference in uptake into the liver. 
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2.2 AZAPHOSPHINIC ACID LIGANDS 
2.2.1 BACKGROUND 
It has been previously found that the complexes of indium and gallium with 
azaphosphinic acid ligands based on a triazacyclononane ring are well suited to 
radioisotope labelling. 1 1" 1 4 One of their main differences from the ot-aminocarboxylate 
ligands described previously is that the phosphinate moiety is more difficult to 
protonate on oxygen than the corresponding carboxylate. This lower p K a is observed 
in both free ligand and metal complex and leads to greater kinetic stability with respect 
to acid catalysed metal dissociation, this in turn should enhance the in vivo stability of 
the complex. An additional difference is that the pentavalency of the phosphorus 
allows functionalisation of the ligand in order to influence, the mass, solubility and 
lipophilicity by variation of the alkyl or aryl substituent at phosphorus. The structures 
of some of these ligands are given below. Each ligand gave a radiolabelling yield of 
>98% at pH5.5 (5|iM, 37°C) and the radiolabeled complex following injection in a 
mouse is excreted quite rapidly (>99.8% after 72hours). 
F I G U R E 2.10 Some azaphosphinic complexes which have been studied in vivo. 
HO 
I 0 
R 
-N 
0 = P - O H 
R 
ligand R substituent molecular weight 
of In complex 
excretion 
of In complex 
N O T P M e 1 5 (2) Me 517 renal 
N O T P P h 1 5 - 1 6 (3) Ph 703 biliary 
N O T P B z 1 5 (4) Bz 745 biliary 
It appears that the mode of excretion of these neutral complexes can vary from 
predominantly renal to biliary. Comparing these data with another class of related 
compounds (figure 2.11) a pattern was seen to emerge. The complexes with the larger 
aromatic groups appeared to excrete via the endogenous faecal route. 
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F I G U R E 2.11 Triazacyclononane complexes studied in vivo. 
R ^ C 0 2 H 
H 0 2 C ^ N ^ R 
A r.( C 0 2 H 
ligand R substituent molecular weight 
of In complex 
excretion 
of In complex 
NOTA (1) H 418 renal 
NOTAiMe 1 7 (5) Me 460 renal 
x m T a n i . 1 St 
i N u i A i i i ' " r ' n 64o biliarv 
2.2.2 B L O O D B R A I N B A R R I E R 
A stable azaphosphinic complex for use in SPECT/PET in the bra in 1 9 was identified as 
an important target. Such a complex should be of relatively low molecular weight (< 
500 - 600) allowing it to cross the blood brain barrier, but of relatively high 
l i p o p h i l i c i t y 2 0 . NOTPPri (16) was chosen as a suitable target molecule having a 
molecular weight of 550 in its Ga complex and a relatively high lipophilicity. 
2.2.3 S Y N T H E S I S O F NOTPPri 
I s o p r o p y l d i e t h o x y p h o s p h i n e (14) was synthesised by slow addition o f 
diethylchlorophosphite to isopropylmagnesiumchloride in anhydrous tetrahydrofuran at 
0»C (scheme 2.2). 
S C H E M E 2.2 
OEt x THF OEk, 
P-Cl + Pr'MaCl . P - P r ' 
OEt " OEt (14) 
Distillation gave a sample of the phosphine which was used immediately in a co-
condensation reaction with 1,4,7-triazacyclononane and paraformaldehyde in 
tetrahydrofuran under anhydrous conditions to yield the triester (15). The triester was 
readily purified by chromatography on neutral alumina, 2 1 before being hydrolysed 
using 6M HC1 to yield the phosphinic acid (16) shown in scheme 2.3. 
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S C H E M E 2.3 
H J \ M 
N N 
(7) 
'PrPfOEt)2 (14) 
(CH 2 0) n 
THF. 4A Sieves 
EtO 
\ 
Pr 1 - o Pr', 
N NN 
Pr1 V OEt 
^ O E t 
o 
(15) 
6M HC1 
A 
Pr1 
HO 
\ 
0 
? y OH 
Pr1 
- P - O H 
O 
(16) 
Admixture of stoichiometric quantities of the ligand (16) with metal nitrate salts in 
aqueous solution led to rapid formation of the metal complexes. In this case neutral Ga 
complex (17) and In complex (18) were formed. 
2.2.4 B I O D I S T R I B U T I O N S T U D I E S 
Biodistribution studies were carried out on the gallium-67 complex of (16) at one and 
24 hours after administration as shown in figure 2.12. The percentage of the injected 
dose of 6 7 G a per gram of tissue was measured in different tissue types: the amount of 
6 7 G a in the kidney after one hour was very large by comparison with other tissues and 
is shown here at one tenth of the actual quantity. The uptake in the brain was examined 
but no significant amount was found to build up there during the time of observation 
indicating that this complex was unable to cross the blood brain barrier as hoped. 
The biodistribution of the Indium-111 complex of (16) was also studied and compared 
with other neutral phosphinic acid ligands. It could be seen from the one hour data 
shown in figure 2.13 that NOTPPri cleared mainly by the endogenous faecal route, as 
did the other more lipophilic benzyl analogue. These complexes cleared rapidly; after 
24 hours most of the activity had cleared from the animal. These properties could 
allow selective imaging of the gall bladder and small intestine using such complexes. 
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F I G U R E 2.12 Biodistnbution of 67Ga complex of (16) at J and 24 hours. 
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2.2.5 R E L A T I V E L I P O P H I L I C I T Y S T U D I E S 
The partition coefficient P is a measure of the amount of a compound dissolved in one 
solvent phase relative to another solvent phase under equilibrium conditions. Here the 
partition coefficients between octanol and water, octanol and phosphate buffered saline 
(PBS), butanol and water, and butanol and PBS are considered as a means of 
comparing lipophilicities of different complexes. PBS was chosen because, being 
buffered at pH 7.4. it provides a better comparison with physiological conditions. 
The relative lipophilicity of the indium-111 complex of (16) was compared with that of 
other 9N3 complexes at the MRC Radiobiology U n i t 2 2 as shown in figure 2.14. A 
reasonably good correlation between the log P values and the route of elimination f rom 
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a mouse that had been injected with the corresponding radiolabeled complex was 
observed. A high (more positive) log P value relates to increased lipophilicity. Table 
2.14 confirms that lipophilic compounds are more likely to be eliminated from the body 
by the hepato-biliary route than the renal route. 
F I G U R E 2.14 Correlation of excretion pathway with partition coefficient (log 
P) for 1 1 1 In labelled 9N3 comple xes 
Loe P 
Octanol- Octanol- Butanoi Butanol- In.9N3 
water PBS -water PBS complex 
-4.51 -4.92 -2.54 -2.98 NOTA (1) 
-3.68 -3.80 -1.88 -2.06 NOTPMe (2) 
-3.62 -3.38 -1.79 .1 TO NOTAMe (5) 
-1.89 -1.92 -0.98 -0.99 NOTPPri (16) 
- -1.34 - - NOTAPh (6) 
+0.10 +0.13 +0.54 +0.34 NOTPBz (4) 
+0.24 +0.33 +0.63 +0.49 NOTPPh (3) 
2.3 A C Y C L I C L I G A N D S 
2.3.1 L I G A N D S F O R G A D O L I N I U M 
Contrast agents for Magnetic Resonance Imaging (MRI) are paramagnetic substances 
that enhance water proton longitudinal (Ti ) and tranverse (T2) relaxation rates. 2 3 Many 
studies have been carried out using Gd ( I I I ) since it is a nine coordinate, spin 7A? 
paramagnetic ion which combines a high magnetic moment with a long electronic 
relaxation time (x s = I0~9s), two features that ensure effective nuclear spin relaxation. 2 4 
Several Gd (III) complexes are now routinely used in clinical practice. 
Macrocyclic and acyclic complexing agents for gadolinium are mainly based on 
diethylenetnamine pentaacetic acid (DTPA) or 1,4.7.10-tetraazacyclododecane 
tetraacetic acid (DOTA) and their analogues. Current examples of commercially 
available compounds are DTPA itself which is marketed by Schering as "Magnevist" 
and DTPA bis methyl amide marketed by Nycomed as "Omniscan". These are less 
stable in vivo compared to the DOTA complexes Gd-DOTA marketed as "Dotarem" 
and Gd-HPD03A marketed as "Prohance" also shown. However they are cheaper and 
CHAPTER 2: Synthesis, Structure and Biodistribution of Simple Complexes ofGa, In, Gdand Y 57 
easier to produce, and since they are cleared from the body relatively quickly they are 
well tolerated and their toxicity is surprisingly low. 
F I G U R E 2.15 Commercially available complexing agents for Gd. 
H 0 2 Q R = Me 
C 0 2 H 
H 0 2 C 
•N 
H 0 2 C ' 
H 0 2 C ' 
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C 0 2 H C 0 2 H 
N N 
•N N-
DTPA 
"Magnevisf 
(Scherinq) 
N CONHR 
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C 0 2 H M c " 
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C 0 2 H C 0 2 H I D o t a r e m . C 0 2 H C 0 2 H 
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Other compounds based on the acyclic DTPA backbone are being developed; these 
include BOPTA produced by the Italian company Bracco of M i l a n 2 5 and EOBDTPA 
produced by Schering 2 6, both of which have been approved for clinical use. 
F I G U R E 2.16 Lipophilic anionic complexing agents approved for clinical use. 
P h ' ^ 0 ^ \ ^ C 0 2 H 
H 0 2 C x f ^ N ^ C O j H 
-N 
N 
s C 0 2 H 
H 0 2 C 
"BOPTA" 
EtO 
H 0 2 Q 
0 ^ \ ^ C 0 2 H 
N 
-N 
^ C 0 2 H 
H 0 2 C 
"EOBDTPA" 
However both of these are lipophilic anionic compounds which causes some 
advantages and disadvantages. The advantage of the lipophilicity is that they clear with 
some selectivity via the biliary system by being taken up into the liver by the "organic 
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ion transporter" 2 7 but they still have the disadvantage as dianionic complexes of the 
hyperosmolality of their aqueous solutions. 2 8 
It seemed desirable therefore to target the lipophilic neutral complex DTPA-bis benzyl 
amide (19) as a potential contrast agent for the biliary system without the problems 
associated with ionic complexes. 
2.3.2 S Y N T H E S I S O F D T P A - B I S A M I D E 
When diethylenetnamine pentaacetic dianhydride in pyridine was treated with 
benzylamine in the presence of D M A P it gave the bis-amide (47) as a white solid from 
a solution at pH 3.5 in high yield. 
S C H E M E 2.4 
O r>co 0 H 0 
o -
N N 
C H ^ M H 2 0 
COoH N N C 0 2 H Pyridine 
DMAP CO N N N H o 
o o COoH 
O 
19 
2.3.3 Y T T R I U M C O M P L E X O F DTPA-BIS A M I D E 
It had previously been demonstrated that yttrium and gadolinium showed very similar 
complexation properties when comparing the crystal structures of G d . D O T A 2 9 and 
Y . D O T A 3 0 . In each case DOTA acts as an octadentate ligand with a ninth site 
occupied by water. In the case of the gadolinium complex of DTPA-bis(ethylamide) 
observed by Raymond 3 1 the gadolinium ion is in a nine coordinate ligand environment 
comprising the three amine nitrogens, three carboxylic acid oxygens, two amide 
oxygens, and one water molecule. It was anticipated that the DTPA-bis(benzylamide) 
ligand could also form a complex in a somewhat similar way with yttrium, with the 
advantage that NMR measurements could also be undertaken. 
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The yttrium complex (20) of (19) was formed by heating the ligand in dilute HC1 with 
yttrium nitrate. In the yttrium complex there was a marked coordination shift in the 
stretching frequency of the amide carbonyl band (37 cm"1 coordination shift) consistent 
with amide oxygen ligation. 
2.3.4 N M R EXPERIMENTS C A R R I E D O U T ON Y T T R I U M C O M P L E X 
The yttrium complex of DTPA bis-benzylamide (20) was characterised by 8 9 Y NMR, 
this clearly showed a peak at +80.0 ppm due to the desired complex. I f the ligand was 
heated for too long during complexation partial hydrolysis of the amide took place and 
a second peak was observed in the 8 9 Y N M R spectrum at 81.6 ppm due to the Y 
complex of DTPA. This 8 9 Y N M R data was compared with 8 9 Y data for a number of 
other Y cnmnexes *)s shown in figure 2.17. The absence of a pattern in the chernicai 
shifts showed that 8 9 Y NMR was not a useful diagnostic tool, although it was observed 
that the Y shift was the same in H2O as D?0 for each complex. 
F I G U R E 2.17 89Y NMR data for a range of Y complexes in D20.39 
Complex 8y (ppm) comment 
Y-EDTA- + 123.5 Same in H?0 
Y - D T P A 2 - +81.6 same in EbO 
Y-DTPA-bis(benzylamide) (20) +80.0 neutral complex 
Y-DOTA" + 111.8 quintet 
Y-DOTPMe- + 156.8 quintet 
Y-DOTPBz- + 152.8 same in H2O 
Y-N4P3CONBU2 + 168.3 neutral complex 
The 1 H N M R spectrum for the complex (20) was found to be quite complicated and 
broad. A series of spectra were obtained in D2O at various temperatures, 5°C, 10°C, 
20°C , 30°C, 40°C and 50°C in an attempt to achieve some resolution. Some further 
broadening of peaks was observed in the spectrum obtained at 5°C, but over this 
temperature range no coalescence was evident indicating that exchange was either very 
fast or very slow in the NMR time scale. An example of one of the spectra recorded at 
50°C is shown in figure 2.18. 
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F I G U R E 2.18 400MHz >H NMR spectrum of (20) in D20 obtained at 50°C 
during VT experiment. j 
i 
ill 
ft M 
y 
27 .24 
3».«2 
2.3.5 C R Y S T A L S T R U C T U R E O F Y T T R I U M C O M P L E X 
Crystals of the yttrium bis benzylamide complex formed overnight from the aqueous 
solution and the molecular structure was established by an X-ray single crystal 
diffraction study, and is shown in figure 2.19 and 2.20. 
Analysis of the bond lengths reveals short M - 0 bonds with a mean value of 2.33A in 
(20) compared to 2.36A and 2.41 A in Gd-DTPA-bis ethylamide and Gd-DTPA. The 
bonding of the negatively charged carboxylate and formally neutral amide groups with 
yttrium has essentially the same character as shown by the similar average M - 0 
distances. The mean M - 0 (amide O) distance was 2.35 A, and 2.33 A for the M - 0 
(carboxylate) bond length. The M - N bonds were longer by about 0.3A at 2.64A in (20) 
compared to 2.70 and 2.64 in Gd DTPA-bis ethylamide and Gd-DTPA. This 
demonstrates the comparative weakness and lability of the less polar M - N bonds in 
these strongly ionic complexes. Amides, and also sulphoxides have large dipole 
moments compared to alcohols, ethers and water for example. Among neutral donors, 
amides and sulphoxides are intrinsically good a-donors for charge dense cations. 
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F I G U R E 2.19 Molecular structure of [Y (19) (H20)].3H20 with hydrogens 
omitted except for the amide group. 
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F I G U R E 2.20 Hydrogen-bonding network in the structure of [Y (19) 
(H20)].3H20]; projection of the (01 1) plane 
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The favoured geometry, at the metal, of such 9-coordinate complexes can be a 
tricapped trigonal prism, as in the case of Gd-BOPTA or a monocapped square 
antiprism as in the case of (20). The chelating octadentate ligand coordinates the Y 
atom in a square-antiprismatic mode. The three amine nitrogen atoms and one carboxyl 
group oxygen comprise one square base of the antiprism, while oxygen atoms of the 
two remaining carboxylate groups and two amide groups form another base. The latter 
is capped by an aqua-ligand. Further details of this structural analysis are reported in 
appendix 1 and are discussed elsewhere.3 2 
F I G U R E 2.21 Tricapped trigonal prismatic Gd-BOPTA and monocapped 
square antiprism (20) 
OS 
HZ 
012 OS 01 
3d 
N1 
02 
ota 
Q2 
OS 
2.3.6 B I O D I S T R I B U T I O N O F DTPA-BIS B E N Z Y L A M T D E 
Until recently 2 7 there has been a lack of published data regarding the pharmacokinetic 
and pharmacological properties of potential MRI contrast agents based on Gd 
complexes of DOTA and DTPA. Two notable exceptions are G d - B O P T A 2 5 and Gd-
E O B D T P A . 2 6 These are both DTPA derivatives and show clearance by the hepato-
biliary pathway. Although the biodistribution pattern and excretion pathway of a 
compound cannot be predicted accurately from the charge or structure it was 
anticipated that the lipophilic neutral DTPA-bis benzylamide might behave in a similar 
way. 
Complexes were prepared using a mixture of stable and radioactive 1 5 3 G d at the M R C 
Radiobiology Unit. About 0.1 (iM of complex per kg body weight was injected into 
nude athymic mice. Biodistribution studies were carried out after 5 minutes in order to 
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determine the excretion pathway, and again at 24 hours as a means of determining how 
much Gd had dissociated and accumulated in the liver and bones. 
Figure 2.22 shows the 5 minute and 24 hour biodistribution of l 5 3 G d - D T P A - b i s 
benzylamide (21) showing the percentage of the injected dose in each tissue type. This 
clearly shows that this complex exhibits mildly hepato-philic properties, the liver, gall 
bladder and small intestine accounting for 10% of the injected dose. Figure 2.23 shows 
how this compares with Gd-DTPA and Gd-BOPTA in which the percentage of the 
injected dose in these tissues is 4 and 33% respectively. 
Figure 2.22 also shows the liver and skeletal content of 1 5 3 G d at 24 hours: at 2% of the 
injected dose this was more than twice the measured amount for either BOPTA or 
DTP A This inHir.ntp<; cnrtip dissociation of the comnlex v.'Vf?. akhcush rnuch less 
than the 74% observed for Gd-citrate. 
In this instance the lipophilic benzyl group was used with some success to target the 
hepato-biliary system. Because of the high dosage of contrast agent required in M R I 
the level of in vivo dissociation observed may render this complex less favourable than 
DOTA based macrocycles for development. However, possessing similar stability to 
the analogous methyl and ethyl amides in clinical use. it may be well tolerated because 
of its rapid excretion. This method of targeting using DTPA-bis amides is further 
developed in chapter 3. 
F I G U R E 2.22 l53Gd Biodistribution of bis benzylamide (21) at 5 mins and 24 
hours 
• blood 
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F I G U R E 2.23 5 minute l53Gd biodistributions of DTPA, DTPA-bis 
benzylcimide and BOPTA 
• blood 
kidney 
EH liver 
0 small intestine 
• large intestine 
DTPA DTPA-bis benzylamide BOPTA 
2.4 9N3 AND 12N3 B A S E D L I G A N D S F O R G A D O L I N I U M 
2.4.1 B A C K G R O U N D 
Current interest in lanthanide complexes as aqueous N M R shift reagents and M R I 
contrast agents has led to the synthesis of many new macrocycles derived f rom cyclic 
polyaza and cyclic polyaza polyoxa ligands with a wide variety of ionizable functional 
groups. The thermodynamic stability constants of these depend upon internal cavity 
size rigidity and the nature of donating atoms. Variation of stability constant with ionic 
radius of the lanthanides for four common ligands is shown in figure 2.24. 
Clearly Ln(NOTA) complexes are much less stable than DOTA and DTPA complexes. 
This is partly due to the fact that it is a hexadentate chelate, and partly due to the 
restricted size of the triazacyclononane ring. 
The work described in the following section examines a group of novel ligands based 
on the triazacyclononane ring, but incorporating a further three nitrogen donor atoms 
and a potentially larger cavity size for lanthanide complexation. 
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F I G U R E 2.24 Literature values for EDTA and DTPA 3 3 (open circles) and 
literature values for DOT A, DTPA and NOT A 3 4 (closed circles) of stability constant 
variation with ionic radius of lanthanides. 
Lo Ct Pr Nd S m E u G d T b O y H o E r TmYbUi 
DOTA 
24 
23 
DTPA 
22 
21 
20 
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19 
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13 
1.06 1.02 0.98 0.94 0.90 Q86 0.82 
Ln 3*radius (A) 
2.4.2 S Y N T H E S I S O F N O V E L 9N3 B A S E D L I G A N D S 
1,4,7-Triazacyclononane (7) was heated to reflux in acetonitrile with potassium 
carbonate and 2-bromo-N-methylethanamide for 24 hours. This afforded the white tns-
amide (22), recrystallised from toluene in 69% yield. Initial attempts to reduce the tris-
amide to the desired tris-amine using sodium borohydride resulted only in a small 
quantity of an intractable pale yellow oi l . However heating to reflux with l i thium 
aluminium hydride in diethyl ether, followed by careful quenching and fil tration 
provided tris-amine (24) in 25% yield. Yields were not optimised but it was believed 
that this relatively low yield was due to the amine being more soluble in water than the 
organic solvents into which it was extracted. It was observed that this compound was 
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somewhat unstable to prolonged storage in air. After a short period the oil became 
discoloured and the accurate mass was unable to be measured. 
The benzyl derivative (23) was synthesised using 2-chloro-N-benzylethanamide in the 
method of (22) and purified by column chromatography in 29% yield. Reduction using 
U A I H 4 afforded tris-amine (25) in 73% yield. 
The introduction of carboxymethyl groups was effected by reaction of amine (24) with 
ethyl bromoacetate (K2CO3, MeCN, 40°C, 3 hours) to afford the triester (26). In the 
same way amine (25) was converted to the triester (27) in 77% yield fo l lowing 
purification by alumina column chromatography. Acid hydrolysis of the latter (6M 
HC1. 24 hours) gave the acid (28) quantitatively. 
Complexation was carried out by reaction of 1.2 equivalents of gadolinium oxide with 
ligand (28) (pH 2. 80°C) until a clear solution was obtained. The pH was adjusted and 
heating continued (pH6. 80°C, 3 hours) to give the desired complex (29) in a 15% yield 
after preparative tic. 
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2.4.3 B I O D I S T I B U T I O N S T U D I E S O F Gd-9N3N3 C O M P L E X 
The biodistribution of the 1 5 3 G d complex of (28) in mice was studied at 5 minutes and 
24 hours after administration of a 0.1 (imol/kg dose of complex. The percentage dose 
in the whole tissue for several types of tissue was studied, the five minute results 
showed little or no preference between clearance by the hepato-biliary route (14% of 
dose) and renal clearance (13% of dose). The biodistribution after 24 hours showed 
that much of the complex had cleared from the animal, however the high percentage in 
the liver and the skeleton indicated that the complex may be somewhat labile and free 
gadolinium was being retained in these tissues. 
F I G U R E 2.25 5 minute and 24 hour hiodistribution of !^Gd in mice after 
administration of OA jlmoi/kg dose. 
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The 0.1 (imol/kg dose of complex administered was relatively low so a further 
biodistribution study was carried out using a sample of radiolabeled complex 
combined with cold gadolinium complex allowing the larger dose of 50 u,mol/kg to be 
administered. The study was also extended to a third time point at seven days. Data 
for the high dose support the findings at the low dose. i.e. retention of gadolinium in the 
skeleton, as shown in figure 2.26. The percentage dose per gram in the femur at seven 
days actually exceeded that at 24 hours while the amount in the liver decreased, this 
was probably due to gradual clearance of Gd from the liver into the blood stream 
followed by re-location in the bone in a similar manner to that observed in the case of 
Gd-DTPA. The relative instability of this complex in vivo may make such a ligand 
undesirable for use as a contrast agent. 
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F I G U R E 2.26 5 minute, 24 hour and 7 davs hiodistribution of 15^Gd in mice 
after administration of 50flmol/kg dose. 
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2.4.4 S Y N T H E S I S O F 12N3 A N A L O G U E 
It was proposed that the 1,5,9-triazacyclododecane ring with its larger cavity size may 
provide a better foundation upon which to build a ligand for complexation of 
gadolinium. A synthetic route somewhat similar to that used for the triazacyclononane 
analogue was employed. 
1,5,9-Triazacyclododecane was heated to reflux in dry ethanol with potassium 
carbonate and 2-chloro-N-methylethanamide for 24 hours. After alumina column 
chromatography this gave a 50% yield of the amide (30). Reduction using LiAlH4 in 
diethyl ether afforded amine (32) in 63% yield. The benzyl derivatives were prepared 
in an analogous way, using 2-chloro-N-benzyiethanamide to provide a 74% yield of 
amide (31), and amine (33) in 6 1 % yield. 
Trialkylat ion of the secondary amine sites of (32) with ethyl bromoacetate in 
acetonitrile in the presence of potassium carbonate gave the triester (34) in 93% yield. 
However the remainder of the synthesis was carried out on the benzyl derivative only 
since it became apparent that the chromophore would be necessary for HPLC 
purification in later stages. 
Treatment of the amine (33) with ethylbromoacetate (ethanol, K2CO3, 50°C, 3 hours) 
to yield the triester (35) (74% after alumina column chromatography), or with t-
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butylbromoacetate (ethanol, K 2 C O 3 , 40°C, 18 hours) to yield the triester (36) ( 8 1 % 
after flash silica column chromatography) appeared to be successful (from N M R and IR 
spectra) although some difficulty was experienced in attempts to obtain accurate mass 
spectra on these molecules having masses of 828 and 914 respectively. These 
difficulties may be due to the problems associated with obtaining a high degree of 
accuracy at such high masses, or due to the structure of the molecules themselves, each 
containing labile ester groups. Each of the esters (35) and (36) underwent acid 
hydrolysis (6M HC1, 110°C, 48 hours) quantitatively to give the same acid (37) which 
was purified by semi preparative HPLC. Unfortunately, due to the use of such a weak 
chromophore, recovery of the material was poor owing to the difficulty of detection and 
collection. 
S C H E M E 2.6 
C I C H , C O N H R n 0 o M e C N or E tOH H 
3 N KoCO c N N c N H H H 
30 R = M e H 
N 
31) R = B z 
O 
UAIH4, E t 2 0 B r C H 2 C H 2 C 0 2 R 
E t O H , K 2 C O M e N M e N 
N O R 
0 
N N N C J N O H O R H N M e O R ' H 32) R = M e O N (34 R'=Et 33) R = B z R 
B r C H 2 C H 2 C 0 2 R ' 
EtOH, K2CO 
6 M HCI, A N Bz B z ay N B z N B z NT N 1 O R ' V_C0 2 H HPLC CO,H O O R ' 
Bz COoH B z O R 
37 O 35) R'=Et 
(36) R '=Bu ' 
The samples obtained were used in attempts to form a gadolinium complex in the 
method of (28) and in the labelling method employed by the MRC radiobiology unit for 
forming l 5 3 G d complexes. However after the standard time period for complexation, 
and also after heating to reflux for a further week, no Gd complex was observed. It was 
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proposed that the complex failed to form because of the high energy barrier to removal 
of the tightly bound H + in the plane of the ring nitrogens and replacement with G d 3 + . 
It had previously been observed 3 5 in the case of triazacyclododecane itself and its 
derivatives that this bifurcated H bond was very strong and a p K a as high as 13 has 
been determined. 
2.4.5 SYNTHESIS OF PHOSPHINIC ACID ANALOGUES 
The ability of azaphosphinic acid ligands to form stable complexes has already been 
discussed in section 2.2. An intrinsic advantage of the -NCtbPRCbH moiety over 
C H 2 C O 2 H is that structural variation is readily achieved at the P-R group. This allows 
for example, groups with chromophores to be incorporated in a ligand to facilitate 
HPL f~ pur i f '~" r ' n r i ~ r r n fr.fli'pr!."." the srshihSlifv n f r. Hcnnjj T h e .;vnfhf»<;i t; o f ! i c a n d c 
based on two ring systems triazacyclononane and triazacyclododecane, and using two 
different dialkoxyphosphines are described below. 
SCHEME 2.7 
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Scheme 2.7 shows that having started with 1,4,7-triazacyclononane the amine (25) was 
synthesised as described in section 2.4.2. Condensation of paraformaldehyde and (25) 
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in dry tetrahydrofuran followed by addition of methyldiethoxyphosphine, synthesised 
using the standard procedure from diethylchlorophosphite and methylmagnesium 
bromide, gave the triphosphinate ester (38) in a yield of 69% following alumina 
column chromatography. Base hydrolysis (MeOH, 1M KOH, reflux. 16 hours) was 
followed by HPLC purification to yield the aminophosphinic acid (39). 
Similarly in scheme 2.8 the route beginning with triazacyclododecane is described. In 
this case condensation of paraformaldehyde and amine (33) in tetrahydrofuran is 
followed by addition of benzyldiethoxyphosphine providing the triphosphinate ester 
(40) in a low yield following column chromatography. Acid hydrolysis was employed 
(6M HCI, reflux, 20 hours) to yield the aminophosphinic acid (41) quantitatively as the 
dihydrochloride salt. 
S C H E M E 2.8 n C I C H 2 C O N H R 0 O M e C N or E tOH 
K2CO N H R N 
O 
N N c H H (30) R = M e H 
O (31) R = B z 
R 
R ' P ( O E t ) 2 
( C H 2 0 ) n 
LiAIH4, E t 2 0 
(40) R '=Bz 
N Bz B z N N R 
\—p'=o 
R = 0 N—> OEt 
OEt Bz P = 0 
'R '  OEt 
6 M HCI, A 
N B z Bz N NT 
V-PROoH 
PRO,H 
THF, 4A S ieves N 
H 
^ — N H 
R 
(32) R = M e 
(33) R = B z 
Bz P R 0 2 H 
(41) R '=Bz 
2.4.6 Y T T R I U M COMPLEXATION 
Since yttrium (III) often exhibits similar complexation chemistry to gadolinium (II I ) (as 
explained in section 2.3.3) it was decided to examine the yttrium complex formation of 
the aminophosphinic acids (39) and (41). It was hoped that 3 1 P N M R would provide a 
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useful tool to follow complex formation and that shifts observed in ' H N M R spectra 
may provide additional information. 
The exploitation of anhydrous lanthanide triflate salts in organic synthesis was reported 
by Forsberg. 3 6 Yttrium triflate (42) was also found to behave in a similar fashion. 
These triflate salts were prepared by treating the oxide with concentrated 
trifluoromethanesulfonic acid and the resulting hydrate dried by heating under vacuum. 
These salts were soluble in organic solvents such as methanol and acetonitrile, indeed 
anhydrous conditions were required to prevent formation of insoluble lanthanide 
hydroxides. 
The use of lanthanide triflates in organic solvents to produce macrocyclic lanthanide 
complexes has also been reported.-7 Here work towards forming yttrium complexes in 
a similar way is described. Initially the well known Iigand DOTA was heated in 
methanol with yttrium triflate and the complex produced (43) 3 8 was characterised and 
compared with an authentic sample of Y-DOTA to verify that this was a viable route to 
such yttrium complexes. 
The triazacyclononane based phosphinic acid ligand (39) was heated with an equimolar 
quantity of yttr ium triflate in methanol. The resulting white complex (44) was 
separated by centrifuge. The triazacyclododecane analogue (45) was prepared using 
the above method from ligand (41). These complexes were examined by 3 1 P N M R and 
' H N M R and IR specrometry. In each case a shift was observed from the ligand 
spectrum, however owing to the difficulty encountered in obtaining FAB mass spectra 
these structures could not be unequivocally assigned. 
2.4.7 CONCLUDING COMMENTS 
While this series of novel ligands for Gd and Y initially showed some interesting 
properties in the instance of (27), problems encountered in purification, with solubility 
and also in complex formation indicate that ligands of this form would not be useful for 
tumour imaging techniques. However there is still scope for modification of this basic 
structure to provide a more suitable ligand. 
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3.1 NITROIMIDAZOLES AS T A R G E T I N G AGENTS 
76 
It has been established that nitroimidazoles tend to localise in poorly oxygenated cells of 
normal and malignant tissues. This binding is related to the presence in the cells of 
reductase enzymes; the effect of these enzymes is enhanced in areas of low oxygen 
tension. 
Misonidazole (45) has been shown to be retained preferentially in oxygen deficient 
(hypoxic) regions of rumours. This work was conducted using both 1 4 C and 3 H labelled 
misonidazole.1 A number of fluorine derivatives of misonidazoie have recently been 
synthesised and studied as potential imaging agents using 1 8 F in PET imaging or 1 9 F for 
possible MRI. 2 - 3 - 4 
F I G U R E 3.1 Misonidazole (45) and three fluorinated derivatives. 
The possibility of targeting hypoxic tumour tissue by conjugating a suitable complexing 
agent to a nitroimidazole has already been surveyed briefly in section 1.5.3.3 with some 
promising outcomes. In this section, conjugates of a 2-nitroimidazole with bifunctional 
complexing agents known to form kinetically stable complexes with n l I n , 6 7 G a or Gd 
are discussed. Biological studies were also carried out at the MRC Unit to determine 
whether attachment of the complexing agent affected the tumour localising properties of 
the 2-nitroimidazole. 
3.1.2 H Y P O X I C C E L L S FOR B I O L O G I C A L STUDIES 
In vitro studies comparing hypoxic and normoxic conditions have been carried out. 
Chinese hamster lung fibroblasts (V-79 cells) were incubated with the radiolabelled 
complex to be tested under either hypoxic (N2 / CO2) or normoxic (air / CO2) conditions. 
— \ OH OH 
N N N N OMe 
r 
N O 2 N O 2 Misonidazole (45) 
OH PF3 
0 2 N N N 0 r N - C y N CF vi 1 r u N N0 2 
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The uptake and retention of the complex in the cells was measured by comparing the ratio 
of activity in cells with that in to the incubation medium. For example in the case of 
tritium labelled misonidazole5 the ratio of activity in the cells to that in the medium was 
5.6 : 1. Later studies revealed that 3 H misonidazole also binds under normoxic 
conditions, showing that further investigations were necessary into suitable in vitro 
experiments. 
In vivo studies required a tumour type with a high degree of hypoxic tissue. A number 
of studies have been carried out using KHT sarcomas6 which typically possess about 
10% hypoxic cells, although other research has suggested that 15-20% hypoxia is 
common. This figure varies, however, depending on the stage of the cell cycle (the 
majority of hypoxia being found in the Gi stage). It may also be altered by addition of 
hydralazine which induces 100% hypoxia within 1 hour of administration.7 
3.1.3 PREVIOUS N I T R O I M I D A Z O L E - M A C R O C Y L E CONJUGATES 
Some pilot studies8,9 have been carried out on conjugates (46) and (47). Since the 
molecular weights of radiometal complexes are three or four times greater than 
nitroimidazoles, such as misonidazole, it was necessary to demonstrate whether the 
attachment of a radiometal complex reduced the binding efficiency or tumour localisation 
of 2-nitroimidazole in vitro or in vivo. The results were compared with radiolabelled 
misonidazole and with the simple complexes of NOTA and DOTA. 
F I G U R E 3.2 Previous nitroimidazole - macrocycle conjugates. 
C 0 2 H 
^ - N N--j C ° 2 H 
C 0 2 H 
1 5 3 G d 3 + 
N—C 
H02C L^yHy 
( 4 7 ) HO2C 
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It was shown that 1 5 3 Gd-(46) and 6 7 Ga-(47) were cleared via the intestinal tract 
(duodenum to large intestine) six to eight times more than 1 5 3 Gd-DOTA and 6 7Ga-NOTA 
were cleared by the same route. The reason for this difference is unclear, however it is 
the first indication that the metabolism of the 2-nitroimidazole complexes is at variance 
with the complexes alone and bears some resemblance to the metabolism of misonidazole 
(45). Excretion via the intestinal tract is one characteristic of misonidazole although 
urinary excretion predominates. 
Compound (46) forms an anionic complex with ^ G d . This consequently was not 
readily taken up by cells and was excreted rapidly. NOTA and the 9N3 conjugate (47) 
on the other hand are charge neutral complexes and are able to diffuse passively into 
cells. In mice bearing the human melanotic melanoma, HX-118, some modest tumour 
localisation was noted for 6 70a-(47); indeed the tumour to blooH ratio w a s higher than 
for tritium labelled misonidazole. A satisfactory explanation for the greater uptake by the 
tumour and tumour / blood ratios of 6 7Ga-(47) and 6 7 Ga-NOTA 1 0 recorded in figure 3.3 
has not yet emerged. The possible application of 9N3 trivalent metal complexes for 
imaging melanoma cannot be dismissed, however it was clear that more extensive studies 
had to be carried out. 
F I G U R E 3.3 Biodistribution in tumour bearing mice of67Ga-(47) compared 
to 67Ga-NOTA and 3H-(45) 
67Ga -NOTA 67Ga -(47) 3H-(45) 
Time (Hours) 4 8 24 4 8 24 24 
Blood (% 
dose/g) 
0.006 0.008 0.0022 0.008 0.005 0.0016 0.0018 
HX118 (% 0.127 0.097 0.042 0.085 0.075 0.022 0.014 
tumour dose/g) 
tumour ratio 21.6 14.8 19 14 15.8 14.0 7.70 
blood 
Following these results it was decided to target the following molecules (48)-(51) as 
primary synthetic goals. It was expected that they would form neutral complexes with 
either In, Ga or Gd making them suitable for tumour diagnosis using SPECT or MRI. 
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F I G U R E 3.4 Target molecules (48) - (51). 
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3.2 A C Y C L I C DTPA - NITROIMIDAZOLE CONJUGATES 
3.2.1 SYNTHESIS O F DTPA - BIS N I T R O I M I D A Z O L E AMIDE 
The nitroimidazole amine (53) was prepared by treating 2-nitroimidazole (azomycin) 
with potassium t-butoxide in DMF to generate the anion and addition of N-(3-
bromopropyl)phthalimide provided the white solid intermediate (52). Deprotection by 
hydrazinolysis gave the desired l-(3-aminopropyl)-2-nitroimidazole (53) in good 
yield.11.12 
S C H E M E 3.1 
t (i) Bu'OK, DMF 
N 0 2 NO? 
JL 2 (ii) Br(CH 2) 3NPhth i^fjVx 5!°* H 2 N N H 2 
^ / = < L V ^ N 
Phth ^ As H N HoN N 
o 53) 
azomycin 
Following the successful synthesis of the DTPA-bis benzylamide (19) the analogous 
reaction with l-(3-aminopropyl)-2-nitroimidazole was attempted. Diethylenetriamine 
pentaacetic dianhydride in pyridine was treated with the nitroimidazole amine (53) in the 
presence of DMAP. Upon work up some white solid did precipitate from methanol in the 
presence of sulphuric acid. This was not the methyl ester as hoped, and was suspected 
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to be the sulphate salt. The desired DTPA bis amide (48) was separated using semi-
preparative reverse phase HPLC, and was isolated as a pale yellow oil in 64% yield. 
S C H E M E 3.2 
0 NO 
r—N N X N 
' ^ 0 HO?c 
J -NO W N 
^ N 
H N 
HoN N 
(53) W 48) N C 0 2 H COoH N 
Pyndine NO mu2 DMAP N 
N O N 
H0 2 C O H 
3.2.2 C O M P L E X A T I O N 
The Gd complex of the DTPA-bis amide was prepared by heating the bis-amide (48) to 
reflux in dilute HCI (pH 2) with gadolinium oxide for 2 hours. After adjusting the pH to 
6 the solution was allowed to cool. As no precipitate formed the product was purified 
using semi-preparative reverse phase HPLC (under the standard conditions, but in the 
absence of TFA) to give the white solid complex (54). The corresponding terbium 
complex was prepared by heating the DTPA-bis amide (48) to reflux in water with 
terbium acetate for 2 hours. The pH was adjusted to 6, the solution cooled and purified 
by HPLC, the terbium complex (55) was isolated as a white solid. 
3.2.3 L U M I N E S C E N C E STUDIES ON T E R B I U M C O M P L E X 
3.2.3.1 LANTHANIDE L U M I N E S C E N C E AND ITS USES 
The luminescence properties of the lanthanide series have been thoroughly 
investigated.13-14 The central five members of the series in particular, Sm 3 + , E u 3 + , 
G d 3 + , T b 3 + and Dy 3 + ; all show long-lived luminescence, although the remainder of the 
series rarely luminesce. Some of the characteristics of these luminescent lanthanides are: 
1) Large Stokes shifts, of the order 250-350nm. 
2) Long-lived luminescence (of the order of milliseconds), allowing 
monitoring after short-lived background fluorescence has decayed. 
3) Narrow lines in the emission spectrum. 
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4) They are very poor light absorbers, (e typically < 1 dm^moHcnr1), so 
they are difficult to excite by direct irradiation unless laser sources are 
used. 
Luminescent lanthanides have found uses as probes in biological systems such as in 
fluoroimmunoassays, replacing conventional fluorescent organic molecules such as 
fluorescein as lumophores. The fine structure of the spectra and the measured lifetimes 
also provide information about local site symmetry and coordination number. 
3.2.3.2 T E R B I U M C O M P L E X CONTAINING N I T R O I M I D A Z O L E 
ANTENNA 
The luminescence propciiies of the ianchanides described above make them highly 
suitable as lumophores with the singular disadvantage that they are very poor light 
absorbers. To make use of their emitting properties it is necessary to indirectly populate 
the excited states. One way of achieving this involves complexation with a ligand which 
incorporates a suitable chromophore, or antenna. A suitable chromophore must absorb 
strongly at a given wavelength such that efficient energy transfer may take place from the 
triplet excited state of the chromophore to the emissive state of the metal (5D4 in the case 
of Tb). 
F I G U R E 3.5 Ultra-violet spectrum ofTb complex of DTP A bis nitroimidazole 
amide (55) 
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In an attempt to determine whether the 2-nitroimidazole chromophore might behave in 
this way, studies were carried out on the T b 3 + complex (55). The ultra-violet spectrum 
shows a strong absorbance at 320nm characteristic of 2-nitroimidazole. However the 
luminescence quantum yield (<j) D20 2 9 8 K ) proved to be low. 
3.2.3.3 D E T E R M I N I N G T H E N U M B E R O F C O O R D I N A T E D 
W A T E R M O L E C U L E S 
It has been observed that the luminescence lifetimes and intensities of Eu and Tb 
complexes are often much greater when measured in D2O than H2O. This occurs 
because there exists a radiationless deexcitation pathway from the lanthanide emissive 
level via energy transfer to the high energy O-H vibrations of coordinated water. The O-
H oscillator then rapidly loses energy to the surroundings. This process takes place to a 
much lesser extent in the case of O-D owing to poorer Franck-Condon overlap of 
vibrational wavefunctions.15 
Horrocks 1 6' 1 7 has exploited this difference in excited state lifetimes as a means of 
calculating the number of water molecules directly coordinated to the lanthanide ion. A 
brief summary of the method follows: 
The rate of depopulation of the emissive state, kd e p 0p, is the reciprocal of the observed 
excited state lifetime, T0hs> and is the sum of several terms including koH- The term koH 
is the rate constant for energy transfer to O-H oscillators and when the lifetime is 
measured in D2O the koH term vanishes. The value of koH m a v be calculated by 
measuring the lifetimes in both H2O and D2O and using the equations: 
The number of water molecules, or number of O-H oscillators, in the first coordination 
sphere, q, is proportional to koH- In the case of Tb3 +< the empirical proportionality 
constant is 4.2 and in the case of E u 3 + it is 1.05: 
koH = Ax-1 = W H 2 O ) - 1 - T 0bs(D 20)-l (1) 
q-Tb = 4.2 koH = 4.2 [T(H 20)-1 - T(D 20)-1] (2) 
q E u = 1.05 kQH = 1-05 [T(H20)"1 - x(D 20)-l] (3) 
This method was employed to determine the number of water molecules directly bound to 
the T b 3 + ion in the DTPA bis nitroimidazole amide complex. The luminescence 
properties of the complex were studied using a Perkin-Elmer LS50B. Lifetime 
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measurements were carried out by monitoring the luminescence intensity after a range of 
delay times. The minimum possible gate times were used, whilst still allowing 
reasonable emission intensities, thereby reducing the uncertainty in the luminescence 
intensity. The emission spectrum (figure 3.6) shows the expected bands typical of Tb 
complexes involving transitions from the emissive state (5D4) to the ground state ( 7 Fj, J 
= 0,1,2,3,4). The excitation spectrum (figure 3.7) does not match the absorption 
spectrum of the nitroimidazole, clearly indicating that energy transfer does not occur from 
the nitroimidazole moiety. It is probable that energy transfer occurs from a charge 
transfer state, (LMCT). 
F I G U R E 3.6 Corrected emission spectrum of (55) in H2O (excitation 
wavelength 320nm, delay time 0.1ms, gate time 10ms, 293K) 
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The luminescence intensity (It) (at 545 nm) in water at a range of times (t in ms) was 
recorded following pulsed excitation at 320nm: it showed exponential decay, consistent 
with first order kinetics of deactivation. These relate to the lifetime (x) by the equation 
(4): 
I T = Ioe-«ft 
In I T = In IQ - t/t (4) 
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F I G U R E 3.7 Phosphorescence excitation spectrum of (55) (emission 
wavelength 545nm, delay time 0.1ms, gate time 10ms, 293K) 
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F I G U R E 3.8 Comparison of corrected emission spectra for (55) measured (a) 
in H2O (lower peaks) and (b) in D2O (upper peaks), excitation wavelength 320nm, delay 
time 0.1ms, gate time 10ms, 293K. 
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Plotting In I t against t for a range of different excitation wavelengths allowed an average 
value for T to be calculated from the gradient The procedure was repeated for a solution 
with an equal absorbance at the excitation wavelength in D2O; the upper trace in figure 
3.8 clearly shows the greater intensity observed in D2O as a solvent, compared to the 
lower trace observed in H2O. 
The values calculated were x (H2O) = 1.49 ms and t (D2O) = 2.22 ms. Using equation 
(2) the number of water molecules (q) was calculated as 0.9. Given the experimental 
uncertainty in these measurements, this result is a clear indication that the complex 
possesses one bound water molecule. 
For many ligands the Gd complex and Tb complex are isostructural.18 This allows 
deductions ahout the Gd complex to be made based on independently determined 
properties of the Tb complex. In simple Gd complexes, the value of the relaxivity at high 
field is mosdy a function of q and the rotational correlation time, with complexes having 
bound water molecules generally displaying higher relaxivities. Since the Tb complex 
(55) possesses one bound water molecule it may be anticipated that the Gd complex 
(54) will also have one coordinated water making it an attractive candidate as an 'inner 
sphere' contrast agent. 
3.2.4 BIODISTRIBUTION STUDIES ON G A D O L I N I U M COMPLEX 
The biodistribution of the 1 5 3 G d complex of DTPA-bis nitroimidazole amide was 
examined in mice. Immunocompetent mice bearing a xenograft of a KHT sarcoma, a 
tumour type in which the proportion of hypoxic cells is particularly high, were used in 
these studies. 
Because the dose of nitroimidazole conjugate to be administered was relatively low, it 
was administered along with a larger dose of misonidazole (100u.mol kg - 1 ) in order to 
avoid the premature bioreduction of the nitroimidazole within the conjugate in the 
bloodstream. A control experiment was also carried out using 1 5 3 Gd-DTPA, co-
administered with the same proportion of misonidazole. 
The neutral 1 5 3Gd-(48) conjugate was slower to clear from the blood than the control 
[ 1 5 3 Gd-DTPA] 2 _ as might be expected. Figure 3.9 shows the percentage dose per gram 
of tissue at 4 and 24 hours for 1 5 3Gd-(48) and 1 5 3Gd-DTPA. The principal differences 
lie in the lower concentration of l 5 3 G d in the blood, femur and tumour of the control 
mice. The greater retention of 1 5 3 G d in the skeleton of the mice given the nitroimidazole 
conjugate at 4 and 24 hours is consistent with release of 1 5 3 G d from the complex. 
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The ratio of the percentage dose per gram of tissue for the experimental versus control is 
shown in figure 3.10. This shows that the tumour uptake of 1 5 3 G d in the experimental 
group was marginally greater than in the control, but taking into account the greater blood 
level in the experimental mice, the comparison reveals that it is unlikely that there is 
significant tumour localisation due to the nitroimidazole groups. 
FIGURE 3.9 Biodistribution of (a) 153Gd-DTPA-nitroimidazole amide and (b) 
153Gd-DTPA in mice bearing the murine KHT sarcoma. 
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FIGURE 3.10 Biodistribution of [153Gd(48)J compared to [153Gd-DTPA]2' in 
mice bearing a KHT tumour (ratio of experimental to control, % injected dose per g 
tissue) 
Tissue 4 hours 24 hours 
Blood 7.1 20 
Kidneys 1.6 1.1 
Liver 1.1 1.0 
Spleen - 0.18 
Femur 4.7 5.6 
Tumour 1.9 1.5 
The interior in vivo stability of DTPA-bis amide complexes compared tc DTPA 
complexes themselves has been noted previously1 9-2 0 and is manifested by deposition of 
the radiolabel in the bone. This disadvantage may reduce tne clinical usefulness of this 
complex in the long term. On the other hand the release of a small amount of 1 5 ^Gd does 
not compromise tumour uptake. Since this complex is relatively cheap and accessible, 
and is cleared from the body relatively quickly it may still find uses in future exploratory 
studies to determine the usefulness of 2-nitroimidazole as a tumour targeting vehicle. 
3.3 12N3 - N I T R O I M I D A Z O L E CONJUGATES 
3 .3 .1 SYNTHESIS OF C-FUNCTIONALISED DERIVATIVES OF 12N3 
Hexadentate macrocycles are also known based on N - and C- substituted 12N3 
ligands.2 1 The 12N3 triacetate derivative n i I n complex has already been shown to be 
kinetically stable in vivo.22 In order to direct the 1 1 *In gamma emitter towards hypoxic 
tissue the synthesis of the novel target ligand (49) was attempted. 
The starting diamide (56) had already been synthesised by reaction of the p-cyanobenzyl 
derivative of diethyl malonate with triazanonane.23 Tosylation of (56) using toluene-p-
sulphonyl chloride and triethylamine in dichloromethane gave (57) quantitatively. This 
sequence of reactions, avoiding direct borane reduction of (56), avoids the possibility of 
formation of a robust boron complex during borane reduction and led to the formation of 
the N-tosylamide (58) in 79% yield. Detosylation with hydrogen bromide in the 
presence of phenol yielded the tetra-amine (59) (62%). 
88 CHAPTER 3: Nitroimidazole Conjugates 
SCHEME 3.3 
TsC 
Et,N 
H H CHpCIp c N N O CN CN N 5s. 
H 6 H 
(56) 57) 
Q 
BH 3 
H HBr/ acetic acid H .H N N phenol N C NH NH 2 N 
H H 
The route to the target 12N3 - nitroimidazole conjugate required coupling of the tetra-
amine (59) with an imidazole acid. The acid chosen was 2-nitroimidazole-1 -acetic acid 
(60) which was synthesised from 2-nitroimidazole by the route shown in scheme 3.4. 2 4 
The coupling techniques initially employed involved coupling in the presence of DCC or 
reaction with the p-nitrophenol active ester of the nitroimidazole acid. 
SCHEME 3.4 
f = \ t-BuOK, DMF f = \ Q T F A f = \ 
N V N - H N V N ^ ' B U ' - N V N ^ . C 0 2 H 
N 0 2 BrCH 2C0 2Bu< ^ 0 J 0 z ( 6 Q ) 
Initial attempts at reaching target (49) involved protection of the tetra-amine (59) with 
molybdenum hexacarbonyl in n-butyl ether leaving only the remote amine group to 
undergo amide coupling with 2-nitroimidazole-1-acetic acid under standard DCC 
conditions. However attempts by this method failed to produce a significant amount of 
the desired compound (62). It was thought that this was due to the air-sensitivity of the 
molybdenum complex (61), and the difficulty in monitoring the reaction's progress. 
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SCHEME 3.5 
89 
(59) 
Mo(CO)6 
Bu n 2 0 
NH; 
H x jhL.Mo(CO)3 
(62) 
(i) DCC 
DMF 
DMAP 
(ii) H + /H 2 0 
n . . H N N 
H 
N ^ N v C ° 2 H 
N 0 2 (60) 
r=\ 
N-C. > J v X N 
H O NO, 
SCHEME 3.6 
H ^ H 
H:N N-H 
H 
(59) 
TFA H , n . . H 
p-nitrophenol 
THF 
DCC, DMAP 
l . H . N 
NH 2 
(63) 
N y N ^ C 0 2 H 
N 0 2 (60) 
+ 
r=\ ° 
n V nA-Q-NO 2 
N 0 2 x — J 
(64) 
N ' H ^ 
H H ° N 0 2 
An alternative method which did not require molybdenum protection but which involved 
protection of the ring nitrogens from electrophilic attack by protonation with TFA 
(pK a=13.2 and 7.4 for the parent amine) was employed. The nitroimidazole-p-
nitrophenol activated ester (64) was formed in situ by DCC coupling, filtered to remove 
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DCU and added directly to the protonated macrocycle (63), and the resulting solution 
stirred at room temperature with tic monitoring for 24 hours. Although LR analysis of the 
resultant material appeared to show the presence of an amide, lH NMR and mass 
spectrometry indicated that an intractable complex mixture had been produced. 
Consequently no definitive statement as to the viability of this sequence could be made. 
3.3.2 A L T E R N A T I V E A M I D E COUPLING REAGENTS - DPPA, PBOP 
Subsequently it was decided to use a different reagent for amide coupling, namely 
diphenylphosphoryl azide (DPPA) which has been used extensively in peptide 
coupling. 2 5 , 2 6 - 2 7 Initially a model reaction was attempted to establish the suitability of 
DPPA as a coupling agent where nitroimidazole acid was involved. 2-nitroimidazole-l-
acetic acid (60) was stirred in DMF with sodium bicarbonate and isobutylamine: DPPA 
was added to the mixture last and stirring continued for 24 hours. Work up and 
purification by alumina PLC gave the desired amide (65). 
Another phosphorus based reagent used in amide coupling is benzotriazol-l-yloxy-
tripyrrolidinophosphonium hexafluoro phosphate (PBOP). 2 8 An analogous model 
reaction was carried out on the imidazole acid using this reagent. 2-Nitroimidazole-l-
acetic acid (60) was stirred in acetonitrile with triethylamine and isobutylamine, PBOP 
was added and stirring continued for a further 18 hours. Work up and alumina PLC also 
gave the desired amide (65) as previously. 
SCHEME 3.7 
Et3N 
N C-N N C O p H N N O H NO (2) PBOP, MeCN, N 0 2 60) 
(1) DPPA, DMF 
EtaN (65) 
SCHEME 3.8 
CH3COOH 
H 
:N N: NH3+ 
CH3C00-
DMF DPPA Et3N H H H O N N N4 
C H 3 
H (59) 
H (66) 
Next it was decided to test the suitability of DPPA for coupling a macrocyclic ligand and 
acid by using it to prepare the known acetamide (66). Tetra-amine (59) was treated 
with glacial acetic acid to protect the ring nitrogens from electrophilic attack, then this salt 
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was dissolved in DMF and was treated with triethylamine, acetic acid and DPPA for 2 
weeks affording the desired acetamide (66). 
3.3.3 SYNTHESIS OF 12N3 - N I T R O I M I D A Z O L E CONJUGATE 
In light of this success, the tetraamine (59) was treated with TFA to protect the ring 
nitrogens. The resultant salt was dissolved in DMF and reaction with triethylamine, 2-
nitroimidazole-1-acetic acid and DPPA (0°C, 4 days, monitored by cation exchange 
HPLC) afforded the desired nitroimidazole conjugate (62) in low yield. Trialkylation of 
the secondary amine sites with ethylbromoacetate in ethanol in the presence of potassium 
carbonate appeared by tic to give the triester (67) but on such a small scale that 
purification proved difficult. Before this procedure was repeated on a more manageable 
scale it was decided to pursue the syntheses of 9N3 - nitroimidazole conjugates being 
carried out in parallel in order to determine whether the nitroimidazole moiety would 
indeed enhance tumour localisation. 
SCHEME 3.9 
f=\ 
N £0?H N 
H H NO 60) N N H H N N NH Ojucr N-C. N DPPA N DMF H H O NO? Et3N H S9) 
(i) BrCH 2C0 2Et 
C s 2 C 0 3 
EtOH 
(ii) Hydrolysis 
C0 2 R 
.N N - ^ R 0 2 C 
N-C. N N 
I t i \ / 
H O N 0 2 
(62) 
(67) R = Et 
(49) R = H 
R0 2 C 
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3.4 9N3 - N I T R O I M I D A Z O L E CONJUGATES 
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3 .4 .1 SYNTHESIS OF C-FUNCTIONALISED DERIVATIVES OF 9N3 
The amino acid (2S)-lysine was used as the starting material for the synthesis of the C-
functionalised derivatives of l,4,7-triazacyclononane-l,4,7-triyltriacetic acid (NOTA), 
target compounds (50) and (51), and the following well established synthesis was 
employed.2 9 Reaction of the methyl ester of lysine (68) (as the dihydrochloride) with 
warm ethylenediamine (in excess) afforded the monoamide (69). Under these 
conditions the competitive formation of the 7-ring lactam by intra molecular cyclisation 
was suppressed, although when methanol was present it did occur. 
SCHEME 3.10 
NH 2 Ethylenediamine 
90°C 
H 2hT C0 2 Me 
(68) 
BH3.1HF 
.NHCOPh 
(i) Cu 2 + , PhCOCI, OH" M e O - @ - S 0 2 C I 
CH 2CI 2 , EtaN 
H 2N ' 
( 7 1 ) 
(ii) H 2S 
MeOTsHN 
( 7 2 ) 
NHCOPh 
MeOTsN 
MeOTsHN 
CsC0 3 
DMF 
c OTs OTs MeOTs-N 
TsOMe „ NHCOPh 
( 7 3 ) 
TsOMe 
The amide was reduced with borane -tetrahydrofuran to yield the tetra-amine (70) and 
reaction with copper (II) ions (as basic copper carbonate) in aqueous solution generated 
the blue diethylenetriamine-copper (II) complex which effectively protected the three 
CHAPTER 3: Nitroimidazole Conjugates 9 3 
nitrogens from electrophilic acyiation. Reaction with benzoyl chloride in the presence of 
base permitted acyiation on the remote amino group and treatment of the copper complex 
with hydrogen sulphide permitted isolation of the free benzamide (71) (53%). 
Protection with p-methoxybenzenesulphonyl chloride afforded (72) which was co-
condensed with ethylene glycol ditosylate under standard conditions (CS2CO3, DMF, 
65°C, 18 hours) to afford the nine membered ring compound (73) in 72% yield. 
SCHEME 3.11 
MeOTs—N 
TsOM 
TsOMe 
(73) 
NHCOPh 
6M HCI 
TsOMe 
/ 
110°C. 4 d a y s M e O T s " / N (74) 
TsOMe 
NH3 +C1-
N0 2 
H O \=J 
(76) 
HBr-acetic acid 
phenol. 110°C 
MeOTs 
H O j C ^ N ^ N 
W 
DCC. DMAP 
TsOMe 
I 
N 
' I < 
(60) 
N0 2 
I II 
H O 
N "*"N 
W 
(75) 
TsOMe 
(i) C s 2 C 0 3 . EtOH N 
Ethylbromoacetate 
(11) Hydrolysis 
H 0 2 C 
H 0 2 C 
> 
N0 2 
N - C ^ N ^ N 
H O W 
CQ 2 H 
(50) 
Initial attempts to prepare ligand (50) involved coupling a 2-nitroimidazoIe directly to the 
amide. The intermediate (73) was prepared and while the triamine was still protected 
debenzylation of the remote amino group was effected using standard conditions (6M 
HCI, 110°C, 48 hours). The relative insolubility of this compound (73) caused this 
reaction to proceed in poor yield (27%) and very efficient stirring and careful monitoring 
by TLC were essential. The amine hydrochloride (74) was converted to the free amine 
before coupling with 2-nitroimidazole-l-acetic acid (60) was attempted using DCC, 
DMAP in dichloromethane at 0°C for 24 hours. Again, with this reaction solubility 
problems were encountered. THF was used as a co-solvent, but the conditions for this 
step were not optimised. When accomplished, deprotection using HBr-acetic acid and 
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phenol followed by addition of carboxymethyl groups provides a well precedented route 
to the desired ligand (50). 
3.4.2 A L T E R N A T I V E 9N3 N I T R O I M I D A Z O L E C O U P L I N G 
REACTIONS 
Another possible route to (50) was explored starting from the protected triamine (73). 
Deprotection was achieved using 98% sulphuric acid to give the triamine (75) which was 
hydrolysed (6M HC1, 110°C, 4 days) affording the tetra-amine (77) quantitatively. The 
ring nitrogens were protected with molybdenum hexacarbonyl in n-butyl ether, leaving 
only the primary amine free to undergo coupling with 2-mtroimidazole-1-acetic acid (60) 
(DCC, DMF, DMAP, 25°C). However when the produc was deprotected with 10% 
HO nop? of the desired product (76) was found. Attempts to effect this couplinc using 
the reagent DPP A as described in section 3.3.3 and using the p-nitrophenyl active ester of 
the nitroimidazole (64) as in section 3.3.1 also failed to produce the desired product. 
SCHEME 3.12 
MeOTs- N 
TsOM 
N 
N-
TsOMe 
( 7 3 ) 
NHCOPh 
(i) H 2 S 0 4 (cone) 
(ii) 6M HCI 
110°C, 4 days 
H-N 
N-
( 7 7 ) 
H 
(i) Mo(CO)6, Bu 2 0 
(ii) DMF, DCC, 25°C 
NO2 
H C ^ C ^ N ^ N 
\=J ( 6 0 ) 
(iii) H3OVO2 
N 0 2 
N — C ^ N ^ N 
1 11 \ / 
H O 
H-N 
( 7 6 ) 
Deprotection of (73) was carried out using the alternative method of hydrogen bromide 
in acetic acid in the presence of phenol (110°C, 48 hours, 70%) and this material (75) 
was used in the synthetic route to target compound (51). The required carboxymethyl 
groups were introduced prior to coupling with nitroimidazole by reaction of (75) with 
ethylbromoacetate (K2CO3, EtOH) to give the triester (78) (63%) which could be 
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purified by gravitational alumina chromatography and then hydrolysed to amino acid 
(79) (6M HC1, 48 hours) quantitatively. 
SCHEME 3.13 
^ ' H ( 7 
NHCOPh 
ethyl bromoacetate 
K2C0 3 
EtOH EtQ2C 
E t 0 2 C 
( 7 5 ) 
HU2U 
6M HC 
NHOOPh 
NH, + 
HQjC 
(a) 
N02 
Pr^NEt 
DMSO 
NO2 
( 8 0 ) 
k - r o _ H Q _ N o 2 
o 
N-Methyl morpholine 
DMSO 
( 8 1 ) 
HO2C. 
N 
HOgC 
\ C02H 
(a) R = H 2 C - ^ ^ - C H 2 ( 8 2 ) 
(b) R = C H 2 C H 2 (83) 
NO, 
DMSO 
NOs 
( 5 3 ) 
HO2C 
HO2C 
H 
l 
N— 
H 
N02 
( 5 1 ) 
> 
HOaC 
CHAPTER 3: NUroimidazole Conjugates 9 6 
The next step involved reacting amino acid (79) with bis-[p-nitrophenyl-
l,4,phenylenediacetate] (80) in the presence of base in DMSO and monitoring by HPLC 
(reverse phase). However despite there being evidence for the formation of the desired 
amide (82) within 20 minutes of the start of the reaction Rt=16 minutes, analytical 
HPLC showed that it had begun to decompose again before it could be purified by 
preparative HPLC. 
Since it was desirable to minimise the molecular weight of the conjugate in order to 
enhance its transport properties in vivo, and also to bring the nitroimidazole moiety into 
closer proximity to the metal complex, the smaller succinate bis ester (81) was 
employed. The above procedure was repeated, then amino acid (79) was treated with 
bis-p-nitrophenyl succinate (81) in DMSO in the presence of N-methyl morpholine and 
formation of the active ester had taken place and that it was beginning to decompose. The 
reaction was 'stopped' by storing the mixture at -78°C, while it was separated by 
preparative HPLC in batches. The active ester (82) was checked for analytical purity by 
HPLC and J H NMR and then used directly in the next step. Treatment with the 
nitroimidazole amine (53) in DMSO afforded the desired nitroimidazole conjugate (51) 
in low yield after HPLC purification. 
3.4.5 BIODISTRIBUTION OF 9N3 - N I T R O I M I D A Z O L E 
The ^ H n complex of the 9N3-nitroimidazole conjugate (51) was formed with a 
radiolabelling efficiency of 87%. The biodistribution was studied in normal mice, and 
0.1 fimol kg - 1 of complex was administered together with 500|imol kg"1 of misonidazole 
to minimise the destruction in the bloodstream of nitroimidazole linked to the macrocycle. 
The recommended interval for optimal uptake of 2-nitroimidazoles in tissues is 24 hours: 
the tissue biodistribution of i n L n was measured at this time. It has been observed that 
labelled 2-nitroimidazoles accumulate by bioreduction in certain normal tissues such as 
the oesophagus, eye lids and liver in addition to hypoxic tumour tissue. In this 
experiment a range of tissues were examined to determine whether the radiolabelled 1 1 ! I n 
9N3 nitroimidazole conjugate (51) showed any behaviour characteristic of the 2-
nitroimidazole moiety. 
It can be seen from figure 3.11 that the biodistribution of m I n - ( 5 1 ) differs from the 
1 1 1 In NOTA control in so far as the percentage dose per gram remaining in the tissues at 
24 hours is statistically greater for i n In - (51 ) . Comparison of the n i I n - N O T A control 
with previous n i I n - N O T A results show that the misonidazole added had no effect on 
distribution. However there is little or no evidence for preferential uptake in hypoxic 
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tissues. Successful imaging of tissues requires, not a high tissue uptake, but a high 
tissue to background ratio. Figure 3.12 shows a comparison of tissue to blood ratios for 
both groups, this demonstrates that in fact the simple l l l I n - N O T A shows greater tissue 
differentiation. 
FIGURE 3.11 1 1 1 In Biodistribution in mice of(51) compared with NOTA in a 
range of tissues. 
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FIGURE 3.12 Ihour 1 1 1 In biodistribution of (51) compared to NOTA (Ratio of 
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3.5 CONCLUDING COMMENTS 
98 
The Gd complex of DTPA bis nitroimidazole amide (48) did show some evidence for 
slight accumulation in hypoxic tissues. Despite its apparent low kinetic stability in vivo it 
may find uses in the future in further investigations into the tumour targeting potential of 
nitroimidazoles. The selective targeting of hypoxic tissues by the 9N3 based macrocyclic 
radiolabelled complex i n In - (51) was not unequivocally established in the animal model 
employed. Further studies in hypoxic tumour bearing mice using the 9N3 or 12N3 based 
conjugates may provide additional useful information. However their relatively poor 
ability to localise in regions of hypoxia may be related to their relatively high molecular 
weight which may preclude cellular uptake. Alternatively it may be due to the fact that 
during this in vivo work these complexes were given at a relatively low dose, even 
though misonidazole was co-administered. 
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4.1 TARGETING TUMOUR MACROPHAGES USING TUFTSIN 
Tuftsin is a naturally occurring linear tetrapeptide (L-Thr-L-Lys-L-Pro-L-Arg) which 
was first isolated in the 1970's.1 It is a non-toxic fragment of the heavy chain of all 
human IgG isotypes. 2 Current interest in this peptide has increased since it was 
discovered that it possesses immunologically mediated anti-tumour potential. 3 The 
accessibility and low toxicity of tuftsin make it attractive candidate for tumour 
targeting. 
The method by which tuftsin may target tumours is via macrophages present on the 
boundary of the tumour or in necrotic regions of tissue. Macrophages possess receptors 
for many ligands including different IgG isotypes and complement components, this 
the macrophage content of tumours varies considerably, it has been shown that the 
macrophage densities are highest at the tumour periphery and in areas of necrosis. 
Targeting tumour-infiltrating macrophages may detect necrotic regions and delineate 
boundaries between normal and infiltrating neoplastic tissue. It may also assist in the 
detection of small metastases since the macrophage densities are highest in smaller 
lesions.5 
4.1.1 F L U O R E S C E N T TUFTSIN CONJUGATES 
F I G U R E 4.1 Fluorescent labelling of tuftsin using fluorescein isothiocyanate. 
N = C = S 
O fluorescein isothiocvanate 
OH 
O 
HO O 
Tuftsin 
Coupling Buffer 
pH8.3 H 2 H 2N 
N-H NHp 
N N 
H O 
N N—C—N 
H N H O H 
HQ Me 
CQ2H 
fluorescein 
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The mechanism of action of tuftsin following binding to its receptor and the fate of the 
tuftsin molecule itself were not known. In order to visualise these interactions via video 
intensification microscopy ( V I M ) , biologically active fluorescent derivatives of tuftsin 
were prepared. 
F I G U R E 4.2Fluorescent labelling of tuftsin using tetramethylrhodamine 
isothiocvanate 
Boc - Thr- Lys (Boc) - Pro - Arg - Gly - Lys (e-NH 2 ) - OH 
TRITC (see below) 
DMF, E t 3 N 
Boc - Thr- Lys (Boc) - Pro - Arg - Gly - Lys - OH 
e I 
TFA / CHX1- , 
N - C - N — T R 
H J H 
N — C — N — T R 
N V-IST CO?H 
H 2 N / V N / > N - - n r N . H » H o« 
O H O 0 
( H 3 C ) 2 N N ( C H 3 ) 2 
S = C = N 
tetra methyl rhodamine isothiocvanate (TRITC) 
Tuftsin was simply coupled with fluorescein isothiocyanate as shown in figure 4 . 1 . 6 - 4 
The labelled tuftsin was separated f rom excess tuftsin using a Sephadex column. 
Characterisation of the coupling site confirmed that the NH^-terminus had been 
modified and that the e-amino group of lysine remained free. This might be expected 
since fluorescein isothiocyanate reacts with unprotonated amino groups; the only 
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unprotonated amino group at the chosen coupling pH of 8.3 exists at the a-amino 
terminus, as can be concluded from the respective p K a values of the tuftsin functional 
groups. The p K a of the a-NH? terminus is 7.1 and tho p K a of the lysine e-NH2 is 10.0.7 
Comparison of the biological activity of tuftsin with the fluorescein derivative revealed 
that the analogue retained both the phagocytic and bactericidal-stimulating activity of 
natural tuftsin. 
Tuftsin was coupled with another highly fluorescent molecule, tetramethyl rhodamine 
as shown in figure 4 . 2 . 8 - 9 1 0 This procedure involved the use of tuftsin which had been 
elongated at the C-terminus by addition of two amino acids, glycine and lysine. 
Coupling was carried out in D M F in the presence of triethylamine, following removal 
of Boc protecting groups the product was purified on a Jephadex column. In this 
^ - i * - ^ t-'- ~ r * T T _ T _ i: . . i - ~ _ , L - _ _ _ : i." J 
i i ib lu i iUC. VViiCiw l i iC ^vjULjiii i^, bilw VV ti6 LiiC C ' i i i i ^ \Ji liiw iy 'o i i iC i-iiv CvJUjU^fcilC W tXj iO'Uiiij. 
to compete specifically for tuftsin binding sites and stimulate phagocytosis. 
4.1.2 STRUCTURES OF B I O L O G I C A L L Y A C T I V E TUFTSIN ANALOGUES 
Binding of tuftsin to macrophages depends on strict conservation of molecular 
structure: 1 1 the formation of conjugates often impairs tuftsin activity. Early reports 1 2 
claimed that the structural requirements for tuftsin activity were so strict as to preclude 
any amino acid substitution or deletion anywhere in the peptide, any absence of free 
amino or carboxyl groups at the peptide termini, any substitution or alteration of the 
guanidine side chain on arginine. or any lengthening of the chain by addition of amino 
acids at either terminus. 
Later however, some analogues in which the N-terminus had been cyclised were 
reported to possess considerable biological activity. 5 The tuftsin fluorescein analogue 
described in section 4.1.1 is a further example of N-terminal substitution in which 
biological activity is retained. Other recent w o r k 1 0 has demonstrated that C-terminal 
additions to tuftsin's backbone often lead to analogues possessing tuftsin-like biological 
activity. It has become clear that the restrictions upon formation of biologically active 
tuftsin analogues are not as rigid as once supposed. Although conservation of the 
molecular structure is clearly of great importance, the most effective ways of forming 
analogues have not been unequivocally established. In this study synthetic tuftsin was 
used in the formation of conjugates through one of the N-termini. 
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4.1.3 CONFORMATION OF TUFTSIN 
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Detailed 2D NMR and NOE spectrographic studies have allowed a conformational 
analysis of tuftsin to be carried out both in aqueous solution and D M S O . 1 3 Since most 
proton resonances were split, it was concluded that there were two families of 
conformations due to cis-trans isomerisation around the Lys-Pro bond. The ' H data in 
(CD3)2SO showed that the Arg N H was internally H bonded to the Pro N and was 
inaccessible to solvent. The rigid folded trans isomer, shown in figure 4.3(A), was 
found to be the preferred conformation in DMSO solution. This is not necessarily the 
bioactive form however, since such a small molecule still retains considerable flexibility 
to adapt to the receptor. 
F I G U R E 4.3 Molecular models of (Aj the only conjormer, among me energy minima, 
that shows a nearly complete solvent inaccessibility' of Arg NH and of (B) the best 
conformer among the energy minima.13 
B 
Q 
One of the major limitations of the use of peptides as pharmaceuticals is their 
susceptibility to proteolysis. In the case of octreotide the four essential amino acids 
were stabilised to proteases in the body by disulphide cyclisation from the two cysteines 
incorporated in the molecule and by the placement of the D-amino acids. In the case of 
tuftsin, work has been carried out using high temperature quenched molecular dynamics 
( Q M D ) 1 4 to simulate cyclic analogues of tuftsin which retain very similar backbone 
structures and side chain conformations. The two derivatives, cyclo[Thr-Lys-Pro-Arg-
Gly] and cyclo[Thr-Lys-Pro-Arg-Asp], were suggested as a result of this work and the 
former of these has been synthesised and shown to be more active than tuftsin. In the 
future, conjugates of such analogues may become desirable targets for synthesis. 
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4.2 12N4 - TUFTSIN CONJUGATE 
Ligands based on the tetraazacyclododecane (12N4) skeleton such as DOTA are well 
known as compiexing agents for lanthanides like gadolinium, and these complexes f ind 
uses as paramagnetic contrast agents in M R I . As can be seen from figure 4.4 a number 
of other metal ( I I I ) ions have very similar ionic radii and so are able to form stable 
complexes with these ligands also. Of particular interest in this study is the T b 3 + ion 
which has excellent long lived luminescence properties, emitting visible photons long 
after other background fluorescence f rom organic molecules has disappeared. Such 
luminescent lanthanide complexes have found uses as probes in biological systems 
replacing conventional fluorescent organic molecules such as fluorescein. One of the 
objectives of this study was to prepare a tuftsin conjugate of a terbium complex for uses 
such as those of the fluorescent tuftsin conjugates described in section 4.1.1. 
F I G U R E 4.4 Effective ionic radii vs coordination number. 
La 3 * 
Ce 1-30 
Sm3 1-20 
m 
Gd 3! 1-10 Tb 3* 
IONIC Y 3*Ho 3* 
ThTEr 3 * RADIUS Yb 3* 1-00 Lu 
I n 3 
90 
So 3* 
80 
70 
8 10 11 12 
COORDINATION 
NUMBER 
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4.2.1 SYNTHESIS OF 12N4 COMPLEXING AGENT 
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Charge neutral complexes were desirable because of their improved transport properties 
and so a tri-acidic ligand was sought, with alkylation of the fourth ring amine allowing 
variation of the side chain enabling conjugation with targeting vehicles. 
SCHEME 4.1 
H /-
c N 
N 
H' L 
,H 
J H 
Mo(CO)6 
BUoO 
H 
^ 0 
H-
Mo 
oc" 1 -to 
CO 
(84) 
H y 
c N 
N 
H'\_ J H 
+ 
H 
H 
I 
N-
HpN 
(85) 
OMe 
BrCHiCOBr 
C 2 H 4 C 1 2 
OMe 
(i) K , C 0 3 . D M F . A r ( g ) 
(ii) HC1 (aq), air 
1 ° H 0 (87) 
MeP(OEt) 2, (H 2 CO) n , 
THF. 100°C, 20 hours 
N—S 
Me O EtO-P=0 
I 
Me 
OMe 
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In practice three of the 12N4 ring nitrogens were protected while alkylation of the 
fourth was accomplished. This type of protection has been reported using either the 
oc t ahed ra l c h r o m i u m 1 5 or m o l y b d e n u m 1 6 t r i ca rbonyl complex o f 
tetraazacyclododecane. In this case tetraazacyclododecane was treated with 
molybdenum hexacarbonyl in dibutyl ether giving the bright yellow molybdenum 
tricarbonyl complex (84). The a-bromoamide (86) had previously been prepared by 
reaction of bromoacetyl bromide with the mono protected butane-1,4-diamine (85). 
Because of the relative instability of the molybdenum complex it was immediately 
suspended in D M F and treated with the a-bromoamide (86). Decomplexation of 
molybdenum was achieved by stirring the reaction mixture in dilute HC1 and the 
monoalkylated amine (87) was subsequently extracted in 62% yield. 
The alkylphosphinate residues were introduced using the standard procedure. The 
monosubstituted 12N4 derivative was condensed with paraformaldehyde in dry 
tetrahydrofuran to f o r m the imine which was trapped in this case by 
methyldiethoxyphosphine. Arbuzov rearrangement led to the desired triphosphinate 
ester (88). HBr in acetic acid was used in the presence of phenol to selectively 
hydrolyse the amide-triester leaving the amide intact while simultaneously deprotecting 
the terminal amine. The trihydrobromide salt (89) was precipitated f rom diethyl ether. 
Such a bifunctional complexing agent has great versatility possessing a pendant amine 
suitable for conversion to an active ester or maleimide and subsequent conjugation with 
a suitable targeting vehicle, in this case tuftsin. 
4.2.2 CONJUGATION WITH TUFTSIN 
Tuftsin was obtained commercially and samples were examined by ' H N M R using D2O 
and (CD3)2SO as solvents. These spectra were compared with previous N M R data 7 and 
were found to be consistent. 
In order to examine the reactivity of the terminal amines with p-nitrophenolate active 
esters a pilot acylation reaction was studied on a small scale by mixing dry p-
nitrophenyl acetate with a solution of tuftsin in deuterated DMSO. The progress of this 
reaction followed by ' H NMR. The appearance of the distinctive p-nitrophenol 
aromatic ' H doublets at 8 8.05 and 6.8 and the disappearance of the starting p-
nitrophenyl acetate confirmed that reaction had taken place. In addition to the 
distinctive acetate peak at 8 1.88 there were also changes in the lysine N H which 
became a triplet at 8 7.93 and the lysine e -CH2 shifted to 8 2.98 ppm. Following 
purification on a Sephadex column, mass spectrometry confirmed that tuftsin acetate 
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(90) had been formed. However it also indicated that a minor amount of the 
diacetamide was present, suggesting that reaction was not entirely selective on the 
lysine amine. 
SCHEME 4.2 
HBr - acetic acid 
phenol. 100°C, 
24 hours 
M e O E t 0 - p = 0 
Me 
O 
7 
HO •—N 
3 HBr 
HO-P=0 
Me^ 
M e O H 0 - P = ° 
Me 
Tuftsin 
DMSO 
H 0 - P = 0 
C0 2H 
DMSO. N-methyl morpholine 
Me ^ 
HO r - N k 
Me x O 
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Since successful reaction of tuftsin with a p-nitrophenolate active ester had taken place, 
it was decided to employ an analagous method in forming the 12N4 - tuftsin conjugate. 
The trihydrobromide salt (89) was stirred in DMSO in the presence of base; p-
nitrophenyl bis ester (81) was added and the reaction was monitored by HPLC. 
Purification by reverse phase HPLC provided the desired active ester (91). 
Subsequent treatment with tuftsin in deuterated DMSO again allowed monitoring of the 
reaction via ' H NMR. An attempt to direct conjugation towards linkage of one tuftsin 
with one molecule of (91) was made by using excess tuftsin. The increased size of the 
p-nitrophenyl ester in this case was anticipated to direct conjugation towards the less 
hindered site on lysine. The product (92) formed as a fine brown precipitate and so 
much of the excess tuftsin and p-nitrophenol were removed by filtration prior to 
purification on a Sephadex column. Eiectrospray mass spectrometry was attempted but 
unfortunately proved unsuccessful. ' H N M R analysis showed that one tuftsin was 
conjugated with the bifunctional complexing agent, although due to the complexity of 
the spectrum the site of conjugation could not be unequivocally assigned. However, 
given the solution conformation of tuftsin, and the results of the model acylation 
reaction, it was assumed that conjugation would occur at the Lys £-amino group. 
4.2.3 COMPLEXATION AND B I O L O G I C A L STUDIES 
An alternative route to (92) was attempted in which the terbium complex was formed at 
an earlier stage in the reaction sequence in order to allow monitoring via luminescence 
techniques and purification by HPLC despite the lack of chromophore. Formation of 
the terbium complex of (89) was accomplished by treatment of the trihydobromide salt 
with aqueous terbium ( I I I ) acetate at reflux followed by adjustment of the pH to 6. 
Purification by HPLC provided the desired complex (93) but the terbium complex 
proved not to be as effective a chromophore for this purpose as expected. In addition 
there was evidence to suggest that the complex was somewhat unstable under the acidic 
conditions employed in this reverse phase HPLC purification. Terbium is known to be 
a poor light absorber, its efficiency can be improved by incorporating an antenna in the 
ligand. In future experiments, such an antenna could be incorporated as a substituent on 
phosphorus and transfer absorbed light to the metal ion. 
It was decided that it was preferable to carry out complexation reactions in the final 
stage of this synthesis, the previous study serving to demonstrate the ease of terbium 
complex formation. The sample of 12N4 - tuftsin conjugate (92) obtained was sent to 
the Royal Marsden Hospital where complexation w i l l be carried out immediately prior 
to some initial biological tests. 
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4.3 9N3 - TUFTSIN CONJUGATE 
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Investigations were also carried out into linking tuftsin to the triazacyclononane moiety 
in a similar fashion to the 9N3 - nitroimidazole conjugate discussed in chapter 3. The 
synthesis of the C-functionalised derivative of NOTA, shown in section 3.4.1, was 
somewhat lengthy and so a shorter route to an N-functionalised dervivative was 
employed. 1 7 
4.3.1. SYNTHESIS OF 9N3 COMPLEXING AGENT 
Synthesis of the N-functionalised NOTA derivative was accomplished using the parent 
polyazamacrocycle triazacyclononane as a starting material. Alkylation of this allowed 
one or more suilauic uminuaikyi Side chains to be attatchsd. 
2-Bromo-N-benzoyl-5-aminopentyl ethanoate (96) was prepared in two steps from N -
benzoyl-5-amino valeric acid (94) available from SIGMA. Bromination of (94) was 
effected with red phosphorus and bromine according to the literature method. 1 8 The 
resulting racemic a-bromoacid (95) was converted to the a-bromoester (96) by heating 
to reflux in ethanol and 5% acetyl chloride, fol lowed by 'flash' silica column 
chromatography. 
S C H E M E 4.3 
H 0 2 C ' 
N H C O P h NHCOPh NHCOPh 
r e d P / B r 2 , > EtOH. 
acetyl cloride 
H 0 2 C ^ " B r E t o 2 C 
racemic racemic 
(95) (96) 
The a-bromoester reacted with the triazacyclononane in a manner analagous to 
ethylbromoacetate. Two equivalents of triazacyclononane were heated in D M F in the 
presence of potassium carbonate. A solution of the a-bromoester (96) was added 
dropwise over several hours in order to direct the reaction towards production of the 
mono substituted product (97). Analytical HPLC showed that the two products (97) and 
(98) were produced in the ratio 3:1. Samples of each product were obtained by 
purification using semi-preparative reverse phase HPLC under standard conditions. 
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SCHEME 4.4 
H ; N ^ N - H w 
H 
Et0 2 C, 
Br 
(96) 
NHCOPh ,—> 9 ° 2 E t 
K N N N ^ N H C 0 P H 
K 2 C 0 3 , DMF H (97) 
^ L ^ ^ N H C O P h 
(98) 
E t 0 2 C 
C 0 2 E t 
K / ^ 1 /v NHCOPh 
N 
(97) 
BrCH-.CO-.Et 
C s , C 0 . 
MeCN " 
E t 0 2 C N 
C 0 2 E t 
I \ 1 ^ NHCOPh 
(99) 
C 0 2 E t 
6M HC1. reflux 
H 0 2 C ^ N ^ 
N 
C 0 2 H 
NH 2 
L. (ioi) 
C 0 2 H 
, , C 0 2 E t 
NHCOPh 
.N N 
-N 
E t 0 2 C 
(98) 
BrCH-.CO-.Et 
C 0 2 E t 
^ I \ I y\ /NHCOPh 
E t 0 2 C ^N 
NHCOPh CsoCO, 
MeCN 
N-
E t 0 2 C 
6M HC1 
reflux 
NHCOPh 
(100) 
, , C 0 2 H 
I \ X y \ NH 2 
H 0 2 C > 
N~ 
H 0 2 C 
A / ^ N H 2 
(102) 
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The monoalkylated compound and dialkylated compound were reacted separately with 
ethyl bromoacetate in acetonitrile in the presence of caesium carbonate to produce the 
triesters (99) and (100) respectively. Subsequent acid hydrolysis gave the triacids (101) 
and (102) quantitatively. When a mixture of the monoalkylated (97) and dialkylated 
(98) compounds was treated with ethylbromoacetate in the same fashion, a mixture of 
the two triesters was obtained as expected. A very careful attempt was made to separate 
these by gravitational alumina column chromatography but only very limited separation 
was achieved due to the very similar Rf values of both compounds under these 
conditions. 
Following the successful formation of tuftsin conjugates f rom p-nitrophenolate active 
esters discussed in section 4.2.1.2, a similar method was employed in the case of the 
QN3 nnniiig.ite The tri.ncid (^02^ was treated with the bis n-nitronhenvl ester (811 in the 
presence of N-methyl morpholine, and purification by HPLC provided the bis active 
ester (103) in 28% yield. Triacid (101) was treated in the same way to give the mono 
active ester (104) in 90% yield. 
Previous studies 1 9 on 'mono' and 'di'- N-functionalised macrocycles in which maleimide 
conjugates were formed had demonstrated that purification could be carried out in the 
final stage of the synthesis. In a similar way a quick and convenient route to the two 
active esters was followed in which a mixture of the 'mono' and 'di-' functionalised 
material was treated with (81) in the method shown in scheme 4.6. HPLC separation 
was readily carried out since the p-nitrophenyl chromophore allowed easy detection and 
the retention times under standard conditions were 13.8 mins and 17 mins for (104) and 
(103) respectively. 
Having obtained the active esters, the mono ester (104) was employed in the formation 
of the tuftsin conjugate. It was dissolved in (CD3)2SO and solid tuftsin added to the 
solution. The progress of the reaction could be monitored by ' H N M R spectrometry as 
before. When complete, the solid product (105) was simply obtained by filtering and 
washing; having a lower molecular weight than (92) the electrospray mass spectrum 
was successfully obtained. 
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SCHEME 4.6 
C 0 2 H / — v 9 ° 2 H H ?\ 
. N > <ML^ X - * J H O 0 
H 0 2 C ^ ^ m 2 N-mtthyl H 0 2 C ^ ' X ' N ' X ^ Y 0 ' ^ 
morpholine X N 0 2 
(102) F 0 
(103) 
N 0 2 
C 0 2 H O COoH (81) H 
H 0 2 C ^ N A / V N H 2 VMS® " H ° 2 C 
' N-methvl mnrnhniine 
o N 
6 C 0 2 H C O ? H (104) (101 
N 0 2 
Tuftsin 
DMSO 
NH 2 HO 
o Me 
N-H C 0 2 H u O H H o 2 c ^ N ^ N A ^ A y V - N ^ ^ V 
S \ O H 
O 
H N N 
C 0 2 H 
H 2 N N H (105) H?N C 0 2 H 
4.3.2 COMPLEXATION AND BIOLOGICAL STUDIES 
The complexation chemistry of NOTA and its derivatives is well understood. Detailed 
studies have also been carried out on the ligand (7?)-l,4,7-tris(2'-methylcarboxymethyl)-
triazacyclononane (5) which has been described as a good model for N-functionalised 
ligands such as those discussed here. 2 0 This novel 9N3 - tuftsin conjugate has potential 
as an imaging agent using either the 6 7 G a , 6 8 G a or 1 1 ' I n complex. Initial biological 
studies w i l l be carried out on the indium complex of (105) at the Royal Marsden 
Hospital in order to determine its biodistribution and tumour targeting ability. 
CHAPTER 4: Tuftsin Conjugates 114 
4.4 CONCLUDING COMMENTS 
Once initial biodistribution results have been obtained it wi l l be possible to determine 
whether the conjugated tuftsin has retained its selectivity for the receptors on the 
macrophages. In addition, some indication of the transport properties of these 
molecules may be available. Based on this information, further studies of these 
conjugates may be initiated on a larger scale, or on possible means of modification of 
these synthetic routes to conjugates with increased receptor selectivity or improved 
transport properties. 
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5.1 ACRIDINE INTERCALATOR CONJUGATES 
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5.1.1 DNA INTERCALATING AGENTS 
The targeting vehicles discussed in previous chapters have been of the type which are 
directed towards a specific tissue type or type of cell. Intercalating agents differ in that 
they bind to DNA, which is present in all cell types. This property of intercalators 
would allow a tumour imaging or therapeutic agent to bind to the DNA of a tumour cell 
after being transported there by means of an antibody fragment or other targeting agent. 
Intercalating agents are cytotoxic to dividing, but not resting cells, and so are 
particularly toxic to rapidly dividing tumour cells. They generally prevent progression 
beyond the G2+M phase of the eel 1 cycle (see. figure 1 31V1 At the M stage nf the cell 
cycle the nuclear membrane is ruptured to allow division. It is at this time that an 
intercalator conjugate could access the DNA of the tumour cells. 
The process of intercalation takes place when a planar intercalator molecule is inserted 
between the base pairs in DNA. 2 The binding is freely reversible, being driven by 
stacking, charge transfer, hydrogen bonding, Van der Waals and hydrophobic 
interactions. The DNA binding activity of Fe (II) methidium propyl-EDTA3 and 
acridine orange linked to [Pt(en)Cl2]4'5 demonstrated that the formation of conjugates 
with metal complexing agents did not reduce intercalation. 
5.1.2 AUGER EMITTING RADIOISOTOPES 
Once the macrocycle-metal complex is bound to the cellular DNA, new possibilities are 
opened up in the field of tumour therapy. The use of short range isotopes in the 
macrocycle complex would become possible. One of their main advantages is that their 
destructive action would concentrate on the DNA of the tumour cells, resulting in less 
damage to healthy tissue. 
F I G U R E 5.1 Auger emitting metal isotopes for use in tumour therapy 
Auger emitter Energy Range (keV) Range in Tissue Relative Abundance 
Ulln 200 - 0.5 480^m - 20nm 
67Ga 7.5 - 0.05 1.3nm - 2nm 
64Cu 6.4 - 0.8 1.7|im - 38nm less than 1 1 lln or 6 7 G a 
6?Cu 7.4 - 0.9 1.3|im - 45nm less than ^ C u 
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The Auger effect is the emission of a second electron after high energy radiation has 
expelled another. The first electron to depart leaves a hole in a low-lying orbital, and an 
upper electron falls into it. The energy released nay result in the ejection of the 
secondary electron of the Auger effect These are characteristic of the element and have 
a short range. A number of Auger emitting metals suitable for therapy have been 
investigated, although 1 2 3 1 is currently the favoured element. Their properties are 
summarised in the table in figure 5.I. 6- 7 
Indium -111 would be the most effective of these since its energy deposition is about 19 
eV per nm;7 it is also readily available commercially. Indeed the m I n in indium oxine 
has been shown to induce cell death. 6 7 G a citrate has also been shown to enhance cell 
death. However it is estimated that 2366 atoms of 6 7 G a mast be incorporated into the 
nuclear DNA to sterilise the cell. This indicates that to kill a cell with Augers 
exclusively may require a large quantity of drug to be administered. An alternative 
approach may be to use the two copper isotopes, combining longer range (3 radiation 
with short range Augers. 
The efficacy of each of these isotopes may be examined by forming their complexes 
with a NOTA-based macrocycle conjugate. 
5.1.3 T A R G E T I N T E R C A L A T O R - M A C R O C Y C L E CONJUGATES 
Acridine is a readily available, stable intercalator with well-understood properties.8 It 
was therefore the intercalator of choice when some initial macrocycle-intercalator 
conjugates were identified as target molecules. Target molecules (107) and (108) also 
bear a maleimide moiety, suitable for attatching an antibody fragment. It was proposed 
that such an antibody fragment would target the tumour tissue specifically and the 
intercalator would bind the molecule to the DNA of the cells in that tissue. 
5.2 SYNTHESIS OF ACRIDINE COMPOUNDS 
Some exploratory studies were undertaken to define the synthetic accessibility of N-
linked acridine derivatives and their ease of conjugation to complexing agents and / or 
proteins. First 9-chloroacridine was prepared by the standard literature procedure.9-10 
N-Phenylanthrolinic acid was heated with phosphorus oxychloride and concentrated 
sulphuric acid in an acid catalysed reaction. Prior to reaction of 9-chloroacridine with a 
C-functionalised NOTA derivative such as (79) to provide target (106), a model 
reaction was attempted using isobutylamine. The acridine was taken up in phenol and 
heated with isobutylamine.11 Recrystallisation from methanol provided the desired 
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compound (109) in 78% yield. An alternative route using more common solvents in 
which the NOTA derivative (79) was soluble was also employed. First sodium 
methoxide was used to convert the 9-chloroacridine to the methoxide and then this was 
treated with isobutylamine hydrochloride in water/methanol to provide the same 
compound (109). However when the analagous reaction with the NOTA derivative was 
carried out, none of the target compound (106) was obtained. 
F I G U R E 5.2 Target acridine-macrocycle conjugates (106) - (108). 
CO?H r 
H H0 2 C N N 
M 
) ) 106) 
HO?C 
CO?H r 
N HO?C H 
N 
107) 
O H0 2 C N 
C0 2 H 
N N 
H0 2 
H 
N 
o 
H0 2 C O 
108) 
As an alternative to reaction of the 9-chloroacridine with a NOTA derivative, a reactive 
acridine compound was sought for direct combination with the terminal amino group of 
the NOTA derivative. The strategy was to use the acridine (110) to alkylate on the 
terminal amine of a NOTA derivative, providing a secondary amine for further 
elaboration, for example with an active ester of a maleimide. The bromo compound 
(110) was synthesised from phenoxy acridine by addition of 3-bromopropylamine 
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hydrobromide in phenol. Tosylation of this compound however proved unsuccessful. 
This protection step was necessary in the proposed route to target (107) in order to 
prevent the subsequent reaction with the maleimide taking place at both sites. 
S C H E M E 5.1 
X ) 
HO 
a N-phenylanthrolinic acid 
N 
H 
POC1 
HoSCL cone. 
NaOMe 
N OMe MeOI 9-chloroacridine N 
aendone PhOH PhOH 
NaOH N 
MeOH OPh 
N 
PhOH HN N 
3-bromo (109) 
propylamine 
hydrobromide 
(109) Br 
(110) 
The strategy using the triacid (102) appeared more straightforward since one of the side 
chains could be used for conjugation with acridine and the other with a maleimide 
suitable for antibody binding. Commercially available 9-acridine carboxylic acid was 
used in an alternative method of forming the macrocycle-acridine linkage. It was 
readily converted into the acid chloride and then treated with the NOTA derivative 
(102) in DMF in the presence of triethylamine. However none of the desired acridine-
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macrocycle conjugate could be identified in the resulting mixture of compounds and so 
target (108) was not achieved. 
The difficulties encountered here in forming an acridine-macrocycle linkage appeared 
to indicate that the simple 9-chloroacridine and 9-acridine carboxylic acids were not 
suitable for direct reaction with the terminal amino group of the NOTA derivatives. 
Studies on previous antitumour acridines had suggested that attachment of a cationic 
side chain to the acridine would improve the binding properties, as in the case of the 
acridine carboxamides discussed in section 1.5.4.3.12 Therefore it was proposed that an 
acridine 9-carboxylic acid derivative with a cationic side chain be synthesised. This 
could be designed with scope for incorporating a macrocyclic complexing agent and 
tumour targeting antibody fragment. The following recently reported work on 
multifunctional acridine and fluorophore DNA probe was used as a starting point for 
developing this strategy. 
5.3 ACRIDINE AND FLUOROPHORE DNA PROBE 
Research has recently been conducted to investigate methods of probing the reversible 
association of oligonucleotides with complementary nucleic acid sequences. Currently 
these association phenomena are detected using the UV photometric method.13 
However this is a time consuming technique which is not suitable for more complicated 
nucleotide molecules. 
Recently Shinozuka14 has developed a novel multifunctional fluorescent labelling agent 
(111). As shown in figure 5.3 it is based on a tris amine conjugated with acridine, 
fluorescein and the oligomer to be studied. It was observed that (111) bound the 
complementary DNA strand more effectively than the unlabelled DNA oligomer. The 
(111) duplex was also more stable at higher temperatures than the unlabelled duplex, 
being stabilised by the intercalative action of the acridine moiety. 
The fluorescein based fluorescence intensity of (111) was detected following irradiation 
at the wavelength of the acridine excitation maximum and subsequent intramolecular 
energy transfer. Examination of the fluorescence intensity showed that the intensity 
was strongly affected by the formation of a double DNA strand. In this way reversible 
association of oligonucleotides could be monitored using this novel multifunctional 
DNA probe. 
This work clearly demonstrated the way in which the acridine intercalator greatly 
enhanced the DNA binding of the conjugate. The use of the central tris-amine allowed 
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development of a multifunctional agent. It was decided to employ a similar strategy to 
construct a novel multifuctionally labelled antibody bearing a macrocycle and 
intercalator. 
F I G U R E 5.3 Multifunctionally labelled DNA probe (111) compared with proposed 
multifunctionally labelled macrocycle-acridine-antibody conjugate (112). 
DNA 
macrocycle 
antibody 
5.4 SYNTHESIS OF MULTIFUNCTIONAL ACRIDINE COMPOUNDS 
9-Acridine carboxylic acid was treated with thionyl chloride to provide the bright 
yellow acid chloride. This was dissolved in anhydrous dichloromethane and added 
dropwise to an excess of stirred and cooled tris(2-aminoethyl) amine. Analytical HPLC 
revealed the presence of three products as shown in figure 5.4. Upon separation by 
semi-preparative HPLC it was determined that the major product was the desired mono-
acridine conjugate (113). The second peak corresponded to the 'di' substituted 
compound (114), and it was expected that the third peak corresponded to the 'tri' 
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substituted compound (115) although only lmg of the material was isolated and a full 
characterisation was not possible. 
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The mono acridine conjugate (113) was used in attempts to prepare the macrocycle 
acridine conjugate (116). Conditions for this reaction were not optimised, but in 
principle, the remaining free amino group is available for reaction with a maleimide 
which can easily be linked to an antibody fragment to provide a compound of the 
desired type (112). 
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F I G U R E 5.4 HPLC chromatogram showing mixture of mono (113), bis (114), and 
tris (115) acridine compounds. 
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A similar procedure was carried out using N^-methyldiethylenetriamine in place of 
tris(2-aminoethyl) amine. 9-Acridine carboxylic acid was converted to the acid chloride 
using thionyl chloride as before. This was added slowly to a five-fold excess of N 2 -
methyldiethylenetriarnine with stirring at 0°C. Upon completion of the reaction the 
excess triamine was removed by distillation. Analytical HPLC showed that there were 
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two acridine products, the major product with retention time 6.1 minutes and the minor 
product at 9.3 minutes. Separation by semi-preparative HPLC provided the mono 
acridine conjugate (117) in 63% yield, and the bis acridine conjugate (118) in 10% 
yield. 
S C H E M E 5.4 
O ^ O H 
l . S O C l 2 
9-Acridine 
carboxylic acid 
CH2CI2 
DMAP 
(118) 
(117) 
DMSO 
N-methyl 
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0 2 N 
N0 2 
0 U N 0 2 
P 0. 
(119) 
The mono acridine conjugate (117) was treated with p-nitrophenyl succinate (81) under 
standard conditions to give the p-nitrophenolate active ester (119) in 96% yield after 
HPLC purification. 
The p-nitrophenolate acridine active ester (119) was not only readily synthesised in the 
method described previously. It was obtainable in high yield, 61% over two steps. 
Optimisation of the conditions for the formation of the mono-acridine compound over 
the bis-acridine would further increase the yield. In addition (119) was readily purified 
by semi-preparative HPLC, bearing two very strong chromophores. Figure 5.5 shows 
the spectral overlay plot of the ultra-violet spectra for the mixture of excess starting 
materials and products of this reaction. The acridine substrate (117) and product (119) 
CHAPTER 5: Acridine Conjugates 126 
are clearly distinguishable from the p-nitrophenyl compounds. The HPLC 
chromatogram shown in figure 5.6 shows the excellent separation obtainable for these 
materials. This combined with the strong yellow colour of the solution of (119) visible 
to the naked eye simplified the practical aspects of preparative HPLC purification. 
F I G U R E 5.5 Spectral overlay plot of Ultra- Violet spectra. 
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5.5 L A B E L L I N G WITH ACRIDINES 
The acridine active ester (119) has potential as a versatile agent for acridine labelling of 
a variety of compounds. In the first instance it will be tested by collaborators at 
Celltech in non-specific acridine labelling of antibody fragments (120) to determine 
whether the presence of the acridine intercalator enhances the binding of the antibody. 
It will also be used to bind to the antibody fragment of a 9N3-antibody conjugate to 
form a compound such as (121) to be used in 1 1 JIn labelling experiments. 
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Since the distance between the radioisotope and acridine in compound (121) may be 
relatively large and not well defined, the short range isotopes may be held at too great a 
distance from the cellular DNA to have maximum effect. Compounds of the type (122) 
may then be developed in which the acridine and radioisotope are in greater proximity; 
the by-product of the synthesis of (122) would be the bis intercalator (123) which may 
itself be of interest. 
A wide range of other possibilities for future development of this work exist. The 
versatility of (119) is such that it may also be used in the formation of conjugates with 
many other macrocycles and in conjunction with many other targeting vehicles. 
F I G U R E 5.6 HPLC chromatogram of reaction mixture in synthesis o/(119) 
3 U . 766 0 .914 
9 . 287 (117) 
1 0 . 3 2 5 
1 1 . 8 4 4 
(119) 
14 .00 
1 6 . 0 3 8 1 6 . 5 0 8 
1 8 . 0 5 5 p-nitrophenol 
2 6 . 1 2 3 (81) 
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F I G U R E 5.7 Proposed structure of acridine-antibody conjugates. 
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6.1 E X P E R I M E N T A L METHODS 
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For all the reactions performed, temperatures are quoted in degrees Celsius. All reactions 
were carried out in apparatus which had been oven dried and cooled under nitrogen. 
Alumina refers to Merck Alumina activity II - III that was soaked in ethyl acetate for 24 
hours prior to use. Silica refers to Merck silica gel F^O (230-400 mesh). 
and NMR spectra were obtained with a Bruker AC 250 operating at 250.13 and 
62.90 MHz respectively, Varian Gemini 200 operating at 200 and 50 respectively or a 
Varian VXR 400S operating at 400MHz. All chemical shifts are given in ppm 
(referenced to Me4Si (TMS) at 0 ppm). 3 1 P NMR spectra were obtained with a Bruker 
A L i J U O p C i c l L i i l g i l l iUilviriz,, cnc l i i iC i i i i>iiilLS d i £ g i V C i i l u d U i g i i C i UeCjUCiiCy >Ji 
H3PO4/H2O (external reference). 8 9 Y NMR spectra were obtained on a Bruker AM-500 
operating at 24.5 MHz, chemical shifts are given to higher frequency of YCI3 (1 mol dm* 
3 , 8 = 0 ppm). 7 1 G a NMR spectra in vitro were obtained using a Bruker AC250 
operating at 76.3MHz. Chemical shifts are given to a higher frequency of Ga(NO"3)3 in 
lmoldnr3 HNO3. 
Mass spectra were recorded on a V G 7070E mass spectrometer, operating on DCI or 
FAB ionisation modes from CH2CI2 or MeOH solutions with ammonia as the impingent 
gas, or using H 2 O as a matrix. Thermospray mass spectra were obtained using a VG 
TRIO 1000 spectrometer. Electrospray mass spectra were obtained using a VG AutoSpec 
or were performed by the SERC Mass Spectrometry Service at Swansea. 
Infra-red spectra were recorded on a Perkin-Elmer 577 or Perkin Elmer 1600 FT-IR 
spectrometer as a thin film, KBr disc or Nujol Mull as stated. 
Melting points were determined on a Kofler block and are uncorrected. 
All solvents used were dried from an appropriare drying agent and water was purified by 
the PURITE system 
Preparative T L C was carried out using MERCK 5726 Alumina PLC 150 F254 (type T) 
pre-coated 1.5mm plates. 
Analytical and semi-preparative HPLC was perfomed with a Varian Vista 5500 or Star 
5065 instruments fitted with reverse phase columns ("Dynamax" or "Spherisorb" 5 ODS 
2). X=254nm unless otherwise stated. Flow rates of 1.4 cm 3min _ 1 and 10.0 cm 3 min - 1 
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were used for analytical and semi-preparative columns respectively. Column and gradient 
elution conditions were as follows: for semi preparative reverse phase "Dynamax", t=0 
min, 90% H 2 O (0.1% trifluoroacetic acid), 10% MeCN (0.1 % trifluoroacetic acid); t=20 
min, 25% H 2 O , 75% MeCN; t=30 mins end time. For analytical reverse phase 
"Spherisorb" ODS t=0 min, 95% H 2 0 (0.1% trifluoroacetic acid), 5% MeCN (0.1% 
trifluoroacetic acid); t=20 min, 5% H2O, 95% MeCN; t=30 mins end time. 
6.2 C H A P T E R TWO E X P E R I M E N T A L 
6.2.1 S Y N T H E S I S O F Ga NOTA 
Triethyl-1,4,7-triazacyclononanetriyltriacetate (8)1 
-L,~r,/ i i iU^Uvj "viwiiviiuiiv \\J.^f^J^, A.^ 4""!" iiiiiivy-Ly Vy' aij i j i i i i i / i* i i i i-itv-/i.A Viii / Vvitii V &2r^ 5 
(1.96g, 6.02 mmol). Ethylbromoacetate was added (0.66 cm 3, 0.99g, 5.92 mmol) and 
the mixture heated to 60°C for 6 hours while monitoring by T L C . When reaction was 
complete the mixture was cooled, filtered and evaporated under reduced pressure and the 
residue taken up in dichloromethane. The insoluble solid material was washed out with 
water (3 x 10cm3) and the organic layer dried ( K 2 C O 3 ) and evaporated. The product was 
purified by gravitational alumina chromatography [gradient 0-5% MeOH in C H 2 C I 2 ] to 
provide a pale yellow oil, (0.48g, 64%); 8 H ( C D C I 3 ) 4.14 (6H, q, C H 2 0 ) , 3.25 (6H, s, 
C H 2 ) , 2.68 (12H, s, ring) and 1.22 (9H, t, C H 3 ) . 
1,4,7-Triazacyclononane-l,4,7-triacetic acid (l) 1 
Triester (8) (0.136g, 0.395 mmol) was hydrolysed in 6 M HC1 (15 cm 3) by heating the 
solution under reflux overnight. The product was cooled and evaporated under reduced 
pressure to yield a white crystalline solid (0.159g, quantitative); 5 H ( D 2 0 ) 3.89 ( 6 H , s, 
C H 2 C O 2 H ) and 3.37 (12H, s, ring). 
Gallium III complex of 1,4,7-triazacyclononane N,N', N" triacetate (9)1 
A solution of gallium nitrate (0.17 mmol, 0.04g) in dilute nitric acid (0.75 cm 3) was 
added to a solution of the ligand (1) (0.05g, 0.17 mmol) in dilute nitric acid (0.75 cm 3) 
and allowed to stand at R.T. for 24 hours. Acetone (2 cm 3) was added to the aqueous 
solution until a slight turbidity remained. A white solid precipitated, this was washed and 
dried under reduced pressure (0.013g, 0.034 mmol, 20%); S H ( D 2 0 ) 3.69 ( 6 H , s, 
CH 2 CO), 3.31 ( 6 H , m, CH 2 N) and 3.06 ( 6 H , m, CH 2 N); 5ca 170.2, external reference 
G a ( N 0 3 ) 3 in H N O 3 (aq). 
71 -Gallium III complex of 1,4,7-triazacyclononane N, N', N" triacetate (10) 
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A solution of 7 ] G a 2 0 3 (0.033g, 0.176 mmol) in HC1 (cone.) (1 cm 3) was added to a 
solution of the ligand (1) (0.107g, 0.353 mmol) in dilute HC1. The mixture was heated 
under reflux overnight until all the solids dissolved. As the solution cooled crystals 
appeared, these were washed in cold water and dried under reduced pressure. (0.018g, 
0.05 mmol, 14%); 8 H ( D 2 0 ) 3.69 (6H, s, CH 2CO), 3.31 (6H, m, CH 2 N) and 3.06 
(6H, m, CH 2 N); 6 G a 170.2. 
6.2.2 S Y N T H E S I S O F NOTPPri 
Isopropyldiethoxyphosphine (14) 
Isopropylmagnesiumchloride (2M in ether, 0.03 mol, 0.015 1) was stirred in a further 15 
cm 3 of ether and cooled in ice/salt/ethanol bath to -10°C. Diethylchlorophosphite (0.03 
moi, 4.7 7g, 4.77 cm J ) was added dropwise maintaining a temperature < 0°C. The 
mixture was allowed to warm to room temperature under Argon then the white solid was 
filtered under Argon giving a clear liquid which was purified by distillation (R.T., 0.01 
mm Hg) and collected in a liquid air cooled trap. (2.339g, 48%). 6p ( C D C I 3 ) 166.6. 
The product was used immediately without further purification. 
Triethyl 1,4,7-triazacyclononane N,N',N" tris[methylene(isopropylphosphinate)J (15) 
1,4,7-Triazacyclononane (0.258g, 2 mmol) was heated to reflux in dry THF over 
activated 4A molecular sieves. Paraformaldehyde (0.237 g, 8.8 mmol) and finally 
freshly prepared isopropyldiethoxyphosphine (14) (1.44g, 8.8 mmol) were added. The 
mixture was heated under reflux for 16 hours and monitored by TLC. Upon completion 
the mixture was filtered and solvent removed under reduced pressure. The resulting pale 
yellow oil was purified by gravitational alumina column chromatography (gradient elution 
0-2% MeOH in CH 2C1 2) to yield a clear oil (0.54g, 47%). R f 0.5 (alumina, CH 2 C1 2 : 
MeOH, 98:2); Found (M++1) 574.330 C 2 4 H 5 4 N 3 O 6 P 3 requires 574.330; m/z (DCI) 574 
(M++1), 454, 438 and 137; 5 H ( C D C I 3 ) 3.94 (6H, m, OCH 2), 2.6 (18H, m, CH 2 N, 
NCH 2 P), 1.95 (3H, m, CH), 1.15 (9H, t, J = 7 Hz, CH 2 CH 3 ) and 1.03 (18H, dd, 3 J P H 
= 16Hz, 3 J = 7 Hz, C H C H 3 ) ; 5 C ( C D C I 3 ) 60.8 (d, J=5Hz, POC), 57.5 (m, 
N C H 2 C H 2 ) , 55.8 (d, J=105Hz, NCH 2P), 26.7 (d, J=88Hz, CH), 17.1 (d, J=15Hz 
C H C H 3 ) and 15.8 (d, J=20Hz, CH 2 CH 3 ) ; 8 P (CDCI3) 57.0; v m a x ( f i l m ) 3400, 1659, 
1024 cm-'. 
1,4,7-Triazacyclononane N,N',N" tris[methylene(isopropylphosphinic)] acid (16) 
Triethyl 1,4,7-triazacyclononane N,N',N" tris[methylene(isopropylphosphinate)] (15) 
(0.187 g, 0.326 mmol) was heated to reflux in 6M-HC1 (70 cm 3) for 48 hours. The 
solvent was removed under reduced pressure to leave a brown glass (0.33 mmol, quant.) 
S H (D2O, pD=0.5) 3.5-3.0 (18H, m, NCH 2 ) , 1.9-1.4 (3H, m, CH), 0.95 (9H, d, 
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J=7Hz, CH 3 ) and 0.87 (9H, d, J=7Hz, CH 3 ); 5 P ( D 2 0 , pD=0.5) 50.8 , 49.7 (major 
peak); 8 C ( D 2 0 , pD=0.5) 17.0 (CH 3), 30.6 (d, J P C = 90Hz, PCH), 54.4 (NCH 2 ring), 
54.5 (d, Jp C = 80Hz, NCH 2P); v m a x (film) 2955vs, 1655, 1471, 1176 and 959cm"1; 
m/z (Thermospray)490(M++l), 449, 436, 418. 
Gallium complex of 1,4,7-triazacyclononane N,N',N" tris[methylene 
(isopropylphosphinic)] acid (17) 
1,4,7-Triazacyclononane N,N',N" tris[methylene(isopropylphosphinic)] acid (16) 
(0.05 g, 0.01 mmol) was heated with Ga(N0 3 ) 3 .H 2 0 (0.01 mmol, 0.026 g) in 0.04M 
H N 0 3 (3.5 cm 3) for 2 hours. The pH was then adjusted to 4 and the solution allowed to 
cool to R.T. The solvent was evaporated under reduced pressure to yield a hydroscopic 
yellow oil (0.01 mmol, quant.). 5 H (D 2 0) 3.5-2.7 (18H, br.m, NCH 2 ) , 2.0-1.7 (3H, 
m, Cri) and 1.15-0.85 (18H, br. m, CH 3 ) . 5 P ( D 2 0 ) 46.5. 5 G a ( D 2 0 ) 132.1. m/z 
(FAB) 556 (M+), 436, 131 and 56. v m a x (KBr) 3416, 2969, 1650, 1644, 1633, 1556, 
1469, 1392, 1368, 1289, 1143vs, 1021vs, 800, 751, 685 and 587cm-'. 
Indium complex of 1,4,7-triazacyclononane N,N',N" trisfmethylene 
(isopropylphosphinic)] acid (18) 
1,4,7-Triazacyclononane N,N',N" tris[methylene(isopropylphosphinic)] acid (16) 
(0.05g, 0.01 mmol) was heated with InCl 3 (0.1 mmol, 0.022 g) in 0.04M HC1 (2 cm 3) 
for 2 hours, the pH was then adjusted to 4.5-5.0 and the solution allowed to cool to R.T. 
The solvent was removed under reduced pressure to yield a hydroscopic pale brown solid 
(0.1 mmol, quant.). 8 H (D 2 0) 3.4-2.8 (18H, br. m, CH 2 N), 2.0-1.7 (3H, m, CH) and 
1.1-0.85 (18H, br.m, CH 3 ) . 5 P (D 2 0) 44.3. m/z (FAB) 602 (M+), 556, 185, 115, 93. 
v m a x (KBr) 3446, 2965, 1684, 1654, 1636, 1559, 1458, 1385, 1144vs, 1020vs, 886 
and 792cm'1. 
6.2.3 SYNTHESIS O F DTPA-BIS AMIDE 
N,N"-Bis(benzylcarbamoylmethyl)diethylenetriamine-N,N',N"-triacetic acid (19) 
To the dianhydride of diethylenetriamine-N,N,N',N",N"-pentaacetic acid (0.357g, 1 
mmol) in pyridine (3 cm 3) was added benzylamine (0.32 lg, 3 mmol) and DMAP (5mg). 
An immediate white precipitate was observed which dissolved after 30 min. The solution 
became clear and yellow, the mixture was heated at 50°C for 14 hours, solvent removed 
under reduced pressure and H2O added (1cm3) to give a solution at pH 4.5. Dilute HC1 
(0.1 mol dm - 3 ) was added dropwise until the pH was 3.5 when a white solid formed 
which was filtered, washed with dilute HC1 (pH 3.5, 3 x 2 cm 3) and dried under reduced 
pressure to yield a white free flowing solid (0.41g, 0.72 mmol, 72%); m.p 112-113°C 
(Found: C, 55.34; H, 6.74; N, 11.28%. C28H37N5O8.2H2O requires C, 55.4; H, 
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6.75; N , 11.53%); Rf 0.4 [silica gel, CH2Cl2-MeOH (95:5)]; Mass spectrum for the 
trimethyl ester: m/z (DCI) 614 (M++1), 237, 150 and 108; m/z (FAB) 572 (M+), 514, 
425, 350, 336, 277 and 249; S H [ ( C D 3 ) 2 S O ] 8.60 (2H, t, N H C O ) , 7.28 (10H, m, 
aromatic H), 4.28 (4H, d, J=15Hz, CH_2Ar), 3.39 (6H, s, CH.2CO2H), 3.32 (4H, s, 
CH2CO), 2.95 (4H, m, CH2N) and 2.83 (4H, m, CH2N); 8c [(CD 3 ) 2 SO] 172.6 
(CONH), 170.4 (CO2H), 169.7 (CO2H), 139.5 (q, aromatic C), 128.3, 127.2, 126.7 
(aromatic CH), 57.4, 55.1, 52.1, 50.8 and 41.9 (CH 2N); v m a x (KBr) 3736m, 3315s, 
3034m, 2550br, 1653, 1630vs (C0 2"), 1559s, 1375, 1222, 1101 (CO), 738 and 695 
cm"' 
Yttrium complex of N,N"-Bis(benzylcarbamoylmethyl)diethylenetriamine-N,N',N"-
triacetic acid (20) 
To a solution of the dibenzylamide (19) (O.lg, 0.175 mmol) in water (0.5 cm j ) was 
added a solution of yttrium nitrate (0.064g, 0.175 mmol) in HC1 (pH2, 1 cm 3) and the 
mixture was heated under reflux until the solution was completely clear. After cooling to 
room temperature, the pH was adjusted to 4. Crystals formed on standing which were 
filtered, washed with cold water (3 x 1cm3) and dried under vacuum (0.095 g, 74%). 
m/z (FAB) 658 (M++1), 600, 367, 277 and 241; (Found: C, 46.36; H, 5.42; N , 9.52. 
C 2 8 H 3 4 N 5 0 8 Y . 4 H 2 0 requires C, 46.03; H, 5.79; N, 9.59%); v m a x (KBr) 3407br 
(OH), 3250s, 3089m, 1616vs, br, 1497m, 1384vs, 1255m, 1097, 1029, 995, 931, 825, 
705 and 619cm"1; 8 R (D2O) 7.37 (10H, m, aromatic H), 4.45 (4H, br. m., Ctf 2 Ph), 
4.12 (2H, br. m, CH 2CO), 3.61-3.38 (10H, br. m, CH 2 N) and 2.9-2.3 (8H, br. m, 
CH 2 N); 6y (D2O) +80.0. 
6.2.4 9N3 BASED LIGANDS FOR Gd 
1,4,7-Tris(methylcarbamoylmethyl)-l,4,7-triazacyclononane (22) 
1,4,7-Triazacyclononane (0.5g, 3.9 mmol) was stirred in dry MeCN, K 2 C O 3 (12 mmol, 
1.66g) and 2-bromo-N-methylethanamide (12 mmol, 1.8g) were added and the mixture 
heated to reflux for 24 hours. Upon cooling the inorganic solids were filtered and the 
solvent removed under reduced pressure, the resulting brown oil was taken up in 1M HC1 
and washed with CH 2C1 2 (10cm3). The pH was adjusted to 14 and the product extracted 
with CH 2 C1 2 (4 x 20cm3), dried over K 2 C O 3 , filtered and evaporated to give a yellow 
oil. This was recrystallised from toluene to give a white solid (0.9lg, 2.7 mmol, 69%); 
Vmax (oil) 1650 cm- 1; 8 H (CDCI3) 7.45 (3H, q, J = 4.7Hz, NH), 3.17 (6H, s, 
NCH 2 CO), 2.74 (9H, d, J = 3.6Hz, CH 3 ) and 2.67 (12H, s, CH 2 N); 8 C (CDCI3) 
172.5 (CO), 62.0 (CH 2 0), 55.4 (CH 2N) and 26.4 (CH 3); m/z (DCI) 343 (M++1), 286, 
272; (Found: M+ 342.2367 C 1 5 H 3 0 N 6 O 3 requires 342.2379). 
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1,4,7-Tris(benzylcarbamoylmethyl)-l,4,7-triazacyclononane(22>) 
1,4,7-Triazacyclononane (0.4814g, 3.7 mmol) was heated to reflux in MeCN (10cm3) 
with 2-chloro-N-benzylethanamide (11.6 mmol, 2.12g) and K2CO3 (11.6 mmol, 1.6g) 
for 24 hours. It was then cooled, filtered and evaporated to give an orange/brown oil. 
This was purified by gravitational alumina column chromatography (gradient eluant 0-2% 
MeOH/ CH 2 C1 2 ) to yield a pale yellow oil (0.613g, 1.05 mmol, 29%). R f = 0.2 
(streaked); Found 570.3696 C33H42N6O3 calculated 570.3318; m/z (DCI) 571 (M++1), 
255; v m a x (oil) 3295 (NH), 3029 (ArCH), 2924, 1665 (amide) and 1529cm"1; 5 H 
( C D C I 3 ) 7.36-7.15 (18H, m, NH and Ar), 4.37 (6H, d, J =5.8Hz, NHCH 2), 3.04 (6H, 
s, CH 2CO) and 2.61 (12H, s, CHN); 8 C (CDCI3) 171.4 (CO), 138.8 (Ar quat), 129.2, 
128.4, 128.1(Ar), 62.3 (NCH 2CO), 56.8 (CH 2N) and 43.7 (CH 2Ar). 
hv!))-I 4 7 trinr-nrvrlnrtnnr^» H4> 
L i A l H 4 (22.2 mmol, 0.84 g) was stirred in dry ether under N2(g), 1,4,7-
tris(methylcarbamoylmethyl)-l,4,7-triazacyclononane (22) (1.28g, 3.7 mmol) in 
CH2CI2 (15 cm 3) was added dropwise over 30 mins and the mixture then heated to 
reflux for 18 hours. The suspension was quenched successively with H2O (2cm3), 15% 
KOH (5 cm 3), filtered through celite, washed with E t 2 0 (2 x 10cm3) and evaporated to 
dryness leaving a clear oil. This was dissolved in 1M HC1 (5cm3), washed with Et20 (2 
x 10cm3), basified with KOH and extracted with CH2CI2 (4 x 10cm3) to yield a clear oil 
(0.275g, 0.93 mmol, 25%); m/z (DCI) 301 (M++1), 288, 244 and 58; v m a x (film) 
3395vs, 2942, 2828, 1649, 1546, 1377, 1300, 1113, 1035, 876, 731 and 607cm"1; 8 H 
(CDCI3) 2.63 (12H, m, CH 2N), 2.56 (12H, t, J = 3Hz, ring CH 2N), 2.38 (9H, s, CH 3 ) 
and 2.17 (3H, s, NH); 6 C (CDCI3) 59.0 (CH 2N), 57.3 (CH 2 N ring), 50.6 (CH 2N) and 
36.9 (CH 3 ). 
1,4,7- Tris(N-benzyl-2-aminoethyl))-1,4,7-triazacyclononane (25) 
l,4,7-Tris(benzylcarbamoylmethyl)-l,4,7-triazacyclononane (23) (1.07 mmol, 0.6129g) 
in CH2C1 2 (10 cm 3) was added dropwise to a suspension of LiAlH4 (13 mmol, 0.5g) in 
Et20 (10 cm 3) and heated to reflux for 18 hours. After quenching the suspension was 
basified (KOH), extracted into CH2CI2 (5 x 10cm3) and evaporated to yield a yellow oil 
(0.414g, 0.78 mmol, 73%); m/z (DCI) 529 (M++1), 410, 396, 374; v m a x (oil) 3406 
(NH), 3084, 3080, 3028 (Ar CH), 2923, 2823, 1647, 1603, 1549, 1453, 737 and 
699cm-'; 5 H (CDCI3) 7.33 (15H, m, Ar), 3.78 (6H, s, CH 2 Ar), 2.66 (12H, m, CH 2 N), 
2.63 (I2H, m, CH 2 N) and 2.05 (3H, br s, NH); 5 C (CDCI3) 141.1 (Ar quat), 128.8, 
128.7 (Ar), 127.3 (Ar), 59.1 (CH 2 N), 57.2 (CH 2 N ring), 54.6 (CH 2 N) and 48.0 
(CH 2 Ar). 
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1,4,7-Tris(N-methyl-N-ethoxycarbonylmethyl-(2-aminoethyl) )-l,4,7-
triazacyclononane(26) 
l,4,7-Tris(N-methyl-2-aminoethyl))-l,4,7-triazacyc]ononane (24) (0.27g, 0.93 mmol) 
was dissolved in dry EtOH (3cm 3) and stirred with dry C S 2 C O 3 (3.1mmol, l.Og). 
Ethylbromoacetate (3.1mmol, 0.52g, 0.34cm3) was added and the mixture heated to 
65°C for 2 hours. A further portion of ethylbromoacetate was then added (0.2cm3) and 
heated to reflux for a further 2 hours. The mixture was cooled, filtered and evaporated to 
yield a brown oil (0.746g) which was purified by gravitational alumina column 
chromatography (gradient elution 0-10% Pr'OH in CI12CI2) to yield a yellow oil (0.2g, 
0.41mmol, 44%). R f 0.45 (streaked) [Alumina, MeOH-CH 2Cl 2 (5:95)]; Found (M++1) 
559.418 C27H 5 4N 6 0 6 requires 559.418; m/z (DCI) 559 (M++1), 532, 505, 475, 224 
and 180; 5 H ( C D C I 3 ) 4.22 (6H, q, J= 6Hz, C O C H 3 ) , 3.25 f6H, s, NCH 2CO), 3.2-2.55 
()TU k r „, pu»M\ o dl fQH s M C H - > and • 2^ ( W t I - 6Hz. CHiV V - ffi!m> 
3440vs, 1737, 1638vs, 1560, 1466, 1412, 1380, 1206s, 1096, 1025 and 909cm"1. 
1,4,7-Tris(N-benzyl-N-ethoxycarbonylmethyl-(2-aminoethyl))-l,4,7-triazacyclononane 
l,4,7-Tris(N-benzyl-2-aminoethyl)-l,4,7-triazacyclononane (25) (0.78mmol, 0.414g) 
was stirred in dry MeCN (3cm3) with K2CC>3 (2.6mmol, 0.36g). Ethylbromoacetate 
(2.6mmol, 0.43g, 0.29cm3) was added and the mixture heated to 40°C for 3 hours. The 
mixture was then cooled, filtered and solvent evaporated to give a brown/orange oil 
(0.48g) which was purified by gravitational alumina column chromatography (gradient 
elution 0-5% MeOH in CH 2C1 2) to yield a yellow oil (0.315g, 0.4mmol, 77%). Rf 0.4 
[Alumina MeOH-CH 2 Cl2, (95:5)]; Mass found 787.5121 C 4 5 H 6 6 N 6 0 6 requires 
787.5122; m/z (DCI) 787 ( M + + l ) , 580, 263, 220, 194 and 148; 5 H (CDCI3) 7.27 (15H, 
m, Ar), 4.13 (6H, q, J = 7.2Hz, C H 2 C H 3 ) , 3.74 (6H, s, C H 2 A r ) , 3.29 (6H, s, 
CH 2 CO), 2.95 (12H, s, CH 2 N), 2.83 (12H, s, CH 2 N) and 1.24 (9H, t, 7=7.1Hz, 
C H 3 ) ; 6 C (CDCI3) 171.7 (CO), 138.8, 129.5, 128.9, 127.8 (Ar), 60.9, 50.1, 55.2, 
54.9 (CH 2 N), 53.0, 51.2 (CH 2Ar) and 14.7 (CH3); v m a x (film) 3422vs, 3027, 2980, 
2843, 1732vs (ester), 1650, 1556, 1453, 1194vs, 1028s, 739vs and 701 cm"1. 
1,4,7-Tris(N-benzyl-N-carboxymethyl-(2-aminoethyl))-l,4,7-triazacyclononane (28) 
^ r~\ _ 
Bz CQ2H 
1,4,7-Tris(N-benzyl-N-ethoxycarbomylmethyl-(2-aminoethyl))-1,4,7-triazacyclononane 
(27) was heated to reflux with 6M HC1 (5cm3) overnight and monitored by TLC. The 
(27) 
N Bz N 
N 
V-CObH 
CObH 
N 
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solvent was removed under reduced pressure to yield a pale yellow glass (0.24g, quant); 
m/z (FAB) 702 ( M + ) , 565, 635, 185, 91 and 75; 5 H ( D 2 0 ) 7.27 (15H, m, Ar), 4.34 
(6H, s, CH 2 Ar), 3.93 (6H, s, CH2CO), 3.55 (6H, br s, CH^N), 3.40 (6H, br s, CH 2 N) 
and 3.17 (12H, br s, CH 2 N ring); 5 C (D 2 0) 170.9 (CO), 134.4, 133.6, 132.4, 130.6 
(Ar), 62.5, 56.3, 56.2, 53.6, 52.6, 52.2 and 52.1; v m a x (nujol) 1731 (CO acid), 747 and 
700cm'1. 
Gadolinium Complex of 1,4,7-tris(N-benzyl-N-carboxymethyl-(2-aminoethyl))-l,4,7-
triazacyclononane (29) 
l,4,7-Tris(N-benzyl-N-acetate-(2-aminoethyl))-l,4,7-triazacyclononane (25) (O.lg, 
0.14mmol) was dissolved in 0.1M HC1 and Gd 203 (s) (0.06g, 0.17mmol) was added, 
the pH was adjusted to 2 and the mixture was heated to 80°C until a clear brown solution 
was formed. The pH was adjusted to 6 using 0.1M NaOH and heating continued for a 
further 3 hours. The solvent was removed under reduced pressure and the product was 
purified by preparative TLC [Alumina MeOH - CH 2 C1 2 (10:90)] R f 0.2 (streaked) to 
yield a white solid (0.018g, 0.021mmol, 15%); m/z (FAB) 858, 641, 551, 493, 462 and 
435; v m a x (film) 3399 (vs, br), 1613vs, 1450, 1416, 1328, 750 and 702cm"1. 
6.2.5 SYNTHESIS OF 12N3 BASED LIGANDS F O R G A D O L I N I U M 
1,5,9-Tris(methylcarbamoylmethyl)-1,5,9-triazacyclododecane (30) 
1,5,9-Triazacyclododecane (0.5g, 2.9 mmol) in dry ethanol (10 cm 3) was heated to 
reflux with 2-chloro-N-methylethanamide (9.6 mmol, l . l g ) and K 2 C03 (9.6 mmol, 
1.32g) for 24 hours. The mixture was then cooled, filtered and evaporated giving a 
yellow oil. This was dissolved in 1M HC1 (5cm 3), washed with CH 2 C1 2 (10cm 3 ) , 
basified with KOH and extracted with CHQ3 (5 x 10cm3). Drying and evaporation gave 
a yellow oil, this was purified by gravitational alumina column chromatography (0.55g, 
1.4 mmol, 50%); (eluant 2% MeOH in CH2C12) R f 0.3 (streaked); Mass found 384.2828 
C i 8 H 3 6 N 6 0 3 calculated 384.2849; m/z (DCI) 385 (M++1), 127, 74; v m a x (oil) 3386 
(NH), 2941, 2812, 1651 (amide) and 1547cm-'; 6 H (CDCI3) 7.08 (3H, brq, NH), 2.91 
(6H, s, CH 2CO), 2.69 (9H, d, J =4Hz, CH 3 ) , 2.45 (12H, t , J =6Hz, NCH 2 ) and 1.53 
(6H, p,J = 6Hz, CH 2 ); 8 C ( C D C I 3 ) 172.0 (CO), 58.9 (NCH 2CO), 50.8 (NCH 2 ), 26.3 
( C H 3 ) and 23.4 (CH 2). 
1,5,9- Tris(benzylcarbamoylmethyl)-1,5,9-triazacyclododecane (31) 
1,5,9-Triazacyclododecane (0.5g, 2.9mmol) in dry ethanol (10cm3) was heated to reflux 
with 2-chloro-N-benzylethanamide (1.8g, 9.6mmol) and K 2 C03 (1.3g, 9.6mmol) for 18 
hours and reaction was monitored by TLC. The mixture was cooled, filtered and 
evaporated giving a brown oil, this was treated with 1M KOH (5cm3) and extracted into 
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CH 2 C1 2 (3 x 10cm3) to yield a pale brown oil (1.32g, 2.2mmol, 74%); R f 0.8 [Alumina 
TLC MeOH-CH 2 Cl 2 (5:95)]; m/z (DCI) 613 ( M + + l ) , 466, 203, 150 and 108; 5 H 
(CDC13) 7.21 (3H, t, NH), 7.15 (15H, m, Ar), 4.28 (6H, d, J =5.4Hz, CH 2 Ar) , 2.78 
(6H, s, CH 2CO), 2.15 (12H, t, J = 5.4Hz, CH 2 N ring) and 1.54 (6H, p, J = 5.4Hz, 
CH 2 ) ; 5 C ( C D C I 3 ) 171.1 (CO), 138.6 (quat Ar), 129.2, 128.2, 128.4, 128.1 (Ar), 58.9 
(CH 2 Ar), 50.6, 43.7 (CH 2N) and 22.8 (CH 2); v m a x (film) 3305, 3062, 3029, 2927, 
2817, 1658.7(vs, amide CO), 1520.9s, 1453.8m, 1127.3w, 1246m, 910.9m, 730.8s 
and 700.0s cm"1. 
1,5,9-Tris(N-methyl-2-aminoethyl)-l,5,9-triazacyclododecane (32) 
l,5,9-Tris(methylcarbamoylmethyl)-l,5,9-triazacyclododecane (30) (0.5524g, 1.4 
mmol) in CH 2 C1 2 (15 cm 3) was added dropwise to a suspension of U A I H 4 (8.4 mmol, 
0.32g) in E t 2 0 (15 cm 3) and heated under reflux overnight. Excess LiAlHU was 
quenched with H 2 0 (2cm3) and 15% KOH (2 cm 3), washed with E t 2 0 (5cm 3) and 
evaporated to yield a yellow oil (0.3028g, 0.88 mmol, 63%); Mass found (M++1) 
343.3549 C i 8 H 4 2 N 6 calculated 343.3549; m/z (DCI) 343 (M++1), 298 and 286; v m a x 
(oil) 3398 (NH), 2956cm"1; 8 H (CDCI3) 2.47 (6H, t, J = 6Hz, CH 2 N), 2.35-2.25 (27H, 
m, CH 2 N, CH 3 N) and 1.40 (6H, p, J = 6Hz, CH 2 ) ; 5 C (CDCI3) 54.0, 50.0 (CH 2 N), 
37.0 (CH 3) and 21.8 (CH 2). 
1,5,9-Tris(N-benzyl-2-aminoethyl)-1,5,9-triazacyclododecane (33) 
l,5,9-Tris(benzylcarbamoylmethyl)-l,5,9-triazacyclododecane (31) (1.3g, 2.2mmol) in 
CH 2 C1 2 (10cm3) was added dropwise to a suspension of U A I H 4 (26.4mmol, lg) in dry 
ether (10cm3) and heated under reflux overnight. After quenching as described for (24), 
the suspension was basified (KOH) and extracted into CH 2 C1 2 (5 x 10cm3), and 
evaporated to yield a yellow oil (0.763g, 1.34mmol, 61%); m/z (DCI) 571 ( M + + l ) , 482 
and 438; 5 H (CDCI3) 7.27 (15H, br s, Ar), 7.20 (3H, br m, NH), 3.73 (6H, s, CH 2 Ar) , 
2.62 (6H, t, / = 5Hz, CH 2 N), 2.42 (6H, t, J = 5Hz, CH 2 N), 2.31 (12H, t, J = 5Hz, 
CH 2 N) and 1.43 (6H, m, CH 2 ); 8 C (CDCI3) 140.8 (Ar quat), 128.8, 128.6, 127.4 (Ar), 
54.5 (CH 2N), 54.1 (CH 2N), 50.0 (CH 2 N, ring), 47.1 (CH 2Ar) and 21.8 (CH 2 ) ; v m a x 
(film) 3300, 3084, 3060, 3025, 2955, 2800vs, 1666s, 1494, 1453vs, 1359, 1245, 
1117s, 735vs and 698vs cm"1. 
/ , 5,9- Tris( N-tnethyl-N-ethoxycarbonylmethyl-( 2-aminoethyl))-1,5,9-
triazacyclododecane (34) 
l,5,9-Tris(N-methyl-2-aminoethyl)-l,5,9-triazacyclododecane (32) (0.2g, 0.58mmol) 
was heated to 40°C for 5 hours in MeCN (3cm3) with K 2 C 0 3 (1.9mmol, 0.26g) and 
ethylbromoacetate (1.9mmol, 0.32g, 0.21cm3). Progress of the reaction was monitored 
by TLC. After filtration and evaporation of the solvent the resulting brown oil was 
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purified by gravitational alumina column chromatography (gradient elution fom 0-10% 
MeOH in CH 2C1 2) to yield a yellow oil (0.322g, 0.54 mmol, 93%); R f 0.6 (streaked) 
[alumina, MeOH - CH 2 C1 2 (5:95)]; (Found 601.4646 C 3 oH6iN 6 0 6 requires 601.4652); 
m/z (DCI) 601 ( M + + l ) , 544, 470, 413 and 213; 5 H (CDC! 3) 4.18 (6H, q, J = 7.2Hz, 
OCH 2 ) , 3.27 (6H, s, CH 2CO), 3.00-2.45 (21H, m, CH 2 N, CH 3 N), 2.38 (12H, m, 
CH 2 N), 1.6 (6H, br m, CH 2 ) and 1.28 (9H, t, J = 7Hz, CH 3 ); 5 C ( C D C I 3 ) 171.3 (CO), 
60.9 (OCH 2), 59.3 (NCH 2CO), 55.3, 52.3, 49.8 (NCH 2), 43.3 ( N C H 3 ) , 21.7 (CH 2 ) 
and 14.7 ( C H 3 ) ; v m a x (film) 3420vs, 2962, 2805, 1732vs, 1633s, 1565vs, 1454, 
I409vs, 1250, 1192vs, 1116 and 1028cm"1. 
1,5,9-Tris(N-benzyl-N-ethoxycarbomylmethyl-(2-aminoethyl))-l ,5,9-
triazacyclododecane (35) 
1,5,9-Tris(N- benzyi-2-aminoethyi)-i,5,9-triazacyciododecanc (33) (0.368g, O.ujmmol) 
was stirred in dry MeCN (3cm3) with K 2 C03 (2.1 mmol, 0.29g). Ethylbromoacetate 
(2.1mmol, 0.36g, 0.24cm3) was added and the mixture heated to 50°C for 3 hours. It 
was then cooled, filtered and evaporated to give a yellow/orange oil (0.7g) which was 
purified by gravitational alumina column chromatography (gradient elution 0-5% MeOH 
in CH 2C1 2) to yield a yellow oil (0.4g, 0.48mmol, 74%). R f 0.35 (streaked) [Alumina 
MeOH-CH 2Cl2, (95:5)]; m/z (DCI) 829 ( M + + l ) , 754, 696, 610, 194, 116 and 58; 8 H 
(CDCI3) 7.15 (15H, s, Ar), 3.97 (6H, q, 7=7.1Hz, OCH 2), 3.55 (6H, s, CH 2 Ar), 3.10 
(6H, s, NCH 2CO), 2.47 (12H, m, CH 2N), 2.10 (12H, m, CH 2 N ring), 1.35 (6H, br 
m, C H 2 ring) and 1.10 (9H, t, 7=7.1Hz, CH 3 ) ; 5 C (CDCI3) 171.7 (CO), 138.5 (Ar 
quat), 129.6, 129.2, 128.0 (Ar), 60.7 (OCH 2), 58.8 (NCH 2CO), 57.4, 55.0, 51.0 
(CH 2 N), 48.7 (CH 2 Ar), 20.1 (CH 2) and 14.3 (CH 3); v m a x (film) 3418vs, 2977, 2812, 
1736vs, 1649.9, 1453, 1379, 1196vs, 1112, 1027, 745, and 701cm"1. 
1,5,9-Tris(N-benzyl-N-t-butylacetate-(2-aminoethyl))-1,5,9-triazacyclododecane (36) 
l,5,9-Tris(N-benzyl-2-aminoethyl))-l,5,9-triazacyclododecane (33) (0.39g, 0.68mmol) 
was stirred in dry EtOH (2cm3) with K 2 C 0 3 (2.26mmol, 0.3lg) and t-butylbromoacetate 
(2.26mmol, 0.44g, 0.367cm3) and heated to 40°C for 18 hours. The reaction was 
monitored by TLC, and further t-butylbromoacetate (0.07g, 0.34mmol, 0.06cm3) was 
added and heated for a further 6 hours. The mixture was filtered and evaporated under 
reduced pressure to give a yellow oil (0.775g) which was purified by flash silica column 
chromatography [MeOH - CH 2C1 2 (5:95)] to yield a pale yellow oil (0.50g, 0.548mmol, 
81%). m/z (DCI) 915 ( M + + l ) 859, 801, 752, 422 and 191; 5 H (CDCI3) 7.21 (15H, s, 
Ar), 3.64 (6H, s, NCH 2 Ar), 3.28 (6H, s, NCH 2CO), 3.08 (6H, m, CH 2 N), 2.92 (6H, 
m, CH 2 N), 2.51 (12H, m, CH 2 N ring), 2.04 (6H, m, C H 2 ring) and 1.37 (27H, s, 
CH 3 ) ; 5 C (CDCI3) 170.9 (CO), 138.9 (Ar quat), 129.9, 128.9, 128.1 (Ar), 81.8 (quat), 
59.0, 55.8, 51.9 (CH 2 N), 48.9 (CH 2 Ar), 28.6 (CH 3 ) and 20.0 (CH 2); v m a x (fi lm ) 
CHAPTER 6: Experimental 141 
3854vs, 2975, 281 1, 1732vs, 1660vs, 1495, 1367, 1250, 1220, 1153, 1077, 1028, 918 
and 843cm"1. 
/,5,9-Tris(N-benzyl-N-acetate-(2-aminoethyl))-1,5,9-triazacyclododecane (37) 
1,5,9-Tris(N-benzyl-N-ethylacetate-(2-aminoethyl))-1,5,9-triazacyclododecane (35) 
(O.lg, 0.12mmol) was treated with 6M HC1 (20cm3) and heated to 110°C for 48 hours. 
The solution was evaporated under reduced pressure and a sample was purified by 
preparative reverse phase HPLC (conditions stated above) R t = 17.9 mins (0.006g, 1%). 
m/z (FAB) 727,115 and 91; v m a x (KBr disc) 3447vs, 1676vs, 1458, 1420, 120 lvs and 
1134s cm- 1; 5 H ( D 2 0 , pD=1.5) 7.41 (15H, s, Ar), 4.30 (6H, s, CH 2 Ar), 3.79 (6H, t, / 
= 5Hz, CH 2CO), 3.62-2.60 (24H, m, CH 2 N) and 1.95-1.65 (6H, br m, CH 2 ) ; 5 C 
( D 2 0 ) 172.4, 172.3 (CO), 134.0, 133.4, 132.4, 132.0, 131.7, 131.2 (Ar), 62.5 
(H 2 Ar) , 57.8 (CH 2CO), 52.8, 52.4, 52.1, 51.5, 50.9 (CH 2N) and 20.2 (CH 2). 
6.2.6 S Y N T H E S I S O F PHOSPHINIC ACID ANALOGUES 
Triethyl 1,4,7-tris(N-benzyl-N-methylenemethylphosphinate-2-aminoethyl)-l,4,7-
triazacyclononane (38) 
l,4,7-Tris(N-benzyl-2-aminoethyl)-l,4,7-triazacyclononane (25) (0.178g,0.34mmol) 
was dissolved in THF (30cm3) and heated to reflux with paraformaldehyde (0.06g, 
1.5mmoI), methyldiethoxyphosphine (0.2 lg, 1.5mmol) in THF (5cm3) was added and 
the mixture heated to reflux over 4 A molecular sieves for 18 hours. The mixture was 
filtered and the filtrate was evporated under reduced pressure to give a yellow oil (0.62g). 
This was purified by gravitational alumina column chromatography [gradient elution 0 
-5% MeOH in CH 2C1 2] to yield a pale yellow oil (0.201, 0.24mmol, 69%); Rf 0.4 
[alumina MeOH - CH 2 C1 2 (10:90)]; Mass found 889.5044 C 45H7 6N 606P3 requires 
889.5039; m/z (DCI) 890, 769, 649, 226, 150, 109 and 91; 5 H (CDCI3) 7.26 (15H, s, 
Ar), 4.02 (6H, q, OCH 2), 3.75 (6H, d, J = 13Hz, CH 2P), 2.79 (30H, m, CH 2 N, ring, 
NCH 2 P), 1.36 (9H, d, 7=14Hz, PMe) and 1.27 (9H, t, 7 = 7Hz, CH 3 ); 5 C (CDC13) 
139.0 (quat), 129.6, 128.8, 127.8 (Ar), 61.3 (d, / = 10Hz), 60.7 (d, / =6Hz), 56.3 , 
55.2, 54.3 (d, lJ = 91 Hz, NCH 2P), 52.2 (CH 2 N), 17.1 (CH 2 CH 3 ) and 14.2 (d, IJ 
92Hz, PCH 3); 5 P (CDCI3) 52.6; v m a x (film) 3417.6vs, 2981, 2835, 1659.5, 1572, 
1453, 1393, 1299, 1190vs, 1037vs, 950s, 720 and 701.5cm"1. 
N N Bz N ( CO N L - C O . H 
CQ,H I N 
Bz C Q , H 
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1,4, 7-Tris(2-aminoethyl-N-benzyl-N-methylenemethylphosphinic acid)-1,4, 7-
triaz.acyclononane (39) 
Triethyl 1,4,7-tris(N-benzyl-N-methylenemethylphosphinate-2-aminoethyl)-1,4,7-
triazacyclononane (38) (0.045g, 0.053mmol) was heated to reflux in MeOH (2.5cm3) 
with 1M KOH (2.5cm3) for 16 hours. The solution was cooled, neutralised using 1M 
HC1 (aq) and evaporated to dryness to yield a yellow oil and KCl(s). This was purified 
using semi-preparative reverse phase HPLC under standard conditions; Rt= 9.9 mins, to 
yield a pale yellow glass (0.02g, 0.0025mmol, 5%); m/z (FAB) 805.5 (M++4H), 779.5, 
741.5, 713.6, 687.5, 226.1, 175.1 and 134.1; 5 H ( D 2 0 , pD = 14) 7.30 (15H, br, Ar), 
3.73 (6H, s, CH 2 Ar), 2.7-2.4 (30H, m, CH 2 N, NCH 2P) ?.nd 1.23 (9H, d, 7 = 13Hz, 
PMe); 8 C ( D 2 0 ) 184.4, 174.0, 139.4 (quat), 132.9, 131.8, 31.2 (Ar), 62.9, 62.7 
(CH 2 Ar), 57.39 (d, J = 10Hz, PCH 2N), 54.8 (CH 2N), 53.8, 53.7 (CH 2N), 52.5 (ring) 
and 18.79 (d, 7 = 9Hz, PMe); 8 P ( D 2 0 , pD=7) 37.9; v m a x (film) 3424vs, 1639, 1135, 
1031 and 739cm-'. 
Triethyl 1,5,9-tris( N-benzyl-N-methylenebenzylphosphinate-2-aminoethyl)-1,5,9-
triazacyclododecane (40) 
l,5,9-Tris(N-benzyl-2-aminoethyl)-l,5,9-triazacyclododecane (33) (0.172g, 0.3mmol) 
was heated to reflux in dry THF (30cm3) over activated 4A molecular sieves with 
paraformaldehyde (0.041g, 1.32mmol), benzyldiethoxyphosphine (0.282g, 1.32mmol) 
was added and the mixture heated to reflux for 16 hours. Reaction was judged to be 
complete when P NMR showed the absence of any phosphine. The mixture was 
filtered and evaporated under reduced pressure and purified by gravitational alumina 
column chromatography [gradient elution 0-10% MeOH in CH 2C1 2] to yield several 
mixed fractions and a pure pale yellow oil (0.0343g, 0.030mmol, 10%) Rf 0.15 
(streaked) [alumina MeOH-CH 2Cl 2 (2:98)]; 8 H (CDCI3) 7.30 (15H, Ar), 7.23 (15H, s, 
Ar), 4.05 (6H, q, OCH 2), 3.72 (6H, s, CH 2 Ar), 3.15 (6H, d, J= 16Hz, PCH 2Ar), 2.9-
2.2 (30H, m, CH 2 N, NCH 2P), 1.35 (6H, br s, CH 2 ) and 1.25 (9H, t, J= 8Hz, CH 3 ) ; 
8 C (CDCI3) 138.5, 129.9, 129.1, 128.9, 128.5, 128.3, 127.2, 126.7 (Ar), 60.4 (d, 2J = 
8Hz, OCH 2 ) , 60.7 (d, J =7Hz, CH 2 Ar), 53.2 (d, 3 J 12Hz, CH 2 N), 51.9 (d, lJ = 
95Hz, PCH 2 ), 51.6 (NCH 2), 49.4 (CH 2N), 35.0 (d, ]J= 84Hz, PCH 2Ar), 21.4 (CH 2 
ring) and 16.5 (d, 3J = 5Hz, CH^Hs) ; 8 P (CDC13) 49.2; v m a x (film) 3486vs, 1634vs, 
1495, 1454, 1404, 1296, 1262, 1160, 1046, 965 and 798cm-'. 
N N Bz Bz 
N 
V - P M e a H N 
PMeOsH k ^ N 
Bz PMeO^H 
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1,5,9-Tris(2-aminoethyl-N-benzyl-N-methylenebenz.ylphosphinic acid)-1,5,9-
triazacyclododecane (41) 
Triethyl 1,5,9-tris(N-benzyl-N-methylenebenzylphosphinate-2-aminoethyl))-1,5,9-
triazacyclododecane (40) (0.039g, 0.036mmol) was heated to reflux in 6M H Q 
(15cm 3) for 20 hours. The solution was then cooled and the solvent removed under 
reduced pressure to yield a clear glass (0.036mmol, 0.041g); m/z (FAB) 1071 ( M + ) , 
986, 908, 819 and 775; 5 H (D 2 0, pD=0) 7.4-7.0 (30H, m, Ar), 4.31 (6H, s, CH 2 Ar) , 
4.20 (oH, s, C H 2 A r j , 3.5y (oH, 111, L r i 2 N ) , 3.19 ^ i 2H, rn, C H 2 N j , 2.93 (12H, in, 
CH 2 N) and 1.81 (6H, br m, CH 2 ); 5 p (CD3OD) 40.8; 5 P ( D 2 0 ) 30.7; v m a x (film) 
3339vs, 3167, 3002, 2578s, 1690vs, 1654, 1495, 1455, 1202, 1170, 1068, 976, 832, 
746 and 700cm"1. 
6.2.7 Y T T R I U M COMPLEXATION 
Yttrium complex of 1,4,7,10-tetraazaclylododecane-N,N',N",N"'-tetraacetic acid (42) 
The ligand DOTA 3 (0.0268g, 0.066mol) was suspended in MeOH (1cm3) and stirred and 
heated to 60°C. Yttrium triflate2 (0.0355g, 0.066mmol) in MeOH (0.5cm3) was added 
to the suspension and heating continued for 48 hours. The mixture was cooled and a 
white solid was collected, washed in MeOH and dried under reduced pressure. lH NMR 
confirmed that the product was Y-DOTA, by comparison with an authentic sample.1 ,4 
Yttrium complex of 1,4,7-tris(2-aminoethyl-N-benzyl-N-methylenemethylphosphinic 
acid)-1,4,7-triazacyclononane (43) 
1,4,7-Tris(2-aminoethyl-N-benzyl-N-methylenemethylphosphinic acid)-1,4,7-
triazacyclononane (39) (0.02g, 0.025mmol) was heated to reflux in dry MeOH (5cm 3) 
with yttrium triflate 2 (0.0134g, 0.025mmol) for 24 hours. 3 1 P NMR of the crude 
reaction mixture gave a broad peak 5p 40.7. E t 2 0 was added carefully and white 
precipitate began to appear. After 12 hours the suspension was centrifuged and washed 
with E t 2 0 and dried under reduced pressure to yield a white solid (0.019g, 0.021 mmol, 
84%); HPLC analytical Rt=10.7mins; v m a x (film) 3385, 1641, 1256, 1171, 1068 and 
1031cm-1; 8 P (CD3OD) 40.7; 5 H (CD3OD) 9.78 (15H, br s, Ar), 5.6-5.0 (28H, br m, 
CH 2 N) and 4.1-2.9 (9H, br m, PMe). 
Bz Bz N 
( CO N' V - P B z 0 2 H 
PBzOoH N 
Bz P B z 0 2 H 
CHAPTER 6: Experimental 144 
Yttrium complex of 1,5,9-tris(2-aminoethyl-N-benzyl-N-methylenebenzylphosphinic 
acid)-1,5,9-triazacyclododecane (44) 
1,5,9-Tris(2-arninoethyl-N-benzyl-N-methylenebenzyl t)hosphiriic acid)-1,5,9-
triazacyclododecane (41) (0.04g, 0.036mmol) in MeOH (1cm3) was heated to 40°C. 
Yttrium triflate2 (0.02g, 0.036mmol) in MeOH (1cm3) was added and the solution heated 
for 16 hours. Upon cooling a white precipitate formed; this was centrifuged and washed 
in cold MeOH to yield a white solid (0.0lg); 5 P (CD 3OD) 30.0 (broad); 5 H ( C D 3 O D ) 7.5 
(30H, m, Ar), 4.0-3.3 (30H, m, CH 2 N, NCH 2P) and 1.22 (6H, m, C H 2 ring); v m a x 
(film) 3568, 3232vs, 1655s, 1458, 1252vs, 1176s, 1030vs and 640cm"1; 
6.3 C H A P T E R T H R E E E X P E R I M E N T A L 
6.3.1. D T P A - N I T R O I M I D A Z O L E - A M I D E 
Diethylenetriamine-N,N"-di-N-( 1-(3-aminopropyl)-2-nitroimidazole)-N,N',N"-
triacetate (48) 
DTPA-anhydride (0.155g, 0.43mmol) was stirred in dry pyridine (5cm3) under N 2 (g). 
l-(3-Aminopropyl)-2-nitroimidazole (53)5-6 (0.175g, 1.3mmol) in pyridine (2cm3) was 
added slowly giving a yellow suspension this was heated to 50°C for 6 hours and 
monitored by HPLC. The pyridine was removed under reduced pressure to give a brown 
oil (0.27g, 0.383 mmol, 90%). This was purified using semi preparative reverse phase 
HPLC. Under analytical conditions R t = 8.0 mins compared to the imidazole (53) with 
an R t = 4.1 mins. Using the preparative conditions the main product peak was collected 
from 9.4-10.3 mins as a pale yellow oil. 5H ( D 2 0 ) 7.32 (2H, s, Im-H), 7.01 (2H, s, 
Im-H), 4.33 (4H, t, J = 7Hz, CH 2-Im), 3.95 (8H, s, CH 2CO), 3.58 (2H, s, CH 2CO), 
3.36 (4H, t, 7= 4Hz, CH 2 NH), 3.18 (4H, d, J = 6Hz, CH 2 N), 3.10 (4H, d, J = 6Hz, 
C H 2 N ) and 1.94 (4H, m, CH 2 ) ; S c ( D 2 0 ) 175.3 (CO carboxylate), 173.4 (CO 
carboxylate), 170.3 (CO, amide), 170.0 (CN0 2 ) , 130.8 (Im), 59.4 (CH 2 N), 58.7 
( C H 2 N ) , 56.6 (CH 2COOH), 55.3 (CH 2COOH x 2), 53.3 (CH 2 CONH), 50.4 
(NHCH 2 ) , 39.3 (CH 2Im) and 31.9 (CH 2); m/z (FAB) 698 (M++1), 422, 337, 303, 271 
and 225; v m a x 3275, 3100, 2930, 1720m, 1674vs, 1375m, 1200s, 1150, 850, 805 and 
780cm"1. 
Gadolinium complex of diethylenetriamine-N,N"-di-N-( 1-(3-aminopropyl)-2-
nitroimidazole)-N,N',N"-triacetate. (54) 
Diethylenetriamine-N,N"-di-N-( 1 -(3-aminopropyl)-2-nitroimidazole)-N,N',N"-
triacetate (48) (0.03g, 0.043mmol) was dissolved in H 2 0 (1cm 3, pH2) and Gd 203 (s) 
(0.043mmol, 0.016g) was added and the mixture heated to reflux for 30 mins. The pH 
was adjusted to 2 using dilute HC1 and heated to reflux for a further 2 hours until all the 
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GCI2O3 had gone into solution. The pH was then adjusted to 6, using NaOH, and the 
mixture allowed to cool. This was purified using semi preparative reverse phase HPLC 
using standard conditions but no TFA was used in the solvents. Product was observed at 
X=320nm, Rt=7.6mins and evaporation of the eluates gave a white solid (9.9mg, 
0.012mmol, 27%); m/z (Electrospray) 891.5 (M++K+), 853 (M+), 717.5, 701.5, 679.5, 
491.2, 453 and 197.1; v m a x (KBr) 3420vs, 3256, 3100, 2944, 1636vs, 1540, 1490, 
1362, 1202, 1164, 1096, 926, 837, 800 and 668cm"1 
Terbium complex of diethylenetriamine-N,N"-di-N-(l-(3-aminopropyl)-2-
nitroimidazole)-N,N',N"-triacetate. (55) 
Diethylenetriamine-N,N"-di-N-(l-(3-aminopropyl)-2-nitroimidazole)-N,N',N"-
triacetate (48) (0.02g, 0.03mmol) was dissolved in H 2 O (1cm 3) and heated to reflux 
. ' :•-• T" * - . \ rr\ n.^ _ l n n i _ • , r - . . - T 1 T^U _ _TT _ J : J «.„ C ; M „ A U 
vvitii 1 U^O A t j j V O.w^ii i i i iKji , u . u i ^ j i\Ji iitJUio. i iiw pi-A VV Ci5 tlUjU^lv^U i.\J O Uoii i^ i l d i j i i 
and the mixture heated to reflux for 18 hours. The solution was cooled and purified by 
HPLC using the conditions described for (54); R t= 8.6mins. The eluates were freeze 
dried to yield a white solid (0.0062g, 0.0073mmol, 26%). v m a x (KBr) 3419vs, 2937, 
1636vs, 1541, 1489, 1362, 1164, 1097, 928, 837 and 668cm"1; m/z (Electrospray) 
854.2, 841.1, 800.1, 583.2, 501.3, 301.3 and 272.3. 
6.3.2 S Y N T H E S I S O F 12N3-NITROIMIDAZOLE C O N J U G A T E 
(p-Cyanobenzyl)-9-(p-tolylsulphonyl)-l,5,9-triazacyclododecane-2,4-dione(57)1 
To a solution of 3-(p-cyanobenzyl)-9-(p-tolylsulphonyl)-l,5,9-triazacyclododecane-2,4-
dione(56)7 (1.82g, 5.8 mmol) in dichloromethane (150 cm 3) was added triethylamine 
(1.17g, 1.61 cm 3 , 11.6 mmol) and toluene-p-sulphonyl chloride (1.57g, 8.7 mmol) and 
the mixture was heated to reflux for 24 hours. Solvent was then evaporated under 
reduced pressure and the residue was purified by flash column chromatography on silica 
(5% MeOH in C H 2 C I 2 ) to yield a white solid (2.84g, 5.8 mmol, quantitative), m.p.258-
260°C l i t 7 258-260°C; 8H(CDC1 3) 7.70 (2H, d, ArH), 7.55 (2H, d, ArH), 7.3 (4H, m, 
ArCN), 6.8 (2H, t, NH), 3.7-3.25 (9H, m), 2.85-3.15 (2H, m), 2.45 ( 3 H , s, CH 3 ) , 
1.85 (2H, m) and 1.65 (2H, m). 
(p-Aminomethylbenzyl)-9-(p-tolylsulphonyl)-l,5,9-triazacyclododecane (58)7 
To a slurry of (57) (2.84g, 5.8 mmol) in tetrahydrofuran (10 cm 3) was added borane-
THF (1M, 90 cm 3) and the mixture was heated to reflux for 48 hours. Excess of borane 
was destroyed with methanol (0°C) after which the mixture was evaporated under 
reduced pressure and the residue heated to reflux with 6M H O (60 cm 3) for 3 hours. 
After removal of water from the mixture the residue was redissolved in aqueous base 
(pH> 13, KOH) and extracted with dichloromethane (4x 50 cm 3). The combined extracts 
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were dried ( K 2 C O 3 ) and evaporated to yield a colourless oil (2.15g, 4.84 mmol, 79%); 
m/z (DCI) 445 (M++1), 419 and 291 (M+-Ts); v m a x (film) 3400, 2250, 1640, 1600, 
1450, 1330 and 1160 cm"1; 5H(CDC1 3) 7.50 (2H, d), 7.12 [2R, d), 7.10 (2H, d), 6.90 
(2H, d), 3.61 (2H, br s, C H 2 N H 2 ) , 3.20-2.95 (4H, m, CH 2NTs), 2.65-2.45 (4H, m, 
CH 2 NH), 2.45-2.15 (4H, m, CH 2NH), 2.22 (2H, s, CH 2 Ar), 1.9-1.6 (5H, m, CH 2 Ar) 
and 1.6-1.4 (4H, m, CH 2C). 
3-Aminomethylbenz.yl-1,5,9-triazacyclododecane (59)7 
To a solution of (58) ( lg, 2.21 mmol) in HBr-acetic acid (45% w/v; 80 cm 3) was added 
phenol ( lg) and the mixture was heated to reflux for 24 hours. Upon cooling a 
precipitate formed and this was filtered off and washed with diethyl ether (3x 20 cm 3) to 
yield the trihydrobromide as a pink salt (0.73g, 1.36 mmol, 62%); 8H ( D 2 0 ) 7.32 (4H, 
m, Ar), 4 . i t (2H, s, CH 2 N), 3.2y-3.i (12H, m, CH 2 N), 2.77 (2H, d, CH_2Ar), 2.55 
(1H, m, CH) and 2.2-2.0 (4H, m, CH 2 ) . 
(2-Nitroimidazole-J-acetamidomethylbenzyl)-1,5,9-triazacyclododecane (62) 
3-Aminomethylbenzyl-l,5,9-triazacyclododecane (59) (0.035g, 0.12 mmol) was 
dissolved in DMF ( 1cm3) at 0°C. 2-Nitroimidazole-1 -acetic acid (60)8 (0.02g, 0.120 
mmol) in DMF (0.5 cm 3) and triethylamine (0.026cm3, 0.033g, 0.120 mmol) were 
added and then finally DPPA (0.05 cm 3, 0.0364g, 0.36 mmol). The mixture was stirred 
under N 2(g) at 0°C for 8 hours, then warmed to room temperature and allowed to stand 
for 4 days. After this period the DMF was removed under reduced pressure and the 
residue taken up in dichloromethane (20cm3), washed with KOH (2x 10cm3 of 1M), 
filtered, evaporated to give yellow oil (0.02g, 0.05 mmol, 41%); m/z (DCI) 523, 454, 
445 (M++1) and 444 (M+); v m a x (soln in CH2C12) 1670 cm-'; 5 H ( C D C I 3 ) 7.18 (2H, d, 
Im), 7.1-6.9 (4H, m, Ar), 4.9-4.85 ( 2H, d, CH 2 -Im), 4.25-4.15 (2H, s, C H 2 N H ) , 
2.8-2.25 (12H, br m, CH 2N), 2.1-2.0 (1H, m, CH) and 1.6-1.4 (4H, br m, CH 2 C). 
(Acetamidomethylbenzyl)-l,5,9-triazacyclododecane (66) 
To a solution of (59) (0.12g, 0.43 mmol) was added acetic acid (2cm 3), this was stirred 
and then the excess acetic acid was removed under reduced pressure. The acetic acid salt 
was dissolved in DMF (1 cm 3) and treated with triethylamine (0. lOg, 0.14 cm 3 , 1.03 
mmol), acetic acid (0.020 cm 3 , 0.020g, 0.35 mmol) and DPPA (0.074 cm 3 , 0.095g, 
0.35 mmol) under N 2(g) at R.T. for 2 weeks. After this period the DMF was removed 
under reduced pressure, the residue was redissolved in CH 2 C1 2 washed with 1M KOH (2 
H O H /= \ 
N 
NO H 
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xlOcm 3), LiCl (aq) (2 x 10cm3), dried over potassium carbonate, filtered and evaporated 
to yield a pale yellow oil; 5 H (CDC13) 7.12 (4H, m, Ar), 4.30 (2H, d, CH 2NH), 2.8-2.3 
(14H, m, CH 2 N, CH 2 Ar), 2.1-1.9 (1H, m, CH), 1.92 (3H, s, C H 3 C O ) and 1.6-1.4 
(4H, m, CH 2C). It was confirmed that this was the desired compound by comparison 
with an authentic sample.7 
DPP A route to l-(Isobutylcarbamoylmethyl)-2-nitroimidazole (65) 
The 2-nitroimidazole-l -acetic acid(60)8 (0.161 g, 0.9^ mmol) was stirred vigorously in 
dry DMF (1.5 cm 3) with NaHC0 3 (5 mmol, 0.42 g). Isobutylamine (0.94 mmol,0.069 
g, 0.094 cm 3) was added and finally DPPA (1.4 mmol, 0.38 g, 0.3 cm 3) and the mixture 
was stirred at R.T for 18 hours. The DMF was removed under vacuum (0.1 mmHg) and 
the mixture washed with H 2 0 , 1M KOH and LiCl (aq) to yield a yellow oil (0.083 g, 
36%). This was further purified by PLC Rf 0.45 (activated alumina, using 2% MeOH/ 
CH 2 C1 2 as eluant) to give a clear oil (0.023g, 0.1 mmol, 11 % ) . m/z (DCI) 227 (M++1). 
Vmax (film) 1680 cnr 1 (C=0). 8 H (CDCI3) 7.11 (2H, s, Ar), 6.26 (1H, br t, NH), 4.95 
(2H, s, CH 2CO), 3.05 (2H, t, / = 6Hz, NCH 2CH), 1.72 (1H, m, CH) and 0.84 (6H, d, 
J= 7Hz, CH 3 ) . 5 C (CDCI3) 166.2 (CO), 128.7 (NCH), 127.8 (NCH), 125.5 (CN0 2 ) , 
52.5 (CH 2CO), 50.0 (NCH 2), 30.3 (CH) and 20.3 (CH 3). 
PBOP route to l-(Isobutylcarbamoylmethyl)-2-nitroimidazole (65) 
To 2-nitroimidazole-l-acetic acid (60)8 (0.1 g, 0.58 mmol) in dry acetonitrile (3cm 3) 
was added isobutylamine (0.58 mmol, 0.043 g, 0.06 cm 3), triethylamine (0.87 mmol, 
0.088g, 0.12cm 3) and finally benzotriazol-l-yloxy- tripyrrolidinophosphonium 
hexafluorophosphate (PBOP) (0.58 mmol, 0.3g). The mixture was allowed to stir at 
R.T. for 18 hours and then the solvent was removed under reduced pressure leaving a 
pale yellow solid. The product was extracted into EtOAc, washed with brine and 
bicarbonate solution, dried and evaporated to give a yellow oil. This was purified by 
preparative alumina TLC. using 2% MeOH / CH 2 C1 2 as eluant (0.103g, 79%). The 
analysis of the product (65) was as described for previous experiment. 
6.3.3 9N3 C - L I N K E D C O N J U G A T E 
(+)-(2S)-Lysine methyl ester hydrochloride (68)9 
L-Lysine ( 20g, 92 mmol) in dry MeOH (200cm3) was heated to reflux under nitrogen in 
the presence of acetyl chloride (4cm3) for 12 hours. The volume of solvent was reduced 
and the resulting white precipitate was filtered and dried under vacuum (18.44g, 81 
mmol, 88%). 5 H ( D 2 0 ) 4.05 (1H, t, CH), 3.71 (3H, s, O C H 3 ) , 2.92 (2H, t, C H 2 N H 3 ) , 
1.85 (2H, m, CH 2CH), 1.61 (2H, m, CH 2CH 2CH) and 1.43 (2H, m, CH 2 CH 2 NH 3 ) . 
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(2S)-N-(2-Aminoethyl)-2,6-diaminohexanamide (69)9 
(+)-{2S )-Lysine methyl ester hydrochloride (7.09g, 30.4 mmol) was added in small 
batches over 2 hrs to ethylenediamine (100cm3) at 90°C, wiin continuous stirring. The 
reaction mixture was heated to 120°C (6 hrs) and the ethylenediamine removed under 
reduced pressure. The residue was taken into aqueous sodium hydroxide (4M, 25 cm 3), 
the solvent was evaporated and the residue was dissolved in MeOH (30cm3). The 
solution was filtered and the filtrate evaporated to leave a residue. This process was then 
repeated from the methanol stage. The subsequent residue was treated with 
dichloromethane (100 cm 3), filtered and the filtrate evaporated to give (69) as a yellow 
oil (5.41g, 28.8 mmol, 95%); 5 H (CDC] 3 ) 7.55 (1H, br s, CONH), 3.35 (1H, t, CH), 
3.25 (2H, t, CH 2NHCO), 2.75 (2H, t, NCH 2 ) , 2.62 (2H, t, NCH 2 ) , 1.83 (2H, br, 
CH 2 ) and 1.38 (10H, m, N H 2 C H 2 ) ; 5 C(CDC1 3) 23.0, 33.3, 34.8 (CH 2), 41.5, 41.7, 
41.8, 44.8 (NCH 2), 55.1 (CH) and 175.3 (CO). 
(5S)-3-Azanonane-l,5,9-triamine (70)9 
The amide (69) (5.424g, 28.8 mmol) was heated to reflux in 1M borane-THF 
(180mmol, 180cm3) for 20 hours. Excess of borane was quenched with methanol 
(100cm3) and solvents were evaporated to leave a residue which was heated to reflux in 
HC1 (6M, 100 cm 3) for 3 hours. Evaporation of solvent followed by entraining in 
methanol (5 x 20 cm 3) gave the title compound as a white oily solid (7.04g, 22.0 mmol, 
76%); 5 H ( D 2 0 ) 3.61 (1H, p, CH),3.5-3.2 (5H, m, NCHH, NCH 2 ) , 3.01 (2H, t, 
NCH 2 ) , 2.95-2.85 (1H, m, NCHH), 1.8-1.5 (4H, m, C H 2 C H 2 C H 2 ) and 1.5-1.3 (2H, 
m, CH 2 CH 2 CH 2 ) . 
(5S)-N-(5,9-Diamino-7-azanonyl) benzamide (71)9 
The tetraamine tetrahydrochloride (70) ( 1.92g, 6 mmol) was dissolved in water (15cm3) 
and converted into the free tetraamine by addition of potassium hydroxide (0.96g, 24 
mmol). Addition of copper carbonate (0.769g, 3.6 mmol) to the stirred solution at 50°C 
gave an intense blue colour. After continued stirring (40 mins, 50°C), benzoyl chloride 
( l . l g , 0.91 cm 3 , 7.8 mmol) was added over 1 hour to the cooled solution (0°C), the pH 
being maintained above 9 with periodic addition of potassium hydroxide pellets. The 
solution was allowed to warm to room temperature and stirring continued for 1 hour. 
The dark solution was filtered and the filtrate treated with hydrogen sulphide over 15 
minutes. Filtration followed by partial evaporation and exhaustive extraction with 
dichloromethane, with subsequent drying and evaporation of the combined extracts gave 
the title compound as a white solid. (0.89g, 3.2 mmol, 53%); v m a x (nujol) 3300 br (NH, 
N H 2 , CONH), 1640 (CO) and 1600 cm"1; 5 H (CDC13) 7.65 (2H, d, ArH), 7.25 (3H, m, 
ArH), 3.25 (2H, dt, CONHCH 2), 2.4-2.7 (6H, m, NCH 2 ) and 1.1-1.7 (11H, m+br s, 
C H 2 , NH and NH 2 ) . 
CHAPTER 6: Experimental 149 
(5S)'5,7,9-N',N",N"'-Tris(p-methoxybenzenesulfonyl)-l-N-benzoyl-7-aza-l ,5,9-
triaminononane (72) 
A solution of the benzamide (71) (0.89g, 3.2 mmol) in H2O was stirred vigorously with 
K2CO3 (1.34g, 9.7mmol) and heated to 80°C, p-methoxybenzenesulphonyl chloride 
(2.5g, 12mmol) was added over a period of 2 hours. The resulting suspension was 
stirred for 15 hours before cooling. The solution was filtered and the solid was dissolved 
in hot CH2CI2 (150 cm 3), this volume was reduced and the product recrystallised from 
CH 2 C1 2 to yield a white solid (0.96g, 1.14 mmol, 42%); R f 0.4 [silica gel; CH 2 C1 2 -
MeOH (95:5)]; m.p. 159-160°C (Found:C, 54.76; H, 5.68; NJ.06. C36H44N4O10S3 
requires C, 54.8; H, 5.62; N, 7.10%); m/z (DCI): 788 (M+ + 1), 617 and 446; 5 H 
[(CD 3) 2SO] 8.35 (1H, t, NHCO), 7.86 (1H, d, J = 6Hz, NHTs), 7.73 (4H, d, J = 9Hz, 
Ar), 7.53 (4H, q, J = 9Hz, A r j , 7.09 <4H, q, j = 9Hz, Ar), 3.87 (3H, s, OMe), 5.85 
(3H, s, OMe), 3.80 (3H, s, OMe), 3.2-2.6 (9H, m, CH 2 NHCO, CH 2 N, CHN), 1.5 
(1H, m, CH 2C), 1.4-1.0 (3H, m, CH 2C) and 1.0-0.8 (2H, m, CH 2C); 5 c [ (CD 3 ) 2 SO] 
166.2 (CO), 162.6, 162.2, 162.1 (ArOMe), 134.7, 233.4, 131.7, 131.0, 129.1, 129.1, 
128.7, 128.2, 127.1, 127 (Ts), 114.5, 114.4, 114.2 (Ph), 112.7 (PhCO), 55.67, 55.61, 
55.56, 53.6, 52.1, 48.8, 41.4 (CH, NCH 2 ) , 30.8, 28.7 and 22.2 (CH 2); v m a x (Nujol) 
3300br (NH), 1630 (CO), 1600 (aromatic ring), 1580, 1530 (NH), 1350 (S0 2 ) and 
1150cm-1 (S0 2). 
2-(4-Benzamidobutyl)-1,4,7-tris(p-methoxybenzenesulphonyl)-1,4,7-triazacyclononane 
(73). 
Caesium carbonate (0.4 lg , 1.26 mmol) was added to a solution of the tri(p-methoxy 
benzenesulphonyl)amide (72) (0.5g, 0.63 mmol) in anhydrous DMF (25 cm 3) under dry 
nitrogen. A solution of ethylene glycol bis(toluene-p-sulphonate) (0.233g, 0.63 mmol) 
in anhydrous DMF (6.5cm3) was added slowly over a period of 4 hours with efficient 
stirring. After the mixture had been stirred for 17 hours (20°C) its temperature was 
raised to 65°C for a further 6 hours. Solvent was removed under reduced pressure and 
the yellow residue was dissolved in chloroform (30cm3) and washed with water 
(3x10cm3). The organic layer was dried (K 2C03), filtered and evaporated under reduced 
pressure. The pale brown residue was purified by flash silica chromatography (gradient 
eluant 2-10% MeOH in CH2C12) to give a white glass (0.36g, 0.45 mmol, 72%); Rf 0.75 
[silica gel; CH 2 Cl 2 -MeOH (95:5)]; m.p. 95-98°C; (Found: C, 55.71; H, 5.92; N, 6.97 
C3 8H46N 4OioS3 requires C, 56.00; H, 5.69; N, 6.87%); [ a ] 2 0 D = +13.67 (CH 2 C1 2 
c=0.13); m/z (DCI) 816 (M++1), 815 (M+), 810, 805, 803, 799, 793 and 791; (Found 
815.2441 C 3 8 H47N40ioS 3 requires 815.2454); 8 H (CDCI3) 7.78-7.69 (7H, m, Ar), 
7.45-7.25 (4H, m, Ar), 7.0-6.85 (6H, m, Ar), 6.80 (1H, t, CONH), 4.15 (1H, br s), 
3.81 (3H, s, OMe), 3.79 (3H, s, OMe), 3.78 (3H, s, OMe), 3.75-2.90 (13H, m, 
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CH 2 N) and 1.6-1.15 (6H, m, CH 2 ) ; 5 C (CDC13) 168.0 (CO), 163.8, 163.61, 163.56 
(CS), 135.1, 130.2, 129.5, 127.5, 132.0, 130.0, 129.3, 131.7, 129.9, 128.9 (aromatic 
C), 1 14.0, 114.95, 114.85 (OCH3), 56.2, 53.0, 51.5 (CH 2N), 40.1 (CH 2NHCO), 29.5 
and 24.5 (CH 2C); v m a x (film) 3400, 2944, 1650, 1633, 1595, 1538, 1495, 1462, 1301, 
1257, 1149, 1090, 1022, 832 and 803cm-1. 
2-(4-Aminobutyl)-l,4,7-tris(p-methoxybenzenesulphonyl)-l,4,7-triazacyclononane (74) 
The benzamide (73) (0.73g, 0.901 mmol) in hydrochloric acid (6M, 25cm3) was heated 
to reflux for 4 days and stirred vigorously to overcome solubility problems. The reaction 
was monitored by TLC and when complete the mixture was cooled, washed with ether 
(3x10cm3) and evaporated to dryness (0.01 mmHg) to yield the hydrochloride salt as a 
cnloi.irle.ss glass The product, was obtained as the free amine by treatment with KOH 
(pH13) and extraction into dichlororomethane (0.227g, 0.304 mmol, 27%); m/z (DCI) 
711 (M++1), 707, 543, 385, 356, 291 and 155; 5 H (CDC'3) 7.78-7.70 (6H, m, Ar), 
7.31 (2H, m, Ar), 6.99-6.94 (6H, m, Ar), 3.86 (3H, s, OMe), 3.85 (3H, s, OMe), 3.85 
(3H, s, OMe), 3.7-2.5 (13H, m, CH 2 N) and 1.8-1.0 (6H, m, CH 2 ); v m a x 3400br s, 
2950, 1640w, 1600s, 1575, 1500s, 1470, 1330, 1300, 1270vs, 1155vs and 1030cm"1; 
5 C (CDCI3) 162.0 (CS), 130.9, 130.5, 129.2, 128.7, 126.0, 125.4 (aromatic C),116.0 
( O C H 3 ) , 59.5, 59.0, 58.8, 54.7, 53.0, 48.2, 46.1 (CH 2 N), 28.7, 22.5 and 14.2 
(CH 2C). 
2-(4-Benzamidobutyl)-1,4,7-triazacyclononane (75)9 
2-(4-Benzamidobutyl)-1,4,7-tris(p-methoxybenzenesulphonyl)-1,4,7-triazacyclononane 
(73) (0.3g, 0.36mmol) was treated with concentrated sulphuric acid (5cm3) at 115°C 
with stirring for 20 hours. To the cooled solution (0°C) was added NaOH (0.1M, 
5cm 3). The precipitate was filtered and washed with distilled water (5cm 3). The 
combined filtrate and washings were extracted with CH 2 C1 2 (5 x 5cm3) and the organic 
layer was dried (K 2C03), filtered and evaporated under reduced pressure to give a pale 
yellow oil (42mg, 0.14mmol, 38%); 5 H (CDCI3) 7.82 (2H, dd, Ar H), 7.42 (3H, m, 
Ar), 3.51 (2H, m, CH 2 NHCO), 3.11 (3H, br s, NH), 2.74 (11H, m, CH 2 N, CHN), 
1.62 (2H, m, CH 2C) and 1.38 (4H, m, CH 2C). 
2-(4-Aminobutyl)-l,4,7-triazacyclononane (77) 
2-(4-Benzamidobutyl)-l,4,7-triazacyclononane (75) (0.12g, 0.395 mmol) was heated to 
reflux with HC1 (6M, 20 cm 3) for 4 days and monitored by TLC. When reaction was 
complete the solution was washed with diethyl ether (3x10 cm 3) and evaporated to 
dryness (0.01 mmHg) to give the hydrochloride salt as a brown oil (0.139g, quant). The 
free amine was obtained by treating with KOH (pH13) and the aqueous phase was 
extracted exhaustively into dichloromethane (3 x 10cm3) and chloroform (2 x 10cm3) to 
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yield a pale yellow oil (0.106g, quant); m/z (DCI) 201 (M++1), 118, 104, 84 and 46; 8 H 
(CDC13) 2.80-2.55 (11H, m, CH 2 N), 2.35 (2H, m, CH 2 N), 1.85-1.60 ( 5H, br s, NH), 
1.35 (3H, m, CH 2C) and 1.25 (3H, m, CH 2 C); 8 C (D 20) 56.1 ( C H 2 C H 2 N H 2 ) , 48.4 
(CH), 45.2, 44.4, 44.2, 42.3, 42.0 (CH 2N), 33.9, 29.3 and 24.7 (CH 2C). 
2-(4-Benzamidobutyl)-1,4,7,triazacyclononanetriyl triacetate (78)9 
To a solution of 2-(4-Benzamidobutyl)-1,4,7-triazacyclononane (75) (0.1 lg , 
0.362mmol) in dry ethanol (5cm3) was added ethylbroinoacetate (0.18g, 1.08mmol) and 
potassium carbonate (0.15g, 1.08mmol) and the mixture heated to 60°C for 3 hours. The 
mixture was cooled, filtered, and evaporated under reduced pressure and the residue was 
taken up in dichloromethane (50cm3). The solution was washed with water (3 xl5cm 3), 
dried (K2CO3) and evaporated and the residue was purified hy gravitational alumina 
column chromatography [gradient eluant 0-3% MeOH in CH2C12] to yield a colourless oil 
(0.13g, 0.23g, 63%); m/z (DCI) 563 (M++1), 477, 204 and 122; 8 H (CDCI3) 7.83 (2H, 
d, ortho aromatic H), 7.40 (3H, m, m and p aromatic H), 7.27 (1H, m, NHCO), 4.12, 
4.08, 4.07 (6H, q+q+q, CH 2 0) , 3.41 (8H, m, C H 2 N and CHN), 1.61-1.42 (6H, m, 
CH 2C) and 1.20 (9H, t+t+t, CH 3 ) ; v m a x (film) 3330 br s (NHCO), 2980, 2930, 2840 
(CH), 1742 (C0 2 Ef), 1649 (NHCO), 1538 (NH bend), 1190 and 1060 cm"1. 
2-(4-Aminobutyl)-l,4,7-triazacyclononane-l,4,7-triyltriacetic acid (79)9 
The benzamide (78) (0.08g, 0.142 mmol) in hydrochloric acid (6M, 20 cm 3) was heated 
to reflux for 24 hours. After cooling, the solution was washed with diethyl ether (3x 
10cm3) and evaporated to dryness (0.01 mmHg) to yield the hydrochloride salt as a 
colourless glass (0.06g, 0.142 mmol, quantitative); 8H ( D 2 0 ) 4.11 (6H, s, CH 2 NC0 2 ) , 
3.8-3.0 (13H, br m, CH 2 N and CHN), 2.90 (4H, t, CH 2 NH 3 ) , 1.62 (3H, br m, CH 2C) 
and 1.33 (3H, br m, CH 2C). 
2-(4-Amidobutyl)-(p-nitrophenyl carboxyethyl)-l,4,7-triazacyclononane-l,4,7-triacetate 
(83) 
CQ>H 
H 0 2 C 
2-(4-Aminobutyl)-l,4,7-triazacycIononane-l,4,7-triacetate (79) (0.03g, 0.073mmol) 
was dissolved in 0.25cm3 of DMSO with gentle warming. N-methylmorpholine (0.292 
mmol, 0.029g, 0.032cm3) and bis-p-nitrophenyl succinate (81) in 0.25cm3 of DMSO 
were added with vigorous mixing under N 2(g) and the mixture was heated to 50°C. The 
reaction was monitored by analytical HPLC observing at 278nm at t=0 and t=30mins. 
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After 1 hour the product R t= 8.4mins was purified using semi preparative reverse phase 
HPLC and the remaining reaction mixture was stored at -78°C. The product was checked 
for purity using analytical HPLC, examined by ' H NMR ard then used directly in the 
next step. 5 H (D 2 0) 8.20 (2H, d, J= 12Hz, Ar), 7.23 (2H, d, J = 9Hz, Ar), 4.07-2.53 
(19H, m, CH 2 N ring, CH 2 N, NCH 2 C0 2 H), 2.57 (4H, t, CH 2CO) and 1.37-1.18 (6H, 
m, CH 2 ) . 
2-(4-Amidobutyl carboxyethyl)-[I -(N-propyI)-2-nitroimidazole] -1,4,7-
triazacyclononane-],4,7-triacetate (51) 
CQ?H 
H O a C ^ J N ^ O 
H 0 2 C ' W N 0 2 
2-(4-Amidobutyl)-(p-nitrophenyl carboxyethyl)-1,4,7-triazacyclononane-1,4,7-triacetate 
(83) (0.02g, 0.034mmol) was dissolved in DMSO (0.5cm3) and l-(3-aminopropyl)-2-
nitroimidazole (53) (0.24mmol, 0.032g) in DMSO (0.5cm3) was added with mixing. 
The mixture was warmed in a water bath to 30°C overnight and monitored by analytical 
HPLC. The product was observed to appear at 10.4 mins and when formation was 
complete it was purified by semi preparative HPLC. After freeze drying a white solid 
was obtained (0.0072g) R t 10.9mins; m/z (Electrospray) 616; § H (D 2 0) 7.32 (1H, s, 
Ar), 7.04 (1H, s, Ar), 4.35 (2H, t, CH 2Im), 3.78-3.15 (13H, m, CH 2 N), 3.10 (6H, br 
s, NCH 2COO), 3.01 (2H, t, CH 2 N), 2.35 (4H, s, CH 2CO), 1.94 (2H, m, CH 2 ) and 
1.35 (6H, m, CH 2 ) ; 5 C ( D 2 0 ) 176.2 (CO), 129.6 (Im), 58.6, 55.7, 49.4, 40.5, 38.0, 
32.9, 30.6, 30.1 and 24.7; v m a x 3310, 2930, 1682, 1188 and 1082. 
6.4 C H A P T E R FOUR E X P E R I M E N T A L 
6.4.1 12N4 - T U F T S I N 
Molybdenum Tricarbonyl-1,4,7,10-tetraazacyclododecane Complex (84) 1 0 
1,4,7,10-Tetraazacyclododecane ( lg , 5.8mmol) and molybdenum hexacarbonyl (1.53g, 
5.8mmol) were heated to reflux in dibutylether (50cm3) under Ar(g) for 3 hours, the 
bright yellow solid was filtered off under Ar(g) and dried under reduced pressure (1.8g, 
5.2mmol, 90%). This was used immediately in the subsequent reaction. 
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[4-(4-Methoxyphenylsulfonamido)butylcarbomylmethyl]-1,4,7,10-tetraazacyclododecane 
(87) 
The molybdenum tricarbonyl 12N4 complex (84) (1.84g, 5.22mmol) was stirred under 
Ar (g) in degassed DMF (50cm3) with potassium carbonate ( lg , 7.3mmol), N-(4-
bromoacetamidobutyl)-4-methoxybenzenesulfonamide (86) (1.98g, 5.22mmol) was 
added and the solution heated to 80°C for 2 hours. The DMF was removed under 
reduced pressure and the resulting sticky brown mixture taken up in 10% HC1 (50cm3) 
and stirred in air overnight resulting in a dark brown solution containing a pale brown 
suspension. The pH was adjusted to 14 using KOH pellets and the black suspension 
filtered to remove decomplexed Mo(CO)3. The yellow filtrate was extracted exhaustively 
with CH2CI2 (6 x 20cm3), the combined organic fractions were dried and evaporated to 
yield a yellow oil (1.51g, 3.23mmol, 62%). 5H(CDC1 3) 7.95 (1H, t, NHS0 2 ) , 7.71 
(2H, d, J = 8.9Hz, CHCOCH3) , 6.90 (2h, d, J= 8.9Hz, CHCSO2) , 3.70 (3H, s, 
OMe), 3.2-2.4 (25H, C H 2 ring, NH ring, NCH 2CO, CH 2NHCO, C H 2 N H S 0 2 ) and 
I . 45 (4H, m, CH 2 ) ; 5C(CDC1 3) 171.2 (CO), 162.2 (COCH3), 131.9 (CS0 2), 128.8 
( C H C O C H 3 ) , 113.9 ( C H C S 0 2 ) , 58.5 (NC_H 2CO), 55.4 (OCH3) , 52.8 
(CH 2 NCH 2 CO), 46.2, 44.6, 42.3 (ring Cs), 42.2 (CH 2 NHS0 2 ) , 38.1 (CH 2 NHCO), 
26.2 and 26.1 (CH 2 CH 2 ) . 
Triethyl l0-[4-(4-methoxyphenylsulphonamido)butylcarbomylmethyl]-l,4,7,10-
tetraazacyclododecane-1,4, 7-triyltrimethylenetri( methylphosphinate) (88) 
To [4-(4-methoxyphenylsulfonamido) butylcarbomylmethyl] -1,4,7,10-
tetraazacyclododecane (87) (1.07g, 2.27mmol) in THF (30cm3) at 100°C were added 
paraformaldehyde (0.35g, 11.4mmol) and diethoxymethylphosphine (1.55g, 1.7cm3, 
I I . 4 mmol). The mixture was heated to reflux for 20 hours at 100°C with azeotropic 
removal of water by 4A molecular sieves then cooled and filtered to remove excess 
paraformaldehyde and evaporated to give a pale yellow oil. Purification was carried out 
using alumina column chromatography (gradient elution 0-5% MeOH in CH2CI2) to yield 
a pale yellow oil (0.997g, 1.2mmol, 53%); 5 H (CDCI3) 7.72 (2H, d, CHCOCH3), 6.90 
(2H. d, CHCS0 2 ) , 4.04 (6H, m, OCH 2 ), 3.82 (3H, s, OCH3), 3.23 (2H, m, 
C H 2 N H S 0 2 ) , 3.34-2.2 (26H, m, NCH 2), 1.47 (13H, m, CH 2 , PCH3) and 1.24 (9H, 
m, CH 2 ) ; 5 C (CDCI3) 161.2 (CO)132.0, 128.2, 113.1 (Ar, 59 (OCH 2), 55.0 (OCH 3), 
52.5-55.0 (12C), 42.1, 38.3, 26.0, 26.2, 15.9 and 13.1 (3C, d, PCH 3); 8 P (CDCI3) 
52.5 (br m). 
/ 0-[4-( 4-Amino jbutylcarbamoylmethyl]-1,4,7,10-tetraazacyclododecane-1,4,7-
triyltrimethylenetri(methylphosphinic acid) (89) 
To the phosphinate ester (88) (0.14g, 0.17mmol) was added phenol (140 mg) and 40% 
w/v HBr in glacial acetic acid (15 cm 3). The solution was heated to reflux at 110° C 
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overnight, and the solution allowed to cool to afford precipitation of the product. The 
reaction mixture was centrifuged, and the solvent decanted off leaving a pale white/brown 
solid which was washed with diethylether (3x15 cm 3 ) , until the washings were 
colourless. The solids were taken up into water, filtered, and the solvents evaporated to 
yield the trihydrobromide salt as an off white solid. Overall yield (0.075mmol, 61 mg, 
44%). 5 H ( D 2 0 ; pD=0) 3.23 (2H, s, CH 2NHCO), 2.95-2.45 (26H, m, CH 2 N ring, 
CH 2 N, NCH 2P, CH 2NHCO, CH 2 NH 3 +), 1.55 (4H, m, CH 2 ) and 1.3-1.2 (9H, d, J = 
13Hz, CH 3P); 8 C (D 2 0) 168.3 (CO), 58.2 (NCH 2CO), 51.1-55.5 (11C, CH 2 N), 41.7, 
41.4, 27.5, 26.5 and 17.3 (d, 7=89Hz, PCH 3); 5 P ( D 2 0 pD=13) 40.0. 
N-Acetyl Tuftsin (90) 
A sample of tuftsin (0.028mmol, 0.014g) was taken up in (CD3)2SO (1cm3) and the lU 
NMR spectrum obtained. Solid p-nitrophenyl acetate (0.003g, 0.014mmol) was added to 
this solution and stirred thoroughly at R.T. under N 2 (g). After 12 hours the ' H NMR 
spectrum was obtained, having established that reaction was complete, the solution was 
purified on a Sephadex® G-25M column using PBS as eluant [PBS, pH7.2]. The 
desired product was detected on TLC [silica, 5% MeOH in CH 2C1 2] Rf = 0.25 using 
ninhydrin spray as an indicator, m/z (FAB) 585 (100%, 2 acetates), 555 (17%), 543 
(54%, 1 acetate), 499 ( 1 % , tuftsin); 5 H [(CD 3) 2SO] 9.01, 8.12 (1H, d, 7=8Hz, Thr 
NHCO), 7.93 (1H, t, J = 5Hz, Lys NHCO), 7.81, 7.47 (4H, m, Arg NH's), 7.39 (1H, 
d, 7 = 7.2 Hz, Arg NHCO) 4.60, 4.51 (1H, m, Lys cc-CH), 4.34 (1H, m, Pro a-CH), 
3.86 (1H, m, Arg a-CH), 3.82 (2H, m, Thr |3-CH 2), 3.71 (2H, m, Pro 5+5'-CH 2 ), 
3.05 (1H, d, J = 4Hz, Thr a-CH), 3.02 (2H, m, Arg 8-CH 2), 2.98 (2H, m, Lys e-CH 2-
Tuftsin), 1.88 (3H, s, acetate), 1.75-1.25 (8H, m, Lys (3-CH2, Lys 5+8'-CH 2 ) Lys y-
C H 2 , Arg CH 2 ) and 1.05 (3H, d, J= 6Hz, Thr CH 3 ) . 
10-[4-((4-Amidobutyl)-4-nitrophenyl carboxyethyl)-carbamoylmethyl]-1,4,7,10-
tetraazacyclododecane-1,4,7-triyltrimethylenetri(methylphosphinic acid) (91) 
H 
o 
Me 
NO N N HO C J O H 
L A HO. • -
Me O H O - P = 0 
I 
Me 
10-[(4-Aminobutyl)carbamoylmethyl]-1,4,7,10-tetraazacyclododecane-1,4,7-
triyltrimethylenetri(methylphosphinic acid) (89) (0.14g, 0.16mmol) was stirred in 
DMSO (0.25cm3) with N-methylmorpholine (0.113g, 0.123cm3, 1.12mmol) and bis p-
nitrophenyl succinate (81) (0.115g, 0.32mmol) at R.T. After 30 mins, HPLC revealed 
that the amount of the desired compound had begun to decrease so the reaction was 
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cooled to -78°C to stop it. The solution was purified using HPLC (standard conditions) 
R t= 16 mins and any remaining p-nitrophenol was washed out with Et20 (3 x 10cm3) to 
yield a yellow oil (0.0127g, 0.016mmol, 10%); m/z (Electrospray) 820.2 (M+Na), 798.3 
(M++1), 699.3 (Mi+Na), 677.3 (Mi=676.3); 5 H (D 2 0) 8.31 (2H, d, J = 8.8Hz, Ar), 
7.35 (2H, d, J = 8.8 Hz, Ar), 3.85 (2H, s, NCH 2CO), 3.5-3.1 (26H, m, CH 2 N), 2.95 
(2H, t, CH 2CO), 2.65 (2H, t, CH 2 0) , 1.52 (4H, m, CH 2 ) and 1.43 (9H, d, 7 = MHz, 
PMe); 5 P (D 2 0 , pD=4) 32.0 . 
12N4-tuftsin conjugate (92) 
M e . p 
riO 
HO NH 2 
H 0 M / > 0 
O ' Yl N - H 
C J 0 
. n V V - W a a / . . . 
H O H 
i—'• N N 
Me' ' o H O - P = 0 H 2 N , 
Me 
" % H 
To 10-[4-((4-amidobutyl)-4-nitrophenyl succinate)-carbomylmethyl]-1,4,7,10-
tetraazacyclododecane-l,4,7-triyltrimethylenetri(methylphosphinic acid) (91) (0.013g, 
0.016mmol) in (CD 3) 2SO (1cm 3) was added tuftsin (0.0192g, 0.038mmol) and the 
mixture was stirred thoroughly under N 2 (g) at R.T. and allowed to settle overnight. A 
fine brown precipitate in a yellow solution resulted. lH NMR revealed that the solution 
contained only p-nitrophenol and excess tuftsin. The solid was soluble in D 2 0 and a 
crude [H NMR was obtained before purification using a Sephadex column with PBS as 
eluant. The desired product was detected using TLC (silica 5% MeOH in CH 2C1 2) Rf= 
0.25; v max (KBr) 3404, 2455, 1653, 1406, 1265, 1121, 1054, 967, 890, 716, 642 and 
516; 8 H ( D 2 0 ) 4.15 ( m, Pro CH, Lys CH, Pro 8-CH 2 , Arg a-CH), 3.91 (m, Thr (3-
CH 2 ) , 3.7-2.9 (m, CH 2 N, CH 2CO, CH 2P, Arg 8-CH 2 , Thr a-CH), 2.52 (m, Pro (3-
CH 2 ) , 2.23 (Lys (3-CH2), 2.1-1.5 (br m, C H 2 ) Lys 8-CH 2, Lys y-CH 2 , Arg y-CH 2) and 
1.50-1.15 (12H, m, CH 3P, Thr y-CH 3); 8 P (D 2 0) 39.8, 33.0. 
Terbium complex of J 0-[(4-amino)butylcarbamoylmethyl] -1,4,7,10-
tetraazacyclododecane-1,4,7-triyltrimethylenetri(methylphosphinic acid) (93) 
10-[(4-Amino)butylcarbamoylmethyl]-1,4,7,10-tetraazacyclododecane-1,4,7-
triyltrimethylenetri(methylphosphinic acid) (89) (0.178g, 0.25mmol) was dissolved in 
H 2 0 (1cm 3) and the solution pH was found to be 1. Terbium (III) acetate hydrate 
(0.08g, 0.25cm3) dissolved in H 2 0 (1.5cm3) was added to the solution and heated to 
90°C, the solution was adjusted from pH 2.5 to pH 6 using NaOH (aq) and heated for a 
further 5 hours. The complexation was monitored by analytical HPLC using the standard 
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conditions. Once complete the product was purified by preparative HPLC (reverse phase 
"Dynamax") observed at A,=254nm with gradient elution. 10.0 cm 3 min _ 1 ; t=0 min, 90% 
H 2 0 (0.1% trifluoroacetic acid), 10% MeCN (0.1 % trifluoroL^etic acid); t=15 min, 40% 
H 2 0 , 60% MeCN; t=30 mins end time. This provided a pale yellow solid (0.261g, 
0.32mmol, 64%) R t = 6.3 mins. 8 P ( D 2 0 , pD = 6) 628.4, 611.7, 521.8 (complex), 
42.5, 39.9, 33.2 (ligand); v m a x (film) 3417, 2978, 2992, 2867, 1678 (amide), 1628, 
1460, 1422, 1303, 1200 (PO), 1134, 1073, 972, 895, 800, 720 and 494cm"1. 
6.4.2 N AND N,N' FUNCTIONALISED 9N3 C O N J U G A T E S 
2-Bromo-N-benzoyl-5-aminopentyl ethanoate (96) 
Synthesis was carried out in two steps starting from N-benzoyl-5-amino valeric acid (94) 
(SIGMA). The brornination step w<u> effected with red phosphorus and bromine 
according to the literature method.11 Esterification was achieved by standard methods 
using ethanol and acetyl chloride and the product purified by 'flash' silica column 
chromatography eluting with ethyl acetate-hexane (1:1). 
(2-(N-Benzoyl-3-aminopropyl)ethoxycarbonylmethyl)-1,4,7-triaz.acyclononane (97) 
Potassium carbonate (0.138g, lmmol) was added to a solution of 1,4,7-
triazacyclononane (0.254g, 1.97mmol) in anhydrous DMF (5cm 3) under a nitrogen 
atmosphere and the mixture heated to 60°C. A solution of the a-bromo ester (96) 
(0.33g, 0.99mmol) in anhydrous DMF (5cm3) was added dropwise over a period of 7 
hours) and the mixture stirred for a further 24 hours at 60°C. The cooled reaction 
mixture was filtered and solvent removed under reduced pressure to give a pale brown 
oil. A small amount of the product (0.053g) was separated by semi preparative HPLC 
(Dynamax), but the remaining product was used without further purification. Purified 
material: HPLC: R t = 1 lmins, observed at X = 254 nm (Dynamax, reverse phase) with 
gradient elution. 10 cm 3min '; A = H 2O/0.1% TFA, B = MeCN/0.1% TFA from t=0 
min; A = 90%, B = 10%; to t = 20 mins., A = 10%, B = 90%; Mass found 377.255 
(M++1) C 2 o H 3 2 N 4 0 3 requires 377.255; V m a x (film) 3306, 2984, 2865, 1676, 1545, 
1448, 1309, 1202 and 1134cm-'; m/z (DCI) 377 ( M + + l ) , 291, 174, 130, 105, 97 and 
85; 5 H (CD 3OD) 7.83 (2H, d, 7=8.3Hz, Ar), 7.48 (3H, m, Ar), 4.23 (2H, q, J = 
7.1Hz, OCH 2), 3.8-3.6 (3H, m, CH 2NCO, CHN), 3.6-3.2 (10H, m, ring CH 2 N), 3.2-
3.0 (2H, m, ring CH 2 N), 2.0-1.7 (4H, m, CH 2 ) and 1.25 (3H, t, J = 6.2Hz, CH 3 ) ; 5 C 
(CD3OD) 175.4 (CO), 170.5 (NHCO), 135.6, 132.7, 129.6, 128.2 (Ar), 64.7, 62.6 
( C H 2 0 , CHCO), 48.1, 45.7, 44.3, 40.1 (CH 2N, CH 2 N ring), 28.3, 27.8 (CH 2 ) and 
14.5 (CH 3). 
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N,N'-Bis(2-(N-benzoyl-3-aminopropyl)ethoxycarbonylmethyl)-l,4,7-triazacyclononane 
(98) 
Potassium carbonate (0.14g, lmmol) was added to a solution of 1,4,7-triazacyclononane 
(0.26g, 2mmol) in anhydrous DMF (5cm3) under a nitrogen atmosphere and the mixture 
heated to 60°C. A solution of the oc-bromo ester (96) (0.33g, 0.99mmol) in anhydrous 
DMF (5cm3) was added over a period of 7 hours and the mixture stirred at 60°C for 20 
hours. The cooled mixture was filtered and solvent removed under reduced pressure to 
give a pale yellow oil. The di-alkylated product was separated by semi preparative 
HPLC (Dynamax, standard conditions) to give a yellow powder R t = 16 mins, observed 
at X = 254nm. Mass found (M++1) 624.376 C34H50N5O6 requires 624.376; v m a x (film) 
3280, 2930, 1675, 1543, 1458, 1311, 1202 and 136cm"1; m/z (DCI) 624 ( M + + l ) , 377, 
291, 203, 174, 144, 122 and 105; 8 H (CDCI3) 9.51 (2H, bi m, NH), 7.79 (4H, m, Ar), 
7.46 (6H, m, Ar), 4.12 (4H, q, / = 7.2Hz, OCK 2 ) , 3.5 2.6 (1811. m, CK 2 N), 1.64 
(8H, m, CH 2 C) and 1.22 (6H, m, CH 3 ) ; 5 C (CDCI3) 172.3 (C0 2 ) , 168.6 (NHCO), 
133.4, 131.9, 128.6, 127.1 (Ar), 64.8, 64.1, 61.1 (CH 2 0, CH 2CO), 44.4, 43.8, 39.7, 
39.3 (CH 2 N, ring CH 2N), 27.3, 27.1 (CH 2C) and 14.2 (CH3). 
(2-(N-Benzoyl-3-aminopropyl)ethoxycarbonylmethyl)-N'-N"-bis-
(ethoxycarbonylmethyl)-l,4,7-triazacyclononane (99) 
Caesium carbonate (0.114g, O.35mmol) and ethylbromoacetate (0.041cm3, 0.059g, 
0.35mmol) were added to a solution of monoalkylated triamine (97) (0.053g, 
0.14mmol) in dry MeCN (2cm3) and the mixture stirred at 60°C for 20 hours. Solvent 
was removed under reduced pressure and the residue taken up in dichloromethane (5cm3) 
and a fine white precipitate was removed by centrifuge. The solution was evapotated to 
dryness and the yellow oily residue (0.062g, 0.1 lmmol) purified by PLC [alumina: 
dichloromethane - methanol (98:2)] to yield a yellow oil (14.7mg, 0.027mmol, 17%); Rf 
0.6 [alumina: CH 2 C1 2 - MeOH (98:2)]; HPLC: R t = 5.5min. observed at k = 254nm 
("Synchropak" CM300 cation exchange) with gradient elution. 1.4 cm 3min" 1 . ; A= 
MeCN, B= H 2 0 , C= 1.0M NH 4OAc from t = Omin.; 20% A, 80% B, 0% C; to t =5 
min. 20% A, 60% B, 20% C; to t = 10 min. 20% A, 0% B, 80% C; v m a x (film) 3409s, 
2981, 1731s, 1692vs, 1650s, 1538, 1426, 1382,1303, 1203vs, 1127vs, 1027, 834, 802 
and 721cm-1; m/z (DCI) 549 ( M + + l ) , 491, 463, 406, 250 and 105; 8 H (CDCI3) 7.75 
(2H, m, Ar), 7.38 (3H, m, Ar), 6.80 (1H, br s, NH), 4.08 (6H, m, C H 2 0 ) , 3.5-3.2 
(7H, m, CH 2NCOPh, CHC0 2 , C H 2 C 0 2 ) , 3.0-2.5 (14H, m, CH 2 N, ring), 2.0-1.5 
(4H, m, CH 2 ) and 1.19 (9H, t, J = 7Hz, CH 3); 8 C (CDCI3) 173.2, 172.2, 171.6, 167.5 
(CO), 134.7, 131.2, 128.3, 127.0 (Ar), 66.1, 60.5, 60.3 ( C H 2 0 , CH 2 CO), 39.6 
(CH 2 N), 27.3, 26.3 (CH 2) and 14.2 (CH 3). 
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N,N'-Bis(2-(N-benzoyl-3aminopropyl)ethoxycarbonylmethyl)-N"-
ethoxycarbonylmethyl-1,4,7-triazacyclononane (100) 
Caesium carbonate (0.0166g, 0.051 mmol) and ethylbromoacctate (0.0059cm3, 0.0085g, 
0.051 mmol) were added to a solution of the dialkylated triamine (98) (0.015lg, 
0.046mmol) in anhydrous MeCN (2cm3). The mixture was stirred at 60°C for 20 hours 
after which the solution was filtered and the solvent removed under reduced pressure to 
yield a yellow oil (0.030g) which was purified by HPLC (Dynamax, reverse phase, 
standard conditions), and freeze dried to yield a yellow oil (0.0232g, 0.032mmol, 70%); 
R t = 19min. observed at X = 254nm; Mass found 710.4123 C38H55N5O8 Requires 
710.4129 ; v m a x (film) 3336, 2982, 1732vs, 1644s, 1538, 1448, 1381, 1304, 1201vs, 
1026, 800 and 709cm"1; m/z (DCI) 710 (M++1), 624, 277, 248, 174, 148 and 122; 5 H 
(CDCI3) 7.81 (4H, m, Ar), 7.45 (6H, m, Ar), 4.20 (2H, q, J = 5Hz, CH 2 CH 3 ) , 4.17 
(4H, q, J = 5Hz, CH2CH3), 4.0-2.9 (20H, m, CH2JN, CHN), 2.10-1.65 (8H, br m, 
CH 2 ) and 1.29 (9H, m, CH 3 ) ; 5 C (CDCI3) 134.2, 131.6, 128.6, 127.1(Ar), 61.7, 60.5 
(CH 2 0) , 39.5, 33.7, 28.9, 22.0 (CH 2 N, CH 2 C0 2 ) , 14.2 and 14.1 (CH 2 , CH 3 ) . 
N-(2-(3-Aminopropyl)carboxymethyl)-N'-N"-bis-(carboxymethyl)-l,4,7-
triazacyclononane (101) 
(2-(N-Benzoyl-3-aminopropyl)ethoxycarbonylmethyl)-N'-N"-bis-
(ethoxycarbonylmethyl)-l,4,7-triazacyclononane (99) (0.lg, 0.18mmol) was heated to 
reflux in 6M HC1 (15cm3) for 3 days. The solvent was removed under reduced pressure, 
the resulting glass was taken up in H 2 0 and washed with E t 2 0 (3 x 5cm3) and evaporated 
to yield a brown glassy solid (0.066g, 0.18mmol, quant.); m/z (FAB) 361 (M++1), 303, 
277, 246, 255 and 207; v m a x (film) 2922, 1725.8vs, 1413, 1210; 5 H (D 2 0) 3.95 (4H, s, 
CH 2 CO), 3.9-3.0 (15H, m, CH 2 N, CHCO) and 2.1-1.7 (4H, m, CH 2 ) ; 5 C ( D 2 0 ) 
178.1, 174.6 (CO), 69.6, 66.9, 62.1, 58.5, 53.8, 49.0, 41.9, 28.1 and 27.2. 
N,N'-Bis(2-(3-aminopropyl)carboxymethyl)-N"-carboxymethyl-l ,4,7-
triazacyclononane (102) 
N,N'-Bis(2-(N-benzoyl-3-aminopropyl)ethoxycarbonylmethyl)-N"-
ethoxycarbonylmethyl-l,4,7-triazacyclononane (100) (0.023g, 0.027mmol) was treated 
using an analogous method to the synthesis of (101) to yield a brown glass (0.01 lg , 
0.027mmol); v m a x (film) 2972s, 173lvs, 1415 and 1216; 5 H ( D 2 0 ) 4.17 (2H, s, 
CH 2 CO), 3.91 (2H, m, CHC0 2 ) , 3.25-2.9 (16H, m, CH 2 N) and 2.1-1.6 (8H, m, 
CH 2 ) . 
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N-[2-(3-Amidopropyl (p-nitrophenyl carboxyethyl) carboxymethyl)]-] ,4,7-
triazacyclononane (103) 
O H C O , H UU2M i 
H 0 2 C N NO 
C 0 2 H 2
To N-(2-(3-aminopropyl)carboxymethyl)-N'-i\ ' '-bis-(carboxymethyl)-l ,4,7-
triazacyclononane (101) (0.0943g, 0.238mmol) in DMSO (0.5cm3) was added solid 
bis-ester (81) (0.214g, 0.595mmol) and N-methyl morpholine (0.168g, 0.18cm3, 
1.6mmol). The mixture was stirred thoroughly at R.T. for 30mins and then purified 
using semi preparative HPLC: Rt=13.8mins, observed at A, = 278nm (Dynamax, reverse 
phase) with gradient elution 10 cm 3min" 1; A = H 2O/0.1% TFA, B = MeCN/0.1% TFA 
from t=0 min; A = 90%, B = 10%; to t = 20 mins., A = 25%, B = 75% to yield a yellow 
brown oil (0.1254g, 0.216mmol, 90%); v m a x (KBr disc) 3420, 2937, 2870, 1762vs, 
1654vs, 1525s, 1349, 1204vs, 1132vs, 1010, 865, 798, 720 and 668; m/z (FAB) 582.4 
(M+); 8 H (D 2 0) 8.30 (2H, d, 7 = 9.2, Ar), 7.33 (2H, d, J = 9.1Hz,Ar), 3.90-3.55 (9H, 
m, C H 2 C 0 2 , CH 2CO), 3.55-2.80 (12H, m, CH 2 N ring), 2.67 (2H, t, 7= 5Hz, CH 2 N) 
and 1.65 (4H, ,m, CH 2 ) ; 5 C ( D 2 0 ) 185.4, 177.2, 176.56, 175.9, 173.6 (CO), 158.0 
(q), 148.4 (q), 128.5, 125.7 (Ar), 66.7, 58.7, 56.1, 53.1 (CH 2CO and CHCO), 52.1, 
49.1, 41.7, 46.1 (CH 2N), 33.0 and 32.3 (CH 2). 
N,N'-Bis-[2-(3-amidopropyl(p-nitrophenyl carboxyethyl)) carboxymethyl]-N"-
carboxymethyl-1,4,7-triazacyclononane (104) 
To N,N'-bis(2-(3-aminopropyl)carboxymethyl)-N"-carboxymethyl -1,4,7-
triazacyclononane (102) (0.01 lg , 0.027mmol) in DMSO (0.5cm3) was added solid bis 
ester (81) (0.025g, 0.068mmol) and N-methyl morpholine (0.019g, 0.02cm 3, 
0.19mmol). The mixture was stirred thoroughly at room temperature for 30mins and 
then purified using HPLC: Rt=17mins, observed at X = 278nm (Dynamax, reverse 
phase) with gradient elution 10 cm 3min-! ; A = H 2O/0.1% TFA, B = MeCN/0.1% TFA 
from t=0 min; A = 90%, B = 10%; to t = 20 mins., A = 25%, B = 75%. The resulting 
brown mixture was taken up in H 2 0 (3cm3) and washed with E t 2 0 (3 x 5cm3) to remove 
excess p-nitrophenol, the aqueous layer was freeze dried to yield a yellow brown oil 
(6.4mg, 0.0075mmol, 28%); v m a x (film) 3018vs, 1722vs, 1633s, 1593s, 1515, 1499, 
1453vs, 1288, 1236, 1170, 1112, 1007, 853 and 754; 5 H (D 2 0) 8.17 (4H, d, J= 8Hz, 
Ar), 7.2 (4H, d, 7= 8Hz, Ar), 3.9-3.25 (12H, m, CH 2CO, CHCO, CH 2CONH), 3.25-
2.8 (12H, m, ring), 2.5 (4H, t, 7= 9Hz, CH 2N) and 1.9-1.4 (8H, m, CH 2 ) . 
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9N3 tuftsin conjugate(l05) 
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To the active ester (103) (0.062g, 0.1 lmmol) in (CD 3) 2SO (1cm 3) was added a solid 
sample of tuftsin (0.13mmol, 70mg). The mixture was mixed thoroughly at R.T. for 3 
hours, after this time some brown precipitate formed. lH NMR analysis revealed that the 
solution consisted of only p-nitrophenoi and excess tuftsin. The solid was washed with 
DMSO (3x 1cm3) and dried under reduced pressure to yield a brown oily solid (13.9mg, 
0.015mmol, 13%); m/z (FAB) 944 (M+H), 922, 645, 459, 367, 275 and 186; m/z 
(Electrospray) 943.2 (M+H)+; v m a x (film) 3405vs, 1633s, 1406, 1016, 952; 5 H 
(D 20)4.6 (1H, br t, a-Lys), 4.35 (1H, br t, a-Pro), 4.05 (1H, br m, a-Arg, 4.00 (1H, 
t, P-Thr), 3.85 (1H, br m, 8-Pro), 3.65 (1H, br m, 6'-Pro), 3.6 (5H, m, C H 2 C 0 2 ) , 
3.54 (4H, m, CH 2CO), 3.5 (1H, m, a-Thr), 3.3-2.85 (12H, m, CH 2 N ring; 2H, m, 5-
Arg; 2H, m, e-Lys), 2.65-2.4 (2H, m, CH 2 N; 1H, m, (3-Pro), 2.3 (1H, m, P'-Pro), 
2.1-1.3 (2H, y-Pro; 2H, [3-Lys; 2H, (3-Arg; 2H, 6-Lys; 2H, 8-Arg; 2H, y-Lys; 4H, 
CH 2 ) and 1.21 (3H, d, J = 6Hz, y-Thr). 
6.5 C H A P T E R F I V E E X P E R I M E N T A L 
9-Acridine carbamoylethyl-2-[bis (2-aminoethyl)] amine(\\3) 
HoN 
\ H 
HoN N 
9-Acridine carboxylic acid (0.2g, 0.90mmol) was heated to reflux in thionyl chloride 
(1.5cm3) for three hours until fully dissolved. The thionyl chloride was then removed 
under reduced pressure and the yellow acid chloride was dissolved in CH 2 C1 2 (2 x 
1.5cm3) and dried to remove all remaining SOCl 2. Tris (2-aminoethyl) amine (0.66g, 
0.7cm3, 4.5mmol) was stirred at 0°C and the freshly prepared acid chloride in CH 2 C1 2 
( lcm 3 ) was added dropwise and allowed to stir and warm up to R.T. The resulting white 
suspension was basified (pH13) and extracted exhaustively into CHCI3, the volume was 
reduced to give a yellow/brown solution which was purified using semi preparative 
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HPLC: Rt=8.8mins, observed at X = 320nm ('Dynamax', reverse phase) with gradient 
elution. 1 Ocm3min-1; A = H2O/0.1 % TFA, B = MeCN/0.1 % TFA from t=0 min; A = 
90%, B = 10%; to t = 20 mins., A = 10%, B = 90%; to yield a yellow oil (91.5mg, 
0.26mmol, 23%); (Mass found 352.2121 C20H25N5O requires 352.2137); m/z (DCI) 
352 (M++1), 321, 180; v m a x (film) 3344, 2944, 1633, 1574, 1484, 1366, 1316, 1153, 
868, 819 and 750cm"1; 5 H (CD3OD) 8.34 (6H, m, Ar), 7.94 (2H, t, J= 7Hz, Ar), 3.85 
(2H, t, J= 7Hz, CH 2NHCO), 3.16 (4H, t, J = 5Hz, C H 2 N H 2 ) and 2.95 (6H, m, 
CH 2 N); 8 C (CD3OD) 167.0(CO), 152.1 (CCO), 143.6, 138.0, 130.2, 130.1, 130.0, 
124.3, 123.3 (Ar), 53.9, 52.6, 38.6 and 38.5 (CH 2N). 
Bis [9-acridine carbomylethyl]- 2-(2-aminoethyl) amine (114) 
Procedure as for (113); purified using semi preparative HPLC: Rt=10mins, observed at 
,\ - 320nra ('Dyuumax', icveise phase) with gradient eiution. 10 em-'min ' ; A = 
H 2O/0.1% TFA, B = MeCN/0.1% TFA from t=0 min; A = 90%, B = 10%; to t = 20 
mins., A = 10%, B = 90%; to yield a yellow oil (0.0533g, 0.096mmol, 10%); m/z (DCI) 
559 (M++l),516, 447, 354, 335, 321 and 180; v m a x (film) 3411, 3233, 3062, 1680vs, 
1550, 1467, 1433, 1202vs, 1132vs, 836, 800, 756 and 722cm"1; 8 H (CD3OD) 8.25 
(12H, m, Ar), 7.88 (4H, t, / = 7.5Hz, Ar), 3.91 (4H, t, J = 6Hz, CH 2 NHCO), 3.17 
(6H, t, J = CH 2N) and 2.85 (2H, t, CH 2 NH 2 ) ; 8 C (CD3OD) 167.8(CO), 152.8 (CCO), 
143.8, 137.6, 130.0, 128.0, 124.1, 123.6 (Ar), 54.8, 52.6, 39.2 and 38.4 (CH 2 N). 
9-Acridine carbamoylethyl-2-(2-aminoethyl)-2-methyl amine (117) 
9-Acridine carboxylic acid chloride was formed in the method of (113). N 2 -
methyldiethylenetriamine (0.59g, 0.65cm3, 5mmol) was stirred at 0°C with DMAP 
(5mg), a solution of the acid chloride (0.9mmol) in CH 2 C1 2 was added dropwise and 
then allowed to warm up to R.T overnight. The resulting white suspension was basified 
(pHI3) and extracted exhaustively with CHCI3, evaporated and the excess triamine 
removed by Kugelrohr distillation. The resulting brown oil was purified by HPLC: 
Rt=8.3 mins, observed at X = 320nm ('Dynamax', reverse phase) with gradient elution. 
10 cm 3min" 1; A = H 2O/0.1% TFA, B = MeCN/0.1% TFA from t=0 min; A = 90%, B = 
10%; to t = 20 mins., A = 10%, B = 90%; to yield a yellow oil (0.182g, 0.57mmol, 
63%); m/z (DCI) 530, 419, 323 (M++1), 280, 223, 180 and 85; m/z(FAB) 324, 249, 
180, 118 and 93; v m a x (film) 3424vs, 3046, 2925, 2524, 1692, I666vs, 1568, 1466, 
1434, 1270, 1199vs, 1130vs, 1023, 976, 837, 799, 758 and 722cm"1 ; 8 H (CD3OD) 
8.29 (4H, m, Ar), 8.23 (2H, t, J = 7Hz, Ar), 7.87 (2H, t, J = 8Hz, Ar), 4.14 (2H, t, J 
= 6Hz, CH 2NHCO), 3.68 (4H, m, CH 2 NMe), 3.54 (2H, t, J = 6Hz, C H 2 N H 2 ) and 
3.11 (3H, s, NCH 3 ) ; 8 C (CD3OD) 167.7 (CO), 150.7 (CCO), 143.9 (q Ar), 137.5 
(Ar), 130.1, 128.0 (Ar), 124.1 (q Ar), 123.7 (Ar), 56.9, 54.6, 41.8, 36.7 and 35.9. 
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N,N'-Bis[9-acridine carbamoylethyl]-2-N-methyl amine (118) 
N 
Me 
N H 
N 
NH 
O 
N 
Procedure as for (117). The resulting mixture was purified by HPLC: R t= 9.7 mins, 
observed at X = 320nm ('Dynamax', reverse phase) with gradient elution. 10 cm 3min"'; 
A = H2O/0.1 % TFA, B = MeCN/0.1% TFA from t=0 min; A = 90%. B = 10%; to t = 20 
mins., A = 10%, B = 90%; to yield a yellow oil (0.0475g, 0.091 mmol, 10%); m/z (DCI) 
528 (M++1), 323, 280, 249, 223, 205, 180 and 133;m/z(FAB) 528, 356, 249, 207, 
180 and 93; v m a x (film) 3417, 1674vs, 1557, 1433, i202vs, i i35vs, 800, 758 and 
722cm-1; 5 H (CD 3OD) 8.27 (8H, m, Ar), 8.10 (4H, t, J = 7Hz, Ar). 7.76 (4H, t, J = 
7Hz. Ar), 4.20 (4H, t, J = 6Hz, CH 2N), 3.85 (4H. t, J = 6Hz, CH 2N) and 3.25 (3H, s, 
NMe); 5 C (CD3OD) 168.5 (CO), 145.1 (CCO), 136.6, 129.9, 127.9, 124.9 (Ar), 56.9, 
41.8 and 36.8 (CH 2N). 
9-Acridine carbamoylethyl-2-(2-(p-nitrophenyl carboxyethyl) amidoethyl)-N-methyl 
amine (119) 
acridine amine (117) (0.074g, 0.23mmol) in dry DMSO (0.5cm3) was added bis p-
nitrophenyl succinate (81) (0.247g, 0.69mmol) and N-methyl morpholine (0.046g, 
0.05cm 3, 0.46 mmol) at R.T with vigorous mixing. Analytical HPLC revealed that 
reaction had taken place within a few minutes, the reaction mixture was then cooled to 
-78°C and only defrosted in portions for HPLC purification. Rt=13.7 mins, observed at 
X = 353nm ('Dynamax', reverse phase) with gradient elution. 10 cm 3 min"' ; A = 
H 2 O/0.1% TFA, B = MeCN/0.1% TFA from t=0 min; A = 90%, B = 10%; to t = 20 
mins., A = 25%, B = 75%; to t = 30 mins. A = 0%. B = 100%; to yield a yellow oil 
(0.0385g, 0.071 mmol, 96%); m/z (Electrospray) 544, 437, 405, 280, 249, 180 and 126; 
v m a x (film) 3380, 1762, 1670vs, 1523s, 1430, 1348, 1202vs, 1129vs, 864, 834, 799, 
753 and 720cm"1; 5 H (CD3OD) 8.17 (4H, m, Ar), 7.89 (2H+2H. m, Acridine + p-
nitrophenol), 7.00 (2H, d j = 9.2Hz, p-nitrophenol), 4.05 (2H, t, J = 5Hz, 
CH 2NHCOAr), 3.70 (4H, t, CH 2NMe), 3.51 (2H, t, CH 2NHCO), 3.11 (3H, s, NMe) 
and 2.69 (4H, m, CH 2 0) ; 5 C (CD3OD) 178.2 (CO), 175.4 (CO), 169.3 (CO), 157.3 (q 
OoN 
Me 
N H 
N 
N N 
H 
To 
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Ar), 151.7 (q Ar), 147.4 (q Ar), 142.7 (q Ar), 140.2 (q Ar), 131.8, 128.6, 127.6, 124.8 
(2C), 122.8 (Ar), 59.2, 59.7, 43.3, 38.0, 37.3, 32.1 and 31.4. 
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IONIC A N D M O L E C U L A R RECOGNITION 
MODERN N M R TECHNIQUES 
NUCLEIC ACIDS 
R E S E A R C H C O L L O Q U I A . S E M I N A R S AND L E C T U R E S 
Organised by the Department of Chemistry (August 1991 - July 1994) 
1991 
October 17 t h Dr. J. A. Salthouse, University of Manchester. 
Son et Lumiere - A demonstration Lecture. 
October 3 1 s t Dr. R. Keeley, * Metropolitan Police Forensic Science. 
Modern Forensic Science. 
November 6 t h Prof. B. F. G. Johnson,t University of Edinburgh. 
Cluster - Surface Analogues. 
November 7 t h Dr. A. R. Butler, * University of St. Andrews. 
Traditional Chinese Herbal drugs - a different way of treating disease. 
November 13 t h Prof. D. Gani,t* University of St. Andrews. 
The chemistry of PLP-dependent Enzymes. 
November 2 0 t h Dr. M . More O' Ferrall,t* University College, Dublin. 
Some Acid-Catalysed Rearrangements in Organic Chemistry. 
November 28 t h Prof. I . M . Ward, IRC in Polymer Science, University of Leeds. 
The SCI Lecture - The Science and Technology of Orientated 
Polymers. 
December 4 t h Prof. R. Grigg,t* University of Leeds. 
Palladium-Catalysed Cyclisation and Ion-Capture Process. 
December 5 t h Dr. A. L. Smith, ex Unilever. 
Soap, Detergents and Black Puddings. 
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December 1 1 t h Dr. W. D. Cooper, Shell Research. 
Colloid Science - Theory and Practice. 
1992 
January 2 2 n d Dr. K. D. M . Harris,t * University of St. Andrews. 
Understanding the Properties of Solid Inclusion Compounds. 
January 2 9 t h Dr. A. Holmes J * University of Cambridge. 
Cycloaddition Reactions in the Service of the Synthesis of Piperidine 
and Indolizidine Natural Products. 
January 3 0 t h Dr. M . Anderson, * Shell Research, Sittingborne. 
Recent Advances in the Safe and Selective Control of Insect Pests. 
February 12 t h Dr. D. E. Fenton,t* University of Sheffield. 
Polynuclear Complexes of Molecular Clefts as Models for Copper 
Biosites. 
February 13 t h Dr. J. Saunders, Glaxo Group Research Limited. 
Molecular Modelling in Drug Discovery. 
February 19 t h Prof. E. J. Thomas j * University of Manchester. 
Applications of Organostannanes to Organic Synthesis. 
February 2 0 t h Prof. E. Vogel,* University of Cologne. 
The Musgrave Lecture - Porphyrins - Molecules of Interdisciplinary 
Interest. 
February 2 5 t h Prof. J. F. Nixon, University of Sussex. 
The Tilden Lecture - Phosphaalkynes - New Building Blocks in 
Inorganic and Organometallic Chemistry. 
February 2 6 t h Prof. M . L . Hitchmann,t University of Strathclyde. 
Chemical Vapour Deposition. 
March 5 t h Dr. N . C. Billingham, University of Sussex. 
Degradable Plastics - Myth or Magic '? 
March 5 t h Dr. S. E. Thomas,t* Imperial College. 
Recent Advances in Organo-Iron Chemistry. 
March 12 t h Dr. R. A. Hann, * ICI Imagedata. 
Electronic Photography - An Image of the Future. 
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March 18 t h Dr. H. Maskell,t* University of Newcastle. 
Concerted or Stepwise Fragmentation in a Diamination Type 
Reaction. 
April 7 i h Prof D. M . Knight, Philosophy Department, University of Durham. 
Interpreting Experiments - The Beginning of Electrochemistry. 
May 13 t h Dr. J-C. Gehret, * Ciba Geigy, Basel. 
Some Aspects of Industrial Agrochemical Research. 
October 15 th Dr. M . Glazer, Dr. S. Tarling, Oxford University & Birbeck College. 
It Pays to be British ! - The Chemist's Role as an Expert Witness in 
Patent Litigation. 
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Svnrhesis, R pactions anrl Tbp«"n\ocheniiRtrv of Metal ( AllfyH CvnniHp 
Complexes and Their Impact on Olefin Hydrocyanation Catalysis. 
October 22 nd Prof. A. Davies,* University College London. 
The Ingold-Albert Lecture - The Behaviour of Hydrogen as a 
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Dr. J. K. Cockcroft, University of Durham. 
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November 2 5 t n Prof. Y. Vallee. University of Caen. 
Reactive Thiocarbonyl Compounds. 
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Fragmentation of Phosphorous Heterocycles as a Route to Phosphoryl 
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November 26^' Dr. D. Humber, Glaxo, Greenford. 
AIDS - The Development of a Novel Series of Inhibitors of H I V . 
December 2 n c * Prof. A. F. Hegarty, University College, Dublin. 
Highly Reactive Enols Stabilised by Steric Protection. 
December 2 n c * Dr. R. A. Aitken j * University of St. Andrews. 
The Versatile Cycloaddition Chemistry of BU3P.CS2. 
December 3 r a Prof. P. Edwards, Birmingham University. 
The SCI Lecture - What is Metal ? 
December 9 t n Dr. A. N . Burgess,t ICI Runcorn. 
The Structure of Perfluorinated Ionomer Membranes. 
1993 
January 2 0 t n Dr. D. C. Clary, 1 University of Cambridge. 
Energy Flow in Chemical Reactions. 
January 2 1 s t Prof. L . Hall, * Cambridge. 
N M R - Window to the Human Body. 
January 2 7 t n Dr. W. Kerr,* University of Strathclyde. 
Development of the Pauson-Khand Annulation Reaction : 
Organocobalt Mediated Synthesis of Natural and Unnatural Products. 
January 2 8 t n Prof. J. Mann,* University of Reading. 
Murder, Magic and Medicine. 
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Enzymes in Organic Synthesis. 
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February 1 l m Prof. S. Knox,* Bristol University. 
The Tilden Lecture - Organic Chemistry at Polynuclear Metal Centres. 
February 1 7 m Dr. R. W. Kemmitt,t University of Leicester. 
Oxatrimethylenemethane Metal Complexes. 
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February 1 8 m Dr. I . Fraser, * I C I Wilton. 
Reactive Processing of Composite Materials. 
February 2 2 n d Prof. D. M . Grant, University of Utah. 
Single Crystals, Molecular Structure, and Chemical-Shift Anisotropy. 
February 2 4 t h Prof. C. J. M . Stirling,"!* University of Sheffield. 
Chemistry on the Flat-Reactivity of Ordered Systems. 
March 10 t n Dr. P. K. Baker, University College of North Wales, Bangor. 
Chemistry of Highly Versatile 7-Coordinate Complexes. 
March 1 l t n Dr. R. A. Y. Jones, University of East Anglia. 
The Chemistry of Wine Making. 
March 17 t h Dr. R. J. K. Taylor, i * University of East Anglia. 
Adventures in Natural Product Synthesis. 
March 2 4 t n Prof. I . O. Sutherland,'''* University of Liverpool. 
Chromogenic Reagents for Cations. 
May 13 t n Prof. J. A. Pople, Carnegie-Mellon University, Pittsburgh, USA. 
The Boys-Rahman Lecture - Applications of Molecular Orbital 
Theory. 
May 2 1 s t Prof. L . Weber, University of Bielefeld. 
Metallo-phospha Alkenes as Synthons in Organometallic Chemistry. 
June 1 s t Prof. J. P. Konopelski, University of California, Santa Cruz. 
Synthetic Adventures with Enantiomerically Pure Acetals. 
June 2 n d Prof. F. Ciardelli, University of Pisa. 
Chiral Discrimination in the Stereospecific Polymerisation of Alpha 
Olefins. 
June 7 t n Prof. R. S. Stein, University of Massachusetts. 
Scattering Studies of Crystalline and Liquid Crystalline Polymers. 
June 16^ Prof. A. K. Covington, * University of Newcastle. 
Use of Ion Selective Electrodes as Detectors in Ion Chromatography. 
June 17 t n Prof. O. F. Nielsen, H . C. 0rsted Institute, Copenhagen University. 
Low-Frequency IR and Raman Studies of Hydrogen Bonded Liquids. 
September 13 t n Prof. Dr. A. D. Schliiter, Freie Universitat Berlin. 
Synthesis and Characterisation of Molecular Rods and Ribbons. 
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September 13 t n Dr. K. J. Wynne, Office of Naval Research, Washington. 
Polymer Surface Design for Minimal Adhesion. 
September 14 t n Prof. J. M . DeSimone, University of North Carolina, Chapel H i l l . 
Homogeneous and Heterogeneous Polymerisations in Environmentally 
Responsible Carbon Dioxide. 
September 2 8 t n Prof. H . Ila,* North Eastern Hi l l University, India. 
Synthetic Strategies for Cyclopentanoids via Oxoketene Dithioacetals. 
October 4 m Prof. F. J. Feher,t University of California, Irvine. 
Bridging the Gap Between Surfaces and Solution with 
Sessilquioxanes. 
October 14^ Dr. P. Hubberstey, Nottingham University. 
Alkali McLais - Alchemist's Nightmare, Biochemist's Puzzle and 
Technologist's Dream. 
October 2 0 t n Dr. P. Quayle j * University of Manchester. 
Aspects of Aqueous ROMP Chemistry. 
October 2 1 s t Prof. R. Adams J * University of South Carolina. 
Chemistry of Metal Carbonyl Cluster Complexes - Development of 
Cluster Based Alkyne Hydrogenation Catalysts. 
October 2 7 m Dr. R. A. L. Jones,1"* Cavendish Laboratory. 
Perambulating Polymers. 
November 10 t n Prof. M . N . R. A s h f o l d j University of Bristol. 
High Resolution Photofragment Translational Spectroscopy : A New 
Way to Watch Photodissociation. 
November 1 7 m Dr. A. Parker, t*Laser Support Facility, RAL. 
Applications of Time Resolved Resonance Raman Spectroscopy to 
Chemical and Biochemical Problems. 
November 2 4 t n Dr. P. G. Bruce,t* University of St. Andrews. 
Structure and Properties of Inorganic Solids and Polymers. 
November 2 5 t n Dr. R. P. Wayne, Oxford University. 
The Origin and Evolution of the Atmosphere. 
December 1 s t Prof. M . A. McKervey,t* Queen's University, Belfast. 
Synthesis and Applications of Chemically Modified Calixarenes. 
December 8 t n Prof. O. Meth-Cohan,t* University of Sunderland. 
Friedel's Folly Revisited - A Super Way to Fused Pyridines. 
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December 1 6 m Prof. R. F. Hudson, University of Kent. 
Close Encounters of the Second Kind. 
1994 
January 2 6 t h Prof. J. Evans,t University of Southampton. 
Shining Light on Catalysts. 
February 2 n d Dr. A. Masters,t University of Manchester. 
Modelling Water Without Using Pair Potentials. 
February 9 t n Prof. D. Young,t University of Sussex. 
Chemical and Biological Studies on the Coenzyme Tetrahydrofolic 
Acid. 
February 16 t n Prof. K. H . Theopold, University of Delaware, USA. 
Paramagnetic Chromium Alkyls - Synthesis and Reactivity. 
February 2 3 r d Prof. P. M . Maitl is , t University of Sheffield. 
Across the Border : From Homogeneous to Heterogeneous Catalysis. 
March 2 n d Dr. C. Hunter j * University of Sheffield. 
Non Covalent Interactions Between Aromatic Molecules. 
March 9 ^ Prof. F. Wilkinson, Loughborough University of Technology. 
Nanosecond and Picosecond Laser Flash Photolysis. 
March 10 th Prof. S. V. Ley, University of Cambridge. 
New Methods for Organic Synthesis. 
March 25 th Dr. J. Dilworth, University of Essex. 
Technetium and Rhenium Compounds with Applications as Imaging 
Agents. 
Ap i l 2 8 t n Prof. R. J. Gillespie, * McMaster University, Canada. 
The Molecular Structure of some Metal Fluorides and Oxofluorides 
Apparent Exceptions to the VSEPR Model. 
May 12 t n Prof. D. A. Humphreys, * McMaster University, Canada. 
Bringing Knowledge to Life . 
i Invited specially for the graduate training programme. *Author's attendance. 
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1. Stereochemistry at Sheffield, 
University of Sheffield. 
December 18"1 1991 
2. North East Graduate Symposium, 
University of Durham. 
April 3 r d 1992 
3. R.S .C. U.K. Macrocycles Group, January 6 t h - 7 t h 1993 
University of Oxford. 
4. International Symposium on Metal Ions in Solution.* April 20th - 23rd 1993 
South Africa 
5. North of England Cancer Research Campaign Meeting * July 21st 1993 
University of Newcastle. 
6. Stereochemistry at Sheffield, December 15th 1993 
University of Sheffield. 
7. North East Graduate Symposium, April 12th 1994 
University of Northumberland. 
8. North of England Cancer Research Campaign Meeting * July 26th 1994 
University of Newcastle. 
* Poster presented 
1. D. Parker, K. Pulukkody, F . C . Smith, A. Batsanov and J.A.K. Howard, J.Chem. 
Soc. Dalton Trans., 1994, 689. 
2. T. J. Norman, F . C. Smith. D. Parker, A. Harrison, L . Royle, and C . A. Walker, 
Supramolecular Chem., 1995, 4, 305-308. 
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3. A. Harrison, C.A. Walker, K.A. Pereira, C . Counsell, D. Parker, L . Royle, R . C . 
Matthews, A.S. Craig and F .C. Smith, Nucl. Med. Commun., 1995, in 
preparation. 
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T A B L E 1: Atomic coordinates (xlO4) and equivalent isotropic displacement 
coefficients ( A 2 x 10 3 ) 
y z rj(eq) 
V 2 3 2 0 ( 1 ) 1789 (1 ) 2956 (1 ) 20(1) 
w I 1 / - 2 3 ( 1 0 ) 2 7 4 6 ( 1 0 ) 2 7 9 1 ( 7 ) 30(5) 
\ — i 3 0 4 8 ( 1 0 ) 173 (10 ) 1 7 3 7 ( 7 ) 25(5) 
•J \ J 3 0 5 2 ( 1 1 ) - 1 4 1 3 ( 1 1 ) 9 7 0 ( 7 ) 3 1 ( 5 ) 
v I *± ; 2 3 6 4 ( 1 0 ) 2 5 9 8 ( 9 ) 1 6 1 4 ( 6 ) 2 2 ( 5 ) 
- ' c . 3 6 0 0 ( 1 0 ) 2 3 2 5 ( 1 0 ) 3 7 1 0 ( 7 ) 2 9 ( 5 ) 
~ '' ^ / 5 5 9 2 ( 1 0 ) 7 281 ' 1 0 ; 
- r\ r\ • " ' ^ i 0 O i O 1 29 (5 ) 
0 ( / / 1140 (10 ) 1936 (10 ) 4 4 6 2 ( 6 ) 2 5 ( 5 ) 
C I o ; 1 3 2 6 ( 1 0 ) 1499(10) 3 3 3 3 ( 7 ) 3 0 ( 5 ) 
? - i / 1115(10 ) 4 2 0 9 ( 1 3 ) 3 3 4 5 ( 6 ) 2 8 ( 5 ) 
; . ; ( ] _ ; 3 7 5 " ; • 1 ) - 3 5 1 ( 1 1 ! 3 5 5 1 ( 3 ) 2 3 ( 6 ) 
: ; ( 2 ; 1026 (12 ) i 5 / i IJ. ) 3 2 1 0 ( 3 ) 2 4 ( 6 ) 
M ( 3 ; - 2 3 4 0 ( 1 3 ) 3129 (12 ) 3 1 8 3 ( 8 ) 3 1 ( 7 ) 
M ( 4 ) 5 1 0 3 ( 1 2 ) 7 4 6 ( 1 1 ) 2 1 1 9 ( 7 ) 2 4 ( 6 ) 
M ( 5 i 4 0 5 2 ( 1 2 ) 2310 (12 ) 1 5 8 ( 8 ) 2 8 ( 6 ) 
C ! i ; 3 3 6 2 ( 1 4 ) - 1 3 8 8 ( 1 4 ) 3 3 2 5 ( 1 0 ) 2 5 ( 7 ) 
1 6 9 5 ( 1 5 ) - 8 7 3 ( 1 4 ) 3 7 6 6 ( 1 0 ) 27(7) 
C ! 3 / - 5 2 4 ( 1 6 ) 1094 (14 ) 3524 (11 ) 31(8) 
C ( 4 ) - 9 6 2 ( 1 6 ) 2382 (15! 3146 (11) 29(8) 
C (5 ) - 2 9 6 1 ( 1 7 ) 4472 (15) 2357 (12) 45 (9 ) 
C ( 5 ) 5 3 7 3 ( 1 5 ) - 8 9 6 ( 1 5 ) 3271 (10) 29(7) 
C ( 7 ) 5 8 1 5 ( 1 7 ) - 7 4 6 ( 1 4 ) 2231 (10 ) 30(8) 
C ( 3) 5 3 3 2 ( 1 4 ) 3 5 4 ( 1 4 ) •• 1 1 4 7 ( 9 ) 22(7) 
• : ; 5) 3 9 8 0 ( 1 6 ) 2035 (14 ) 998 (10 ) 24(8) 
C ( 10) 2 8 6 4 ( 1 4 ) 3 4 1 2 ( 1 4 ) - 9 8 ( 1 0 ) 25(7) 
C ( I I ) - 3 8 0 1 ( 1 0 ) 4 4 9 3 ( 1 2 ) 2245 (6) 32(4) 
C ( 1 2 ) -5318 5185 2567 48(5) 
C (13 ) -6163 5258 2017 70(6) 
3(14 ) - 5 4 9 1 4640 1146 62(6) 
C(1S) -3974 3949 824 61(5) 
C ( 1 6 ; -3129 3875 1374 49(5) 
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1 2 0 9 ( 1 4 ) - 4 6 3 ( 1 5 ) 2347 (9 ) 2 6 ( 7 ) 
r i i s j 2 5 8 7 ( 1 5 ) - 6 0 5 ( 1 8 ) 1 5 3 2 ( 1 0 ) 3 0 ( 8 ) 
; 3323 (15) 5 6 ( 1 4 ) 4627 (9) 2 8 ( 8 ) 
C.2Z, 1 8 2 3 ( 1 5 ) 1 2 5 5 ( 1 4 ) 5 0 1 1 ( 1 0 ) 2 2 ( 8 ) 
c ( 2 1 : 1 8 2 7 ( 1 0 ) 3 0 0 9 ( 1 0 ) -332 (6 ) 28 (4 ) 
C ( 2 2 , 1588 1968 55 33(4) 
c; 22 , 628 1634 -175 4 8 ( 5 ) 
C!24) -93 2 3 4 1 -793 5 1 ( 5 ) 
C(25) 145 3382 - 1 1 8 1 4 7 ( 5 ) 
C(26) • 1106 3716 - 9 5 1 4 2 ( 4 ) 
0 ( 2 7 ) 5 7 4 6 ( 1 6 ) 1469 (14) 2 4 6 3 ( 1 0 ) 2 7 ( 8 ) 
C(2S) 4 9 1 9 ( 1 7 ) 2 0 3 5 ( 1 4 ) 3 4 2 7 ( 1 1 ) 3 0 ( 8 ) 
0(2W) 3 5 3 2 ( 1 8 ) 4 2 6 5 ( 1 7 ) 5 4 1 6 ( 1 0 ) 9 6 ( 5 ) 
0(2W) 1 6 8 6 ( 2 1 ) 3 6 6 5 ( 2 1 ) 6 3 3 5 ( 1 2 ) 1 2 2 ( 6 ) 
0(4W)/H 3 6 6 6 ( 2 5 ) 4 2 0 2 ( 2 4 ) 5 2 0 2 ( 1 4 ) 7 1 ( 7 ) 
0(4W)B 4 4 1 9 ( 3 2 ) 4 8 3 4 ( 3 0 ) 4 7 8 9 ( 1 9 ) 53 (8) 
* E q u i v a i e n c i s o c r o p i c (J d e f i n e d as one c h i r d o f t h e 
c r a c e o f t h e o r c h o g o n a l i z e d U — t e n s o r 
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T A B L E 2: Bond Lengths (A) 
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: - u ( i ; 2 . 234 ( 1 2 ) 
"i"-C f 4 ) 2 . 360 ( 1 1 ) 
'•' ' 7 ) 2 . 341 ( 1 0 ) 
2 . 562 ( 1 2 ) 
V - H { 4 ) 2 . 624 (12 ) 
1. 256 ( 2 6 ) 
i_ _ 233 ( 1 4 ) 
7 ! 6 ) - 7 ( 2 3 ) 1 . 276 ( 2 5 ) 
7 ( 3 1 - C 120) 1. 
i 
244 ( 1 3 ) 
: : c ; - : ( 2 ; _j_ 452 ( 1 9 ) 
1:(2; - 7 ! 17) 1_ 475 ( 2 1 ) 
: : ( 3 ) - 7 ( 5 ) 1. 468 ( 2 0 ) 
11(4 i - 7 ( 3 ) 1. 489 ( 1 8 ) 
: ; (5) - c ; 3 ) 1_ _ 219 ( 1 9 ) 
- c (2 ) 1. (21 ) 
2 ! ^ ; -•_ ! '.i J- . 486 ( 2 5 ) 
7 ( 3 ) - 7 ( 5 ) ' 1. 510 •; 19) 
7 ; : ^ ; - 7 ; i 3 ) 1. 554 ( 2 1 ) 
7 ( 2 7 ; - 7 ( 2 3 ) 1. 520 (21 ) 
Y - Q ( 2 ) 2 .220 (11) 
Y - 0 ( 5 ) 2 .332 (14) 
Y-O( IW) 2 .402 (11) 
Y - M ( 2 ) 2 .739 (16) 
0 ( 1 ) - C ( 4 ) i .262 (23) 
0 ( 3 ) - 7 ( 1 3 ) .222 (20) 
0 ( 5 ) - 7 ( 2 3 ) 1 .259 (20) 
0 ( 7 1 - 7 ( 2 0 ) 1 .278 (19) 
N ( 1 ) -C ! 1) i .437 (24) 
i'J 1 1 ; i 1 ? 1 . ; 0 J (19) 
N (2 ) - C ( 3 ) I .464 (16) 
M ( 3 ) - 7 ( 4 ) 1 .207 (19) 
M(4) - 7 ( 7 ) X .517 (18) 
M ( 4 ) - 7 ( 2 7 ) 1 .487 (26) 
M ( 5 ) - 7 ( 1 0 ) L . 4 5 1 (18) 
7 ( 3 1 - 7 ( 4 ) I .525 (22) 
7 ( 6 ) - 7 ( 7 ) 1 .529 (21) 
7 ( 1 0 ) - 7 ( 2 1 1 1 .525 (23) 
7 ( 1 9 1 - 7 ( 2 0 ) 1 .514 (16) 
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T A B L E 3: Bond Angles (°) 
0 ( 1 ) - Y - 0 ( 2 ) 87 . 3 ( 4 ) 0 ( 1 ) - Y - 0 ( 4 ) 84 . 8 ( 4 ) 
0(-2) - Y - 0 ( 4 ) 71 . 7 ( 4 ) 0 ( 1 ) - Y - 0 ( 5 ) 138 . 7 ( 3 ) 
0 ( 2 ) - Y - 0 ( 5 ) 133 . 0 ( 3 ) 0 ( 4 ) - Y - 0 ( 5 ) 98 . 6 ( 4 ) 
0 ( 1 ; - Y - 0 ( 7 ) 84 . 3 ( 4 ) 0 ( 2 ) - Y - 0 ( 7 ) 130 . 8 ( 4 ) 
0 ( 4 ) - Y - 0 ( 7 ) 154 . 2 ( 3 ) 0 ( 5 ) - Y - 0 ( 7 ) 75 . 1 ( 4 ) 
C O - Y - O ( I W ) 71 . 1 ( 4 ) 0 ( 2 ) - Y - O ( I W ) 141 . 7 ( 4 ) 
0 ( 4 ) - Y - O ( I W ) 75 . 1 ( 3 ) 0 ( 5 ) - Y - O ( I W ) 70 . 2 ( 4 ) 
0 ( 7 ) - Y - O ( I W ) 79 . 3 ( 3 ) 0 ( 1 ) - Y - M ( l ) 130 . 9 ( 4 ) 
0 ( 2 ) - Y - N ( l ) 31 . 4 ( 4 ) 0 ( 4 ) - Y - N ( l ) 1 3 4 , . 3 ( 3 ) 
, r . . y _ ? . T 1 1 . 
i J . 0 1 4 / 0 \ / ! - 1 -L-t ( L i 68 , . 7 ( 3 ) 
0 ( ivv") - Y - M ( 1) 136 . . 6 ( 4 ) 0 ( 1 ) - Y - M ( 2 ) 6 3 . . 3 ( 4 ) 
0 ( 2 ) - Y - N ( 2 ) 63 . . 5 ( 4 ) 0 ( 4 ) - Y - N ( 2 ) 1 2 4 . , 8 ( 4 ) 
0 ( 5 ) - Y - M ( 2 ) 1 3 5 . . 4 ( 4 ) 0 ( 7 ) - Y - N ( 2 ) 6 9 . , 5 ( 4 ) 
0 ( 1 W ) - Y - M ( 2 ! 1 2 6 . , 2 ( 3 ) M ( l ) - Y - M ( 2 ) 6 8 . 9 ( 4 ) 
0 ( 1 ) - Y - M ( 4 ) 1 4 5 . 1 ( 4 ) 0 ( 2 ) - Y - M ( 4 ) 6 7 . 8 ( 4 ) 
0 ( 4 ) - Y - M ( 4 ) 6 4 . 8 ( 3 ) 0 ( 5 ) - Y - M ( 4 ) 6 6 . 6 ( 4 ) 
0 ( 7 ) - Y - M ( 4 ) 1 3 0 . 5 ( 4 ) 0 { 1 W ) - Y - N ( 4 ) 1 1 3 . 6 ( 4 ) 
N( 1 ) - Y - N ( 4 ) . 7 1 . 1 ( 4 ) N ( 2 ) - Y - N ( 4 ) 120. 0 ( 4 ) 
Y - O ( l ) - C ( 4 ) 125 . 5 ( 9 ) Y - 0 ( 2 ) - C ( 1 8 ) - 133 . 5 ( 8 ) 
Y - 0 ( 4 ) - C ( 9 ) 1 2 2 . 3 ( 9 ) Y - 0 ( 5 ) - C ( 2 8 ) 126. 1 ( 1 1 ) 
Y - 0 ( 7 ) - C ( 2 0 ) 1 2 2 . 3 (8 ) Y - N ( l ) - C ( l ) 110. 5 ( 9 ) 
Y - M ( l ) - C ( 6 ) 1 1 0 . 8 ( 9 ) C ( l ) - N ( l ) - C ( 6 ) 111 . 0 ( 1 0 ) 
Y - N ( l ) - C ( 1 9 ) 1 0 6 . 4 ( 7 ) C ( l ) - N ( l ) - C ( 1 9 J 109. 3 ( 1 2 ) 
C ( 6 ) - M ( D - C ( 1 9 ) 1 0 8 . 7 ( 1 2 ) Y - N ( 2 ) - C ( 2 ) 108. 5 ( 1 1 ) 
Y - M ( 2 ) - C { 3 ) 1 0 5 . 1 ( 1 0 ) C { 2 ) - N ( 2 ) - C ( 3 ) 1 1 3 . 3 ( 1 1 ) 
Y - N { 2 ) - C ( 1 7 ) 1 0 9 . 9 ( 9 ) C ( 2 ) - N ( 2 ) - C ( 1 7 ) 110 . 6 ( 1 1 ) 
C ( 3 ) - N ( 2 ) - C { 1 7 ) 1 0 9 . 3 ( 1 3 ) C ( 4 ) - N ( 3 ) - C ( 5 ) 124. 3 ( 1 6 ) 
Y - M ( 4 ) - C ( 7 ) 1 0 6 . 6 ( 9 ) Y - N ( 4 ) - C ( 8 ) 110 . 9 ( 8 ) 
C ( 7 ) - N ( 4 ) - C ( 8 ) 1 0 9 . 4 ( 1 0 ) Y - N ( 4 ) - C ( 2 7 ) 110 . 4 ( 7 ) 
C ( 7 ) - M ( 4 ) - C ( 2 7 ) 1 1 0 . 8 ( 1 2 ) C ( 8 ) - N ( 4 ) - C ( 2 7 ) 108. 8 ( 1 3 ) 
C ( 9 ) - M ( 5 ) - C ( 1 0 ) 123 . 6 ( 1 0 ) N ( l ) - C ( l ) - C ( 2 ) 114 . 7 ( 1 1 ) 
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M ( 2 ) -C ( 2 ! -C ( 1 ) 111 . 0 ( 1 3 ) 
0 ( 1 ) - 0 ( 4 ) - M ( 3 ) 122 . 4 ( 1 4 ) 
M (3 i - 0 ( 4 ) - 0 ( 3 ) 117 . 7 ( 1 5 ) 
M ( 1 ) - 0 ( 6 ) - 0 ( 7 ) 112 . 6 ( 1 3 ) 
M (4 ) - 0 ( 8 ) - 0 ( 9 ) 108 . 9 ( 9 ) 
0 ( 4 ) - 0 ( 9 ) - 0 ( 8 ) 122 . 3 ( 1 3 ) 
M (5 ) - 0 ( 1 0 ) - 0 ( 2 1 ) 114 . 4 ( 1 3 ) 
0 ( 5 ) - 0 ( 1 1 1 - 0 ( 1 6 ) 122 . 5 ( 6 ) 
0 ( 2 ) - 0 ( 1 8 ) - 0 ( 3 ) 127 . 8 ( 1 5 ) 
0 ( 3 ) - c u a ) - 0 ( 1 7 ) l i b . 9 ( 1 8 ) 
0 ( 7 ) - 0 ( 2 0 ) - 0 ( 8 ) 124 . 5 ( 1 0 ) 
.013) - 0 ( 2 0 ) - 0 ( 1 9 ) 118 . 3 ( 1 3 ) 
0 ( 1 0 ) - C ( 2 1 ) - C ( 2 6 ) 118 . 2 ( 7 ) 
0 ( 5 ) - 0 ( 2 8 ) - 0 ( 6 ) 123 . 6 ( 1 4 ) 
0 ( 6 ) - 0 ( 2 8 ) - 0 ( 2 7 ) 116 . 3 ( 1 5 ) 
N(2) - 0 ( 3 ) - 0 ( 4 ) 107 . 9 ( 1 3 ) 
0 ( 1 ) - 0 ( 4 ) - 0 ( 3 ) 119. 6 (14 ) 
N ( 3 ) - 0 ( 5 ) - 0 ( 1 1 ) 109. 7 ( 1 6 ) 
N(4) - 0 ( 7 ) - 0 ( 6 ) 110. 5 (10 ) 
0 ( 4 ) - 0 ( 9 ) - N(5) 121 . 8 (13 ) 
N(5) - 0 ( 9 ) - 0 ( 8 ) 115 . 9 ( 1 1 ) 
0 ( 5 ) - C ( l l ) -CC12) 117-. 5 ( 6 ) 
N(2) - 0 ( 1 7 ) - C ( 1 8 ) 1 1 1 . 8 ( 1 5 ) 
0 ( 2 ) - C ( 1 8 ) - C ( 1 7 ) 115 . 2 (13 ) 
N (1 ) - 0 ( 1 9 ) - C ( 2 0 ) 1 1 5 . 9 ( 1 2 ) 
0 ( 7 ) - C ( 2 0 ) - C ( 1 9 ) 117 . 2 ( 1 2 ) 
C ( 1 0 ) - 0 ( 2 1 ) - C ( 2 2 ) 121 . 8 ( 7 ) 
M(4) - 0 ( 2 7 ) - C ( 2 8 ) 110. 3 (14) 
0 ( 5 ) - 0 ( 2 8 ) - C ( 2 7 ) 119. 4 (17 ) 
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T A B L E 4: Anisotropic displacement coefficients ( X 2 x 103) 
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U l l u 2 2 U 33 U 1 2 U 13 U 2 3 
•r 13(1) 21(1) 3 9 ( 1 ) - 1 6 ( 1 ) - 1 2 ( 1 ) 3 ( 1 ) 
0 ( 1 ) 23(6) 30(6) 49(7) - 2 4 ( 5 ) - 2 0 ( 5 ) 9 ( 5 ) 
0 ( 2 ) 32 (6) 29(6) 4 6 ( 7 ) - 3 6 ( 5 ) - 2 1 ( 5 ) 1 0 ( 5 ) 
0(3 ) 31(6) 43 (7) 31(6) - 2 9 ( 6 ) - 6 ( 5 ) - 6 ( 6 ) 
0 ( 4 ) 23 (6) 24 (6) 35(6) - 2 1 ( 5 ) - 1 3 ( 5 ) 7 ( 5 ) 
0 ( 5 ) 14 (6) 32(6) 4 7 ( 7 ) - 1 2 ( 5 ) - 1 4 ( 5 ) 1 (5 ) 
0 ( 6 ) 20(5) 3 8 ( 7 ) 42(6) - 2 3 ( 5 ) - 1 2 ( 5 ) 8 ( 5 ) 
0 ( 7 ) 21(5) 3 0 ( 6 ) 30(6) -16(5^ -8 ( 5
1 - 1 0 ( 5 } 
0 (3 ) 24 (6) 3 6 ( 6 ) 31(6) - 1 8 ( 5 ) - 3 ( 5 ) - 9 ( 6 ) 
C(1W) 27 (6) 3 1 ( 6 ) 3 8 ( 6 ) - 2 3 ( 5 ) - 9 ( 5 ) 7 ( 5 ) 
M ( 1 ! 11 (6) 23 (7) 3 9 ( 7 ) - 1 2 ( 6 ) - 3 ( 6 ) 3 ( 6 ) 
M (2 i 15 (6) 29 (7) 39(8) - 2 0 ( 6 ) - 7 ( 6 ) 7 ( 6 ) 
M (3 ) 2 4 ( 7 ) 29 (8) 52 (8) - 2 1 ( 7 ) - 1 2 ( 6 ) 8 ( 7 ) 
M (4 ) 2 7 ( 7 ) 24 (7) 29 (7) - 1 3 ( 6 ) - 9 ( 6 ) - 3 ( 6 ) 
•I (5 i 27 (7) 34(8) 35(8) - 2 5 ( 7 ) - 9 ( 6 ) 6(7) 
C(l ) 21(8) 24 (9) 36(9) - 1 3 ( 8 ) - 4 ( 7 ) 1 ( 8 ) 
C ( 2 ) 25 (8 ) " 19(9) 46 (10) - 1 3 ( 8 ) - 1 8 ( 8 ) 1 ( 8 ) 
C ( 3 ) 31(9) 27(9 ) 53(10) - 2 8 ( 8 ) - 1 1 ( 8 ) 1 0 ( 8 ) 
0 ( 4 ) 30 (9 ) 31(10) 54(10) - 3 0 ( 9 ) -24(8) 1 1 ( 8 ) 
C ( 5 ) 35(10) 31(10) 88(14) - 2 4 ( 9 ) - 3 4 ( 1 0 ) ' 2 1 ( 1 0 ) 
C ( 6 ) 24 (8) 18(8) 39(9) - 7 ( 7 ) -5 (7 ) - 7 ( 8 ) 
C ( 7 ) 38(9) 18(9) 37(9) - 1 9 ( 8 ) -5 (8 ) 1 0 ( 8 ) 
C ( 8 ) 17 (8) 29(9) 37(9) - 2 1 ( 7 ) -13(7) 1 ( 8 ) 
C ( 9 ) 30 (9 ) 25(9) 23 (8) - 2 2 ( 8 ) 6(7) - 1 5 ( 8 ) 
C ( 1 0 ) 19(8) 18(8) 48(9 ) -9 (7) -20 m - 9 ( 7 ) 
0 ! 17) 12(7) 40(10) 32(8) - 1 6 ( 8 ) -6(7) - 6 ( 8 ) 
C ( 1 3 ) 18 (8) 48(11) 21 (9 ) - 1 6 ( 9 ) 1(7) 6 (9 ) 
0 ( 1 9 ) 27 (8 ) 29(9) 40(9 ) - 2 1 ( 8 ) -13(7) -3 (8) 
0 ( 2 0 ) 23 (8) 22(9 ) 43(10) - 2 3 ( 8 ) -19(8) 1 ( 8 ) 
0 ( 2 7 ) 31(9 ) 17 (8) 46(10) - 2 1 ( 8 ) -15(8) 7 (8) 
0 ( 2 3 ) 30(10) 16(8) 62(11) - 1 7 ( 8 ) -29(9) 1 2 ( 8 ) 
The a n i s o t r o p i c d i s p l a c e m e n t f a c t o r e x p o n e n t t a k e s the f o r m : 
- 2 J T 2 ( h 2 a - 2 U 1 1 + . . . +• 2 h k a * b * U 1 2 ) 
APPENDIX 2: X-Ray Crystallographic Study lol 
T A B L E 5: H-atom coordinates (x 104) and isotropic displacement coefficients 
(A 2 x io 3) 
X y z U 
H(3) -2954 2800 3428 80 
H (5) 4874 1771 -257 80 
H { I A ! 3775 -2109 3881 80 
r. i J_ B } 3737 -1764 2914 80 
1509 -1616 3698 80 
:-; {2 B ) 1262 -496 4376 80 
H ; 3 3 ) -692 1311 4243 80 
H(3C) -1091 672 3568 80 
H(5B) -2173 4637 2539 80 
H(5C) -3 572 5173 3343 80 
K(oA) 5386 -1838 3371 80 
H(5B) 5666 -394 3581 80 
H(7A) 5853 -1128 2056 30 
H(7B) 5517 -1237 1969 30 
H(3A) 5516 24 855 80 
H!3B) 6155 997 902 80 
H(10A) 3261 3770 -597 80 
H(10B) 2314 4126 384 80 
H U 2 ) -5780 5610 3166 80 
H(13) -7207 5734 2238 80 
H(14) -6073 4691 768 80 
H(15) -3512 3523 225 80 
H(16) -2086 3399 1153 80 
H(17A) 361 85 2152 80 
H(17B) 1289 -1350 2418 80 
H(19A) 4022 286 4736 80 
H{19B) 3391 -711 4946 80 
H(22A) 2085 1481 481 80 
H(23A) 464 917 92 80 
HI24A) -754 2111 -952 80 
H(25A) -351 3868 -1607 80 
H(26A) 1270 4433 -1218 80 
H(27A) 5716 2198 2111 80 
H(27B) 6748 841 2418 80 
